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CalCIum-PhoSPhaTe homeoSTaSIS
The parathyroid glands play an important role in calcium and phosphate homeostasis. 
The glands secrete parathyroid hormone (PTH) in response to a decrease in serum cal-
cium concentration. This response is mediated by the calcium-sensing receptor (CaSR)1 
on the parathyroid glands. PTH has important skeletal and renal effects. Next to PTH 
there are two other important hormones in calcium and phosphate homeostasis. This 
are 1,25(OH)2-vitamin D (calcitriol) and fibroblast growth factor 23 (FGF-23).
The action of PTH on bone results in an increase of calcium release by 2 pathways2. It 
mobilizes calcium from skeletal stores that are readily available and PTH stimulates bone 
resorption and subsequent calcium release. PTH also stimulates the production of FGF-
23 by bone osteocytes and osteoblasts3. 
PTH has three renal actions. It stimulates the reabsorption of calcium in the distal neph-
ron by increasing the expression of several calcium transport proteins4. PTH also inhibits 
the renal reabsorption of phosphate in both the proximal and distal tubule. Third, PTH 
stimulates the renal production of calcitriol by stimulating renal 1-alpha-hydroxylase5. 
Calcitriol has skeletal, renal and intestinal effects. The skeletal effects of calcitriol consist 
of an increase in bone resorption and of stimulation of the production of FGF-236. The 
renal effects of calcitriol on calcium are in the distal and collecting tubule, where it 
increases the reabsorption of calcium by increasing the expression of calcium transport 
proteins7. In the proximal tubule, calcitriol increases phosphate reabsorption.8 Calcitriol 
stimulates the intestinal uptake of phosphate and also increases the expression of the 
transient receptor potential channel 6 receptor on the apical membrane of the duode-
num and proximal jejunum thereby increasing the intestinal uptake of calcium8,9. The 
resulting rise in serum calcium concentration results in a decreased secretion of PTH by 
the parathyroid glands.
FGF-23 inhibits renal phosphate reabsorption and renal calcitriol production. It inhibits 
intestinal phosphate uptake and inhibits PTH production10,11. 
To summarize, PTH causes a rise in serum calcium and a fall of serum phosphate con-
centrations; calcitriol causes serum calcium and phosphate concentration to increase. 
FGF-23 causes serum phosphate concentrations to decrease.
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DISorDerS of The ParaThyroID
Primary hyperparathyroidism
In primary hyperparathyroidism (HPT) there is an overproduction of PTH. The subsequent 
increase in bone resorption, intestinal calcium absorption and renal calcium absorption 
result in hypercalcaemia. In 80-85% of patients the PTH overproduction is the result of 
a single parathyroid adenoma whereas double adenomas occur in approximately 5% of 
patients12. Other causes of primary HPT can be glandular hyperplasia (about 6%) or para-
thyroid carcinoma (<1%). Conditions associated with primary HPT are MEN syndrome, 
familial hypocalciuric hypercalcaemia, thiazide therapy and lithium therapy13-16. 
The incidence of primary HPT has increased in the last decades. However, the introduc-
tion of routine measurement of serum calcium in biochemical screening has led to an im-
mediate increase in the incidence of primary HPT17. After this introduction the incidence 
of primary HPT has continued to rise and primary HPT is often found by chance18,19. 
The classical symptoms of primary HPT are also known as “bones, stones, abdominal 
moans and psychic groans”. The most common classical symptoms are renal stones and 
osteoporosis20. Other common symptoms are constipation, anorexia, nausea and fatigue. 
However, the introduction of routine measurement of serum calcium has identified a 
group of patients with biochemical hyperparathyroidism without classical symptoms, 
referred to as asymptomatic primary hyperparathyroidism21. These “asymptomatic” pa-
tients represent the majority of patients diagnosed with primary hyperparathyroidism. 
The indications for treatment of these patients are summarized in a consensus state-
ment of the fourth international workshop22. 
Patients with primary HPT are known to also have neuropsychiatric symptoms which 
can include impaired mental functioning, lethargy and depressive symptoms23. Primary 
HPT can also influence the Quality of Life (QoL) of patients24. Although this is known, 
these symptoms are not part of the criteria for treatment of primary HPT. However, dur-
ing the international workshops of 2008 and 2014 these symptoms were identified as a 
recommended area for further studies22,25.
Treatment of primary HPT consists of surgical excision of the pathologic parathyroid 
gland(s). Historically this was by means of a bilateral neck exploration where all parathy-
roid glands are identified and pathological glands are removed26. However, in a majority 
of patients the cause of primary HPT is a single parathyroid adenoma12. The combination 
of this fact and the availability of ultrasound and sestamibi scanning has led to the intro-
duction of the minimal invasive parathyroidectomy (MIP). After successful identification 
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1by both ultrasound and sestamibi scan the MIP has a success rate of 95%
27,28. Besides be-
ing very effective the MIP is also a safe and cost-effective procedure, with some centers 
also performing the MIP as a day-care procedure29,30. 
Secondary hyperparathyroidism
The PTH overproduction in secondary HPT occurs as a response to metabolic abnor-
malities, and is very common among patients with chronic kidney disease (CKD)31. 
Important consequences of CKD that contribute to the development of secondary HPT 
are decreased phosphate excretion resulting in hyperphosphatemia, decrease in serum 
calcium concentration, decreased calcitriol concentration, an increase in FGF-23 con-
centration and also in reduced expression of the calcium-sensing receptor (CaSR) and 
vitamin D receptor (VDR) on the parathyroid32. Continuous stimulation of the parathy-
roid glands due to this abnormalities leads to diffuse hyperplasia followed by nodular 
hyperplasia and results in autonomous production of PTH33. 
A variety of symptoms is associated with secondary HPT and can include fatigue, 
abdominal pain, pruritus, forgetfulness and concentration difficulties34. A rare complica-
tion of long standing secondary HPT is calcific uremic arteriolopathy, or calciphylaxis, 
which has a poor survival rate of only 45% after 1 year35. Secondary HPT also has various 
negative effects on health status. There is an increased risk of fractures, cardiovascular 
disease and overall mortality and a reduced quality of life36-40. 
First line treatment of secondary HPT used to consist of correction of metabolic abnor-
malities by means of phosphate binders and vitamin D analogs, and if unsuccessful 
followed by treatment with calcimimetics or parathyroidectomy41. The recommenda-
tion from the updated KDIGO guideline is to treat with cinacalcet, calcitriol or vitamin D 
analogs, or a combination of these therapies36. 
Until 2004 a parathyroidectomy (PTx) was the only treatment option for patients 
with insufficient response to phosphate binders and vitamin D analogs. A PTx in 
hyperparathyroidism due to renal failure encompasses two procedures. In a subtotal 
parathyroidectomy a 4-gland exploration is performed, with excision of 3,5 glands. A 
total parathyroidectomy consists of a 4-gland exploration, excision of all 4 glands and 
a auto-transplantation of 0.5 of the parathyroid glands. The results of these procedures 
are comparable, and the term total-PTx can refer to both procedures42-44. Even though 
patients on dialysis represent a fragile population, complication rates are low45. A large 
advantage of PTx in treatment of secondary HPT is that it lowers the risk of major cardio-
vascular events and death as well as lower the risk of fractures46-48. 
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In 2004 the calcimimetic drug cinacalcet was introduced (Mimpara®; Amgen, Thousand 
Oaks, California, USA) and registered for use in patients with secondary HPT. This drug 
acts on the calcium-sensing receptor on the parathyroid glands, and increases the 
sensitivity to extracellular calcium and reduces PTH secretion49. This drug successfully 
lowers serum PTH, calcium and phosphate50,51. These promising results caused in a shift 
in treatment of secondary HPT, and in the 2009 KDIGO guidelines it was recommended 
to treat with cinacalcet before considering PTx41. However, in 2012 the results from the 
EVOLVE trial were published52. This large multinational randomized controlled trial did 
not demonstrate a significant effect of cinacalcet on cardiovascular events of death 
in 3883 hemodialysis patients, compared with placebo, but did report a 45,9% rate of 
adverse effects such as vomiting and nausea. This was supported by a meta-analysis of 
randomized trials53. It has been calculated that treatment of 1000 patients for 1 year “has 
no effect on mortality, prevents 3 patients from experiencing parathyroidectomy and 
leads to 60 individuals experiencing hypocalcemia and 150 individuals experiencing 
nausea”. These findings resulted in the removal of cinacalcet from the national pharma-
ceuticals benefits scheme in Australia54. 
In the 2017 KDIGO guideline update cinacalcet remains the treatment of choice for sec-
ondary HPT, and parathyroidectomy is the option only if other PTH-lowering therapies 
fail36. Prospective randomized trials comparing these treatment modalities have not yet 
been performed, and the optimal treatment of secondary HPT remains unclear.
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to assume a central role in growth and metabolism in 
higher organisms.22–24 In higher animals, the primitive 
insulin–IGF-1 pathway diverged to perform a more 
circumscribed set of functions.22 In mammals, insulin 
serves primarily metabolic functions, whereas IGF-1 
functions predominantly to regulate growth, develop-
ment and, perhaps, longevity.22 A paucity of nutrients 
and/or the increased complexity of new terrestrial 
organisms might have provided substantial evolution-
ary pressure to further separate the actions of insulin 
and IGF-1. The requisite demands for growth in large, 
complex organisms would far exceed the nutritional and 
energy content derived from a single feeding episode. 
Ultimately, through the expansion and modification of 
primitive pathways, successful tetrapods reorganized 
their metabolic regulatory machinery to accommodate 
the storage and distribution of fuel among metabolically 
active tissues, and neuroendocrine pathways provided 
the means to regulate metabolic homeostasis. With these 
evolutionary considerations in mind, let us now turn 
to two recent discoveries that, we argue, establish the 
skelet on as a true endocrine organ.
Phosphate homeostasis and the skeleton
The first discovery that implicated bone as an endocrine 
organ concerns the role of bone in regulating phosphate 
homeostasis through the hormone FGF23.25 As discussed 
earlier, the mammalian skeleton represents the largest 
reservoir in the body of both calcium and phosphate in 
the form of hydroxyapatite crystals, the main inorganic 
component of the mineralized bone matrix.26 Phosphate 
ingested through the diet is absorbed by the small 
intestine through sodium–phosphate co-transporters 
(sodium dependent), as well as by diffusional absorp-
tion across intercellular spaces in the lumen (sodium 
independent).25 However, the major control point for 
phosphate homeostasis is the kidney, which expresses 
numerous hormone-regulated proteins to modulate 
phosphate filtration. In particular, a sodium– phosphate 
co-transporter (SLC34A1, also known as NPT2) is 
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 | The regulation of calcium and phosphate homeostasis by PTH, vitamin D and FGF23. The parathyroid gland 
detects changes in the level of calcium in blood by means of the calcium-sensing receptor, which then modulates the 
secretion of PTH. A decrease in circulating calcium stimulates the parathyroid gland to produce and release PTH. 
Circulating PTH then works in a rapid, pleiotropic fashion to increase blood calcium levels by stimulating osteoclastic 
bone resorption to release calcium and phosphate, calcium reabsorption and phosphate excretion in the renal distal 
convoluted tubule by downregulating the sodium–phosphate co-transporters SLC34A1–SLC34A3, and production of 
1,25(OH)
2
D by 1α-hydroxylase in the kidney, which, in turn, increases intestinal calcium and phosphate absorption. The 
kidney is the principle physiological target, where FGF23 signalling acts to promote phosphate excretion by downregulating 
SLC34A1–SLC34A3 and inhibiting 1,25(OH)
2
D production, thus preventing vitamin-D-mediated phosphate absorption in 
the gut. Serum levels of FGF23 increase in response to increased serum phosphate and 1,25(OH)
2
D, and furthermore, 
FGF23 inhibits the production of PTH. Boxes in pink show input into the system, boxes in green show the output. 
Abbreviations: 1,25(OH)
2
D, active vitamin D; 25(OH)D, 25-hydroxyvitamin D;  Ca2+, calcium; FGF23, fibroblast growth 
factor 23; FGFR, fibroblast growth factor receptor; PO
4
, phosphate; PTH, parathyroid hormone; SLC34A1, sodium-
dependent phosphate transport protein 2A (also known as NPT2a); SLC34A3, sodium-dependent phosphate transport 
protein 2C (also known as NPT2c).
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figure 1. The regulation of calcium and phosphate homeostasis by PTH, vitamin D and FGF23. 
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Tertiary hyperparathyroidism
The metabolic abnormalities leading to secondary HPT can be corrected by a successful 
kidney transplantation55. The decline of PTH after transplantation is the greatest in the 
3 months after transplantation, but PTH continues to decline during the first post-trans-
plant year. Further decline after this period is unlikely42. After a successful transplanta-
tion 17-50% of patients remain hyperparathyroid42,56,57. This condition is called tertiary 
or post-transplant HPT58. 
Tertiary HPT has several effects. It increases the risk of both renal allograft dysfunction 
as well as renal allograft loss59,60. It is also a major risk factor for bone fractures and 
osteoporosis61,62. 
The only registered treatment for tertiary HPT is PTx. The procedure in patients with 
tertiary HPT is the same procedure as in patients with secondary HPT. In recent years the 
off-label use of cinacalcet in patients with tertiary HPT has gained popularity. The use 
of cinacalcet in patients after kidney transplantation appears to be safe, although has 
been studied mainly in small non-randomized studies63. The two treatment modalities 
(PTx and cinacalcet) have only been compared directly in one randomized controlled 
trial. In this study with 30 patients, PTx was superior in achieving normocalcemia than 
cinacalcet.
hypoparathyroidism
A majority of the parathyroid disorders exist of the different forms of hyperparathyroid-
ism. Another parathyroid disease is hypoparathyroidism, which is very uncommon and 
results in hypocalcaemia. The deficit in PTH results in less calcium mobilization from bone, 
less reabsorbing of calcium in the distal nephron and it stimulates renal 1α-hydroxylase 
activity insufficiently. As a result 1,25-dihydroxyvitamin D is insufficiently generated and 
therefore intestinal calcium absorption is inadequate64. 
The most common cause of hypoparathyroidism is anterior neck surgery65, and consti-
tutes about 75% of all cases. Other diseases causing hypoparathyroidism are rare but 
include autoimmune hypoparathyroidism, radiation-induced destruction of parathyroid 
tissue, deposition of heavy metals in parathyroid tissue, severe magnesium depletion or 
hypermagnesemia and mutations in the PTH gene or mutations in transcription factors 
and mitochondrial DNA64. 
Hypoparathyroidism after thyroid surgery is a common complication. Hypocalcaemia 
resulting from hypoparathyroidism occurs in up to 60% of patients undergoing a 
total or completion thyroidectomy66-68. In a minority of patients parathyroid function 
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does not recover, and if patients still require calcium supplementation one year after 
thyroidectomy the hypoparathyroidism is very unlikely to improve, and this is called 
persistent hypoparathyroidism. Rates of persistent hypoparathyroidism are reported up 
to 14% after thyroid surgery69-72. Treatment consists of symptom control by means of 
supplementation of both calcium and active vitamin D73. 
At this moment it’s not possible to reliably predict which patients will develop persistent 
hypoparathyroidism and in which patients parathyroid function will recover. Being able 
to predict persistent hypoparathyroidism will help clinicians counsel their patients and 
will help tailor individual treatments. Recent studies have described various risk factors 
for persistent hypoparathyroidism which cannot be influenced, but have also described 
the value of postoperative PTH levels to determine the chance of direct postoperative 
hypocalcemia74. One study has evaluated the value of PTH levels one month after 
surgery for predicting persistent hypoparathyroidism75. It has not yet been evaluated 
whether direct postoperative PTH levels can predict which patients will develop persis-
tent hypoparathyroidism.
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outline of thesis
Chapter 2 presents the results of a prospective study on surgical treatment of primary 
hyperparathyroidism. In this study it is investigated if parathyroidectomy in a daycare 
setting is safe and feasible.
Chapter 3 describes the results of a retrospective analysis and prospective study on 
patients undergoing hemithyroidectomy. It is investigated whether it is safe to perform 
a hemithyroidectomy in a daycare setting. 
Chapter 4 presents the results of a case-control study on quality of life of patients with 
primary hyperparathyroidism. In this study it is investigated whether surgical treatment 
of primary hyperparathyroidism improves quality of life.
Chapter 5 presents a systematic review of studies describing quality of life in dialysis 
patients treated for secondary hyperparathyroidism. It is investigated whether surgical 
or medical treatment by means of cinacalcet has the most beneficial effect on quality 
of line. 
Chapter 6 presents a systematic review of studies describing treatment for tertiary hy-
perparathyroidism. In this study the results of surgical treatment and medical treatment 
with cinacalcet are compared. 
Chapter 7 presents the results of a retrospective study on tertiary hyperparathyroidism. 
The outcomes of surgical treatment and medical treatment by means of cinacalcet are 
described in this study.
Chapter 8 presents the results of a prospective study of patients undergoing total or 
completion thyroidectomy. In this study it is investigated whether postoperative PTH 
values can predict which patients develop persistent hypoparathyroidism. 
16 Chapter 1
referenCeS:
 1. Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 
1995;333:234-40.
 2. Talmage RV, Mobley HT. Calcium homeostasis: reassessment of the actions of parathyroid hor-
mone. Gen Comp Endocrinol 2008;156:1-8.
 3. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene ex-
pression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid 
feedback loop. Am J Physiol Renal Physiol 2010;299:F882-9.
 4. van Abel M, Hoenderop JG, van der Kemp AW, Friedlaender MM, van Leeuwen JP, Bindels RJ. 
Coordinated control of renal Ca(2+) transport proteins by parathyroid hormone. Kidney Int 
2005;68:1708-21.
 5. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Endocrinol 
Metab Clin North Am 2010;39:243-53, table of contents.
 6. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic 
hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15.
 7. Lambers TT, Bindels RJ, Hoenderop JG. Coordinated control of renal Ca2+ handling. Kidney Int 
2006;69:650-4.
 8. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. 
Clin J Am Soc Nephrol 2015;10:1257-72.
 9. Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev 2005;85:373-
422.
 10. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007;18:1637-47.
 11. Prie D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involv-
ing the FGF23/Klotho system. Clin J Am Soc Nephrol 2010;5:1717-22.
 12. Ruda JM, Hollenbeak CS, Stack BC, Jr. A systematic review of the diagnosis and treatment of 
primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005;132:359-72.
 13. Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene 
cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 
1993;75:1297-303.
 14. Christensson T, Hellstrom K, Wengle B. Hypercalcemia and primary hyperparathyroidism. 
Prevalence in patients receiving thiazides as detected in a health screen. Arch Intern Med 
1977;137:1138-42.
 15. Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S. Lithium treatment increases intact and 
midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab 1989;68:654-
60.
 16. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia 
type 1 (MEN1). J Clin Endocrinol Metab 2012;97:2990-3011.
 17. Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ, 3rd, Wermers RA. Secular trends in the 
incidence of primary hyperparathyroidism over five decades (1965-2010). Bone 2015;73:1-7.
 18. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in 
a racially mixed population. J Clin Endocrinol Metab 2013;98:1122-9.
 19. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-
related protein in investigation of hypercalcaemia. Lancet 1992;339:164-7.
 20. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in 
clinical, densitometric and biochemical features. J Intern Med 2005;257:6-17.
General Introduction 17
1
 21. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl 
J Med 2004;350:1746-51.
 22. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary 
hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endo-
crinol Metab 2014;99:3561-9.
 23. Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperpara-
thyroidism: a prospective study. J Clin Endocrinol Metab 2009;94:1951-8.
 24. Coker LH, Rorie K, Cantley L, et al. Primary hyperparathyroidism, cognition, and health-related 
quality of life. Ann Surg 2005;242:642-50.
 25. Bilezikian JP KA, Potts JT. Guidelines for the Management of Asymptomatic Primary Hyper-
parathyroidism: Summary Statement from the Third International Workshop. Journal of Clinical 
Endocrinology and Metabolism 2009;94:335-9.
 26. van Heerden JA, Grant CS. Surgical treatment of primary hyperparathyroidism: An institutional 
perspective. World Journal of Surgery 1991;15:688-92.
 27. Smit PC, Borel Rinkes IH, van Dalen A, van Vroonhoven TJ. Direct, minimally invasive adenomec-
tomy for primary hyperparathyroidism: An alternative to conventional neck exploration? Ann 
Surg 2000;231:559-65.
 28. Arici C, Cheah WK, Ituarte PH, et al. Can localization studies be used to direct focused parathyroid 
operations? Surgery 2001;129:720-9.
 29. Shin SH, Holmes H, Bao R, et al. Outpatient minimally invasive parathyroidectomy is safe for 
elderly patients. J Am Coll Surg 2009;208:1071-6.
 30. Gurnell EM, Thomas SK, McFarlane I, et al. Focused parathyroid surgery with intraoperative para-
thyroid hormone measurement as a day-case procedure. Br J Surg 2004;91:78-82.
 31. Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J. International burden of chronic kidney 
disease and secondary hyperparathyroidism: a systematic review of the literature and available 
data. Int J Nephrol 2015;2015:184321.
 32. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease 
progression, and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-21.
 33. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 
2000;11:1141-52.
 34. Pasieka JL, Parsons LL. A prospective surgical outcome study assessing the impact of parathy-
roidectomy on symptoms in patients with secondary and tertiary hyperparathyroidism. Surgery 
2000;128:531-9.
 35. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Ar-
teriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol 
2015;10:800-7.
 36. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney 
Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it 
matters. Kidney Int 2017;92:26-36.
 37. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a 
European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-55.
 38. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage 
renal disease. Kidney Int 2001;60:472-9.
 39. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mor-
tality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
18 Chapter 1
 40. Cheng SP, Lee JJ, Liu TP, et al. Parathyroidectomy improves symptomatology and quality of life in 
patients with secondary hyperparathyroidism. Surgery 2014;155:320-8.
 41. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for 
the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and 
Bone Disorder (CKD-MBD). Kidney Int Suppl 2009:S1-130.
 42. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of para-
thyroid function and calcium metabolism after kidney transplantation: A single-centre study. 
Nephrol Dial Transplant 2004;19:1281-7.
 43. Riss P, Asari R, Scheuba C, Niederle B. Current trends in surgery for renal hyperparathyroidism 
(RHPT) - An international survey. Langenbeck’s Arch Surg 2013;398:121-30.
 44. Chen J, Jia X, Kong X, Wang Z, Cui M, Xu D. Total parathyroidectomy with autotransplantation 
versus subtotal parathyroidectomy for renal hyperparathyroidism: A systematic review and meta-
analysis. Nephrology (Carlton) 2017;22:388-96.
 45. van der Plas WY, Engelsman AF, Ozyilmaz A, et al. Impact of the Introduction of Calcimimetics on 
Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism. Ann Surg Oncol 
2017;24:15-22.
 46. Trombetti A, Stoermann C, Robert JH, et al. Survival after parathyroidectomy in patients with 
end-stage renal disease and severe hyperparathyroidism. World J Surg 2007;31:1014-21.
 47. Costa-Hong V, Jorgetti V, Gowdak LHW, Moyses RMA, Krieger EM, De Lima JJG. Parathyroidec-
tomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery (USA) 
2007;142:699-703.
 48. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy 
among chronic hemodialysis patients. J Am Soc Nephrol 2007;18:2401-7.
 49. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid 
hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney International 
2003;63:248-54.
 50. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease 
treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71.
 51. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treat-
ment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, 
double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7.
 52. Evolve Trial Investigator CG, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog 
CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Ef-
fect of cinacalcet on cardiovascular disease in patients undergoing dialysis. New England Journal 
of Medicine 2012;367:2482-94.
 53. Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in Patients with Chronic Kidney Disease: A Cumula-
tive Meta-Analysis of Randomized Controlled Trials. PLoS Med 2013;10.
 54. https://www.nps.org.au/radar/articles/sensipar-cinacalcet-pbs-listing-to-be-deleted#article.
 55. Evenepoel P. Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant 
Recipients. Semin Nephrol 2013;33:191-203.
 56. Jeon HJ, Kim YJ, Kwon HY, et al. Impact of parathyroidectomy on allograft outcomes in kidney 
transplantation. Transplant International 2012;12:376-7.
 57. Copley JB, Wuthrich RP. Therapeutic management of post-kidney transplant hyperparathyroid-
ism. Clin Transplant 2011;25:24-39.
 58. Gioviale MC, Bellavia M, Damiano G, Lo Monte AI. Post-transplantation tertiary hyperparathyroid-
ism. Ann Transplant 2012;17:111-9.
General Introduction 19
1
 59. Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal 
transplantation is a risk factor for graft failure. Clin Transplant 2007;21:558-66.
 60. Ozdemir FN, Afsar B, Akgul A, Usluogullari C, Akcay A, Haberal M. Persistent hypercalcemia is a 
significant risk factor for graft dysfunction in renal transplantation recipients. TRANSPLANT PROC 
2006;38:480-2.
 61. Akaberi S, Lindergard B, Simonsen O, Nyberg G. Impact of parathyroid hormone on bone density 
in long-term renal transplant patients with good graft function. Transplantation 2006;82:749-52.
 62. Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroidism is a major risk factor for frac-
tures in the five years after kidney transplantation. Am J Transplant 2013;13:2653-63.
 63. Cohen JB, Gordon CE, Balk EM, Francis JM. Cinacalcet for the treatment of hyperparathyroid-
ism in kidney transplant recipients: A systematic review and meta-analysis. Transplantation 
2012;94:1041-8.
 64. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med 2008;359:391-403.
 65. Bilezikian JP, Khan A, Potts JT, Jr., et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, 
pathophysiology, target-organ involvement, treatment, and challenges for future research. J 
Bone Miner Res 2011;26:2317-37.
 66. Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. Hypoparathyroidism after total thyroidec-
tomy: a prospective study. Arch Surg 2008;143:132-7; discussion 8.
 67. Raffaelli M, De Crea C, Carrozza C, et al. Combining early postoperative parathyroid hormone 
and serum calcium levels allows for an efficacious selective post-thyroidectomy supplementation 
treatment. World J Surg 2012;36:1307-13.
 68. Goncalves Filho J, Kowalski LP. Surgical complications after thyroid surgery performed in a cancer 
hospital. Otolaryngol Head Neck Surg 2005;132:490-4.
 69. Gupta S, Chaudhary P, Durga CK, Naskar D. Validation of intra-operative parathyroid hormone and 
its decline as early predictors of hypoparathyroidism after total thyroidectomy: A prospective 
cohort study. Int J Surg 2015;18:150-3.
 70. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis 
of predictors of post-thyroidectomy hypocalcaemia. Br J Surg 2014;101:307-20.
 71. Garrahy A, Murphy MS, Sheahan P. Impact of postoperative magnesium levels on early hypocal-
cemia and permanent hypoparathyroidism after thyroidectomy. Head Neck 2016;38:613-9.
 72. Banach R, Bartes B, Farnell K, et al. Results of the Thyroid Cancer Alliance international patient/
survivor survey: Psychosocial/informational support needs, treatment side effects and interna-
tional differences in care. Hormones (Athens) 2013;12:428-38.
 73. Brandi ML, Bilezikian JP, Shoback D, et al. Management of Hypoparathyroidism: Summary State-
ment and Guidelines. J Clin Endocrinol Metab 2016;101:2273-83.
 74. Kakava K, Tournis S, Papadakis G, et al. Postsurgical Hypoparathyroidism: A Systematic Review. In 
Vivo 2016;30:171-9.
 75. Sitges-Serra A, Ruiz S, Girvent M, Manjon H, Duenas JP, Sancho JJ. Outcome of protracted hypo-
parathyroidism after total thyroidectomy. Br J Surg 2010;97:1687-95.

Chapter 2 Operative treatment of primary 
hyperparathyroidism in daycare 
surgery
R.R. Dulfer MD, T.M. van Ginhoven MD Dr., W. Geilvoet, 
W.W. de Herder MD Prof. Dr., C.H.J. van Eijck MD Prof. Dr.
Scandinavian Journal of Surgery. 2015; 104(3): 196-199.
22 Chapter 2
abSTraCT
objective
The standard of care for primary hyperparathyroidism is surgical removal of hyperfunc-
tional parathyroid tissue. Here we describe twenty patients with PHPT who were treated 
surgically in the setting of daycare surgery. 
Design
Prospective observational study
methods
Twenty patients with primary hyperparathyroidism were operated between March 
2005 and May 2010. The follow-up period had a median of 41 weeks (5-245). Results are 
presented as mean (± standarddeviation) or median (minimum-maximum).
results
Twenty patients (15 women, mean age 54±14 years) were included. Nine patients were 
provided with postoperative calcium supplementation. One of them patient visited the 
emergency department (ED) the next day with paresthesias and normocalcaemia, this 
patient was send home. Four patients, without prophylaxis, also reported themselves 
to the ED. Only one had a mild hypocalcaemia (2,09 mmol/L) and was supplemented. 
Comparing the ED-group (n=5) with the others, we found that preoperative calcium 
levels were similar (p=0.40), however the ED-group had significantly lower postopera-
tive calcium levels (2.27±0.14 vs. 2.55±0.25, p=0.008) and the decrease-percentage was 
significantly higher (17.5% ±5.4 vs. 10.5% ±6.4, p=0.21). 
Conclusion
Parathyroidectomy in the daycare setting is feasible and safe. However many patients re-
turn to the ED. This could be related to the strict information that is provided or due to a 
large decrease in their calcium levels, albeit normocalcaemia. Calcium supplementation 
is cheap and safe, so we will provide all future patients with calcium supplementation 
and herewith aim to reduce the amount of emergency department visits.
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InTroDuCTIon
Primary hyperparathyroidism (PHPT) is caused by one or more overactive parathyroid 
glands producing high levels of parathyroid hormone (PTH) which leads to hypercalcae-
mia. It is seen in about 20 per 100.000 people, with 2-3 times as many women affected as 
men1. PHPT is often detected by chance when elevated serum calcium levels are found2. 
Operative treatment is the treatment of choice, since it is the only curative therapy. Until 
the 1990s the bilateral neck exploration was the golden standard. In this procedure 
the surgeon tries to identify all parathyroid glands and excises only the pathologically 
enlarged glands. For that matter, in 90% of the cases there is only one enlarged hyper-
active gland. This fact, combined with the introduction in the mid 1990s of imaging 
studies with high sensitivity and specificity – such as radionucleotide scans– has led to 
a new approach: minimally invasive parathyroidectomy. (MIP) After identification of the 
pathological gland by ultrasound, nuclear imaging or computed tomography, MIP has a 
95% chance of success3, 4. 
Benefits of a minimal invasive procedure are, besides the better cosmetic outcome, 
decreased risk of post-operative hypocalcaemia and shorter operating times. The 
success rate and the risk of complications of a MIP are equal to those in the bilateral 
neck exploration5. Furthermore, an increasing number of patients undergoing MIP can 
be discharged on the day of surgery. MIP in one-day surgery is safe, also for over-70-
year-olds6, cost-effective and the patients are satisfied7, 8. In the Netherlands more and 
more non-parathyroid surgeries are being carried out as day care procedures9. In view 
of the favourable results in international literature, and the potentially higher cost-
effectiveness, and patient satisfaction, we introduced day care surgery for PHPT in our 
centre in 2005. In this article we describe our care pathway and present the results of the 
first 20 patients with special attention to postoperative hypocalcaemia. 
meThoDS
Between March 2005 and May 2010 a total of 139 patients underwent parathyroid-
ectomy in our centre. These patients had either primary, secondary or tertiary hyper-
parathyroidism or MEN syndrome. The diagnosis PHPT was based on elevated serum 
calcium levels in combination with high normal or elevated PTH levels. Pre-operative 
imaging consisted of an ultrasound of the neck and a ⁹⁹ᵐTechnetium-sestamibi scan, 
completed with a computed tomography if needed. All patients were discussed in a 
multi-disciplinary meeting pre-operatively and were operated by or under the supervi-
sion of the last author. The 20 patients considered fit for day surgery were included at 
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the joint clinic of the endocrinologist, surgeon and nurse practitioner. The inclusion and 
exclusion criteria are listed in table 1. They consist of both daycare specific criteria, e.g. 
the availability of a person who would accompany the patient after discharge and the 
first night, and of disease specific criteria, e.g. MEN syndrome.
Demographic and clinical data were collected prospectively. All operations were 
conducted on a Friday morning under general anaesthesia with the patient in supine 
position and the neck in slight hyperextension. Both the anaesthesiologist and the sur-
geon needed to consent for discharge on the same day. On discharge, patients received 
information about the operation, a letter to the general practitioner and standardized 
discharge instructions. These instructions included information about hypocalcaemia, 
pain medication, outpatient wound control and monitoring. Patients were instructed 
to contact the general practitioner or the hospital upon signs of hypocalcaemia (e.g. 
paraesthesia and muscle cramps). The study protocol did not provide for prophylactic 
calcium supplementation; however, some patients received it at surgeon’s own discre-
tion. All patients were contacted by telephone after the operation, in accordance with 
the Erasmus MC daycare surgery standards, and were asked about pain, satisfaction and 
any other problems. Patients were either seen in the outpatient setting in our hospital 
or patients’ general practitioners or referring specialists from other hospitals checked 
calcium levels and noted possible complications of surgery. This is according to patients 
preferences. All patients were monitored for wound healing and serum calcium and PTH 
levels. We aimed to check all patients at one, six and 52 weeks after surgery or advise 
the other physicians to do so accordingly. Low or normal calcium levels during the first 
six months post-operatively are indicative of recovery; rising levels point at persisting 
disease. Hypercalcaemia after this six month period is considered relapse. 
Table 1. In- and exclusion criteria for parathyroidectomy in day care surgery
Inclusion criteria ASA1 classification 1 of 2
Concordant localizing study (Sestamibi scan and ultrasound neck)
Adequate informal care
Primary hyperparathyroidism
Exclusion criteria ASA1 classification 3 or higher
Discordant localizing study (Sestamibi scan and ultrasound neck)
Absent informal care
Intra-operative PTH3 measurements 
 - Secondary or tertiary hyperparathyroidism
 - Genetic disorders (e.n. MEN2-syndrome)
 - Familiary primary hyperparathyroidism
 - Lithium use
 - Re-exploration for relapsing hyperparathyroidism 
1ASA (American Society of Anesthesiologists), 2MEN (Multiple endocrine neoplasia), 3PTH (parathyroid hor-
mone)
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Results are presented as mean ± standard deviation (normal distribution) or as median 
(minimum – maximum, no normal distribution). The non-parametric Mann Whitney U 
test was used to compare groups. A p-value of less than 0.05 was considered significant. 
All data were analysed by SPSS statistics version 18.0 (IBM)
reSulTS
Twenty patients, mean age 54 ± 14 years, underwent a day care procedure between 
March 2005 and May 2010. Fourteen had been referred by external specialists. On pre-
sentation at the outpatient clinic patients complained about fatigue (n=6), depression 
(n=2), gastro-intestinal symptoms (n=7) and myogenic complaints (n=2). Six patients 
had no complaints. 
The medical histories entailed kidney stones (n=7), chronic obstructive pulmonary 
disease (n=2), hypertension (n=1), peripheral vascular disease (n=1) and coronary artery 
bypass grafts (n=1). 
Pre-operative serum calcium and PTH levels were mean 2.84±0.20 mmol/L and 19.9±11 
pg/ml respectively. All patients received a pre-operative sestamibiscan and an ultra-
sound of the neck, which led to the removal of one enlarged parathyroid gland in 18 
patients. In the remaining two cases, one gland was removed, however a re-operation 
was needed due to persistent disease. These cases are described below. The mean op-
erating time was 56±19 minutes. Kocher’s incision was used in six patients, MIP in the 
other 14. There were no perioperative complications, and all patients were discharged 
the same day.
Nine patients received post-operative calcium supplementation based on high pre-
operative serum calcium levels or at the surgeon’s discretion. One of these reported 
at the emergency department with paraesthesia and normocalcaemia the day after 
discharge, but was sent home after reassurance. Four patients without supplementation 
also reported at the emergency department with paraesthesia the day after discharge. 
One of them received calcium supplementation as mild hypocalcaemia (2,09mmol/L) 
was noted. Pre-operative (p=0.40) and post-operative (p=0.38) serum calcium levels 
did not significantly differ between patients who received calcium supplementation 
and those who did not. Also, the decrease in serum calcium levels (pre vs. post) did not 
significantly differ between these groups (p=0.85). Pre-operative serum calcium levels 
did not significantly differ between the five patients who reported at the emergency 
department and the others (p=0.40). However, those five had significantly lower post-
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operative calcium levels (2.27±0.14 vs 2.55±0.25, p=0.008) and showed a significantly 
greater drop in serum calcium levels (17.5%±5.4 vs. 10.5%±6.4, p=0.021). 
The median follow-up was 41 (5-245) weeks. Two patients showed persisting hyper-
parathyroidism (PTH>40 pg/ml) at follow-up. One had a parathyroid adenoma in the 
aortopulmonary window, which was not shown on the sestamibi scan. The other had 
hyperplasia of all four parathyroid glands, not shown on pre-operative imaging stud-
ies. Both patients were cured, one after thoracotomy and one after conventional neck 
exploration. All other 18 patients had serum calcium and PTH levels within the normal 
range during follow-up (Fig 1). There were no wound infections, wound hematoma’s or 
laryngeal nerve problems.
ConCluSIon
In this article we describe our experience with parathyroid surgery in a day care set-
ting. Despite the relative small sample size we may draw some important conclusions. 
Patient satisfaction, as measured by the telephone interviews postoperatively, is high 
due to intensive cooperation between the endocrinologist, surgeon, nurse practitioner 
and anaesthesiologist, so that patients can be placed on the waiting list after only one 
hospital visit. By selecting relatively healthy patients we can safely perform parathyroid 
surgery in the day care setting, with similar outcomes like reported internationally10. 
Calcium levels are not checked before discharge but we inform patients clearly about 
the signs of hypocalcaemia and urge them to contact the hospital when these signs 
occur. There were no patients who failed to report to the emergency department. Four 
persons without calcium supplementation reported to the emergency department 
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figure 1. Pre- and post-operative serum levels of calcium and PTH. 1 PTH = parathyroid hormone * Post-
operative follow-up = longest follow-up possible. Median follow-up is 41 weeks (range 5-245 weeks). Data 
represent median values and full range.
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the day after surgery with symptoms, but had no hypocalcaemia. Perhaps they were 
sensitive to symptoms because of the extensive instructions they had received and 
therefore more likely to visit the emergency department. Perhaps we need to tone down 
the post-operative information to prevent these unnecessary visits. On the other hand, 
the decline in serum calcium levels was significantly greater in these patients. Therefore 
we assume that not absolute levels, but rather relative declines in serum calcium levels 
lead to calcium deficits. This means that these patients validly visited the emergency 
department and should have been supplemented with calcium. These visits could per-
haps have been prevented by prophylactic calcium supplementation, which was shown 
successful in large series in international literature11. It is also known that the absolute 
perioperative serum calcium levels are less predictive12. 
Based on our experience and the findings from the present study we can recommend 
parathyroid surgery in day care. We would like to propose prophylactic calcium supple-
mentation for a few weeks as needed. The costs are low, and it can be given safely11. This 
is now standard care after parathyroid surgery in the day care setting in our hospital.
28 Chapter 2
referenCeS:
 1. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, 
Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 
2006;21:171-7.
 2. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-
related protein in investigation of hypercalcaemia. Lancet 1992;339:164-7.
 3. Henry JF. Minimally invasive surgery of the thyroid and parathyroid glands. Br J Surg 2006;93:1-2.
 4. Smit PC, Borel Rinkes IH, van Dalen A, van Vroonhoven TJ. Direct, minimally invasive adenomec-
tomy for primary hyperparathyroidism: An alternative to conventional neck exploration? Ann 
Surg 2000;231:559-65.
 5. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for 
primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 2002;236:543-
51.
 6. Shin SH, Holmes H, Bao R, et al. Outpatient minimally invasive parathyroidectomy is safe for 
elderly patients. J Am Coll Surg 2009;208:1071-6.
 7. Chen H, Sokoll LJ, Udelsman R. Outpatient minimally invasive parathyroidectomy: a combina-
tion of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid 
hormone assay. Surgery 1999;126:1016-21; discussion 21-2.
 8. Gurnell EM, Thomas SK, McFarlane I, et al. Focused parathyroid surgery with intraoperative para-
thyroid hormone measurement as a day-case procedure. Br J Surg 2004;91:78-82.
 9. Wasowicz-Kemps DK. Trends in day surgery in the Netherlands [Thesis]; 2008.
 10. Norman JG, Politz DE. Safety of immediate discharge after parathyroidectomy: a prospective 
study of 3,000 consecutive patients. Endocr Pract 2007;13:105-13.
 11. Vasher M, Goodman A, Politz D, Norman J. Postoperative calcium requirements in 6,000 patients 
undergoing outpatient parathyroidectomy: easily avoiding symptomatic hypocalcemia. J Am 
Coll Surg 2010;211:49-54.
 12. Zuberi KA, Urquhart AC. Serum PTH and ionized calcium levels as predictors of symptomatic 
hypocalcemia after parathyroidectomy. Laryngoscope 2010;120 Suppl 4:S192.


Chapter 3 Introduction of daycare thyroid 
surgery in a Dutch non-academic 
hospital
R.R. Dulfer*, K.S. de Valk*, F. Gilissen, T.M. van Ginhoven, P.C. Smit 
* Joint first authors
Netherlands Journal of Medicine. 2016; 74(9): 395-400
32 Chapter 3
abSTraCT 
objective
The hemithyroidectomy is the most common endocrine surgical procedure performed 
with low complication rates. Multiple international reports indicate that thyroid surgery 
in day care setting is feasible and safe. Despite these results, thyroid surgery in daycare 
setting is not yet implemented in the Netherlands. The objective of this study is to as-
sess the safety of thyroid surgery in our institution and, when deemed safe, implement 
daycare thyroid surgery. 
methods
All patients who underwent a hemithyreoidectomy in our institution between January 
2010 and December 2014 were included in the retrospective analysis. Hypothetical can-
didates for daycare surgery were identified. All patients undergoing thyroid surgery in 
2015 were included in a prospective cohort. Data regarding baseline characteristics, sur-
gical procedures, complications and adherence to the daycare schedule are presented. 
results
210 patients were included in the retrospective cohort. 149 patients complied with the 
daycare criteria. No complications occurred that would prevent daycare surgery, or make 
it unsafe. Daycare thyroid surgery was implemented from January 2015. In one year 43 
patients underwent a hemithyroidectomy. 31 patients were eligible for daycare surgery 
of which 18 patients were treated in daycare. Failure of the daycare regimen was due to 
the patients’ own choice (n=5), large retrosternal goiter (n=2) or failure of logistics (n=6). 
Besides transient hoarseness, no complications occurred in this group. 
Conclusion
Based on a retrospective safety analysis we successfully introduced daycare thyroid 
surgery in our clinic. Hemithyroidectomy can safely be conducted in day care setting. 
However, patient selection is of vital importance to minimize the risk of complications. 
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InTroDuCTIon
A hemithyroidectomy is the most common endocrine surgical procedure performed in 
daily practice and indicated mainly due to mechanical and/or cosmetic complaints of a 
multinodular goitre or a solitary thyroid nodule. Furthermore it is performed for diag-
nostic purposes in case of indeterminate cytology. Despite the increased rate of daycare 
surgical procedures, thyroid surgery in the Netherlands is currently solely performed 
with overnight stays. It is assumed that the potential risk of life threatening respiratory 
problems caused by postoperative bleeding, laryngeal nerve injuries or hypocalcaemia 
warranting (intravenous) supplementation are reasons for which thyroid surgery is not 
performed in the daycare setting. Recently, Segel et al1. published their results regarding 
over 1000 thyroidectomies in outpatient setting. The most feared complication, acute 
postoperative haemorrhage is and potentially life-threatening airway obstruction did 
not occur. In general, the incidence of postoperative bleeding varies between 0.1 – 1.1%, 
and seldom cause acute airway problems or need for reinterventions2. In addition, la-
ryngeal nerve injury after a hemithyroidectomy is uncommon and the literature reports 
incidence rates of up to 3,7% of patients, with 0,4% permanent injuries to the laryngeal 
nerve3-7. Temporary hypocalcaemia occurred in about 3% of the outpatient patients 
treated in the study of Segel1. Wound infections occur in less than 1% of the patients, 
but is a late complication and poses no threat in the daycare setting4,6. 
Worldwide, the number of outpatient thyroidectomies has increased by 39% over 
the last 10 years8. Technological advancements in anesthesiological care and the 
widespread introduction of minimally invasive surgical techniques have fuelled this 
trend. The first report regarding thyroid surgery in daycare setting dates back to 1986 
by Steckler9. Since then, multiple studies have shown that day care thyroid surgery is 
safe and feasible with regard to the hemithyreoidectomy and even the total or comple-
tion thyroidectomy1,2,4-7,10-13. The American Thyroid Association published a statement 
regarding outpatient thyroid surgery describing important safety criteria for selecting 
eligible patients14. 
Given all the encouraging reports it is peculiar why daycare thyroid surgery is not yet 
implemented in the Netherlands. One can only assume that the risk, albeit utterly 
small, of losing a patient due to respiratory distress caused by massive bleeding after 
discharge is the main reason. Therefore our first aim was to assess the safety of thyroid 
surgery in our institution by means of a retrospective risk analysis of all patients who 
underwent a hemithyroidectomy in a five year period from 2010 to 2014. Hereafter we 
present the initial results of implementing daycare thyroid surgery in our daily practice, 
strictly adhering to the international guidelines14. 
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meThoDS
All patients are operated in the ‘Reinier de Graaf Gasthuis’ in Delft, a non-academic 
teaching hospital in the Netherlands, by one of two dedicated endocrine surgeons (P.C.S 
and F.M.G.). The retrospective cohort (part A) consists of all consecutive patients who 
underwent a primary hemithyroidectomy between January 2010 and December 2014. 
These patients were identified by means of surgical codes from the hospital software 
system. All electronic patient charts were reviewed and baseline characteristics, medical 
history, indication for surgery, postoperative complications and hypothetical eligibility 
for daycare surgery were noted. Complications were retrieved by manually checking 
the charts in conjunction to checking our prospective database where all operations 
and complications are prospectively recorded. The data was analysed and an overall 
judgement was made regarding the safety of daycare thyroid surgery in our hospital. All 
patients in the retrospective cohort who were eligible for daycare surgery14 but received 
necessary in hospital interventions from six hours to 24 hours postoperatively are con-
sidered “daycare safety failures”. As no “daycare safety failures” occurred, we proceeded 
to part B of the study: implementation of daycare surgery. 
All patients scheduled for their first hemithyroidectomy in 2015 were included in the 
prospective cohort (part B). Baseline characteristics, medical history, indication for sur-
gery and postoperative complications were prospectively collected. All patients were 
assessed for eligibility for daycare surgery according to the criteria published by the 
American Thyroid Association14, as listed in table 1. Patients eligible for daycare surgery 
and willing to participate were discharged the same day at least six hours after skin clo-
sure with permission of the surgeon and consent from the patient. All patients received 
information about the surgical procedure, a letter addressed to the general practitioner 
and standardized discharge instructions when discharged. These instructions provided 
information regarding pain and pain medication, wound dressings and signs of infec-
tion. Patients were instructed to contact the hospital in case of, but not limited to, voice 
changes, stridor, swelling of the wound and/or problems swallowing. All patients were 
contacted by telephone one day after discharge. Two weeks after surgery all patients 
were seen at the outpatient clinic for their first post-operative check-up. Hereafter, 
patients were referred back to their treating endocrinologist.
Statistical analysis was done using IBM SPSS software (version 21). Descriptive analysis 
is performed, where categorical data are expressed as frequency with percentage and 
nominal data are expressed as mean with standard deviation. Group differences were 
analysed with the Chi-square test for categorical data, and the unpaired t-test for nomi-
nal data. Significant differences are defined as p < 0.05. 
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reSulTS
retrospective analysis
A total of 210 patients were included in our retrospective risk analysis cohort, of which 
149 patients (71.0%) were eligible for daycare surgery. Baseline characteristics and 
complication rates are summarized in table 2. Patients eligible for day care surgery were 
significantly younger (48 vs 55 years, p=0.001) and had lower ASA-classifications. The 
overall complication rate is 4.4% and in the hypothetical daycare group this was 2,0%. 
Five patients experienced transient hoarseness or vocal changes, one developed an 
anaphylactic reaction of unknown aetiology, and one patient experienced recurrence 
of a spontaneous tachycardia for which she required medical treatment. In the group 
not eligible for daycare surgery, one patient required a re-operation due to a wound 
infection (0.5%) and one postoperative hematoma occurred (0.5%), which was managed 
conservatively. There were no complications in the “eligible daycare group” comprising 
patients safety in the hypothetical outpatient setting.
Table 1a. Eligibility criteria for outpatient thyroidectomy14 
No major comorbidities or ASA 4
Provision and understanding of preoperative education
Team approach to education and clinical care
Primary care giver willing and available
Social setting conductive to safe postoperative management
Proximity to skilled facility
Table 1b. Relative contra-indications to outpatient thyroidectomy14 
Clinical Social Procedure
Uncompensated cardiac or 
respiratory disease
Dialysis for renal failure
Anticoagulant or antiplatelet 
therapy
Seizure disorder
Anxiety disorder
Obstructive sleep apnea
Hearing loss
Visual impairment
Mental impairment
Pregnancy
Excessive distance from skilled 
facility
Living alone with no person to 
accompany
Lack of transportation
Patient preference
Communication barriers
Massive goiter
Extensive substernal goiter
Locally advanced cancer
Challenging hemostasis
Difficult thyroidectomy with Hashimoto’s 
thyroiditis or Graves disease
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Since this retrospective analysis showed low complication rates, we concluded that a 
hemithyroidectomy can be performed safely in a day care setting in our institution, and 
proceeded to implement this new strategy (part B). 
In 2015 a total of 43 patients underwent a primary hemithyroidectomy and were 
included in the prospective cohort. A total of 31 (72%) patients met the international 
guidelines for daycare thyroid surgery published by The American Thyroid Association, 
of which 58% (n=18) was eventually treated by means of daycare surgery. Twenty-five 
(58%) patients stayed overnight after surgery. A flowchart of patients undergoing 
hemithyroidectomy is illustrated in figure 1. Baseline characteristics and complication 
rates for the prospective cohort are summarised in table 3. The daycare group was 
younger than the clinical group (median 50 resp. 61 years). Indication for surgery in the 
daycare group was mechanical complaints in 89% and suspected malignancy in 11%, 
in the clinical group the indication was mechanical complaints in 56% and suspected 
malignancy in 32%.
There were two minor complications (transient vocal changes, n=2) in the clinical group 
and there was 1 minor complication (transient vocal change) in the daycare group. There 
were no emergency department visits or readmissions following surgery. There were no 
wound infections, hematoma’s or laryngeal nerve damage. 
Thirteen patients (30%) were eligible for daycare surgery, but were not treated as such. 
Five patients (12%) chose to stay overnight, two patients had a retrosternal goiter which 
was larger than anticipated, and in the remaining six (14%) patients our logistics failed 
for example as these patients were scheduled for surgery late in the afternoon.
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figure 1. Flowchart
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DISCuSSIon
The retrospective analysis shows that daycare surgery could be safely implemented in 
our institution. Thereafter, daycare thyroid surgery was implemented and 58% of the 
eligible patients were treated as such. This is the first cohort in the Netherlands where 
thyroid surgery is performed in the daycare setting. Patient safety is of paramount 
importance when installing a new regimen. Only one patient in the daycare group ex-
perienced a complication, namely temporary hoarseness. No postoperative hematomas 
necessitating urgent interventions occurred. However, even though daycare thyroid 
surgery was already reported in 19869, it remains an delicate topic as airway compro-
mise due to hematoma formation is a feared complication. This complication did not 
occur in both our retrospective and prospective cohort. We do have to acknowledge 
the fact that our low number of patients if prone to be biased with respect to complica-
tion rates. In the literature, Snyder et al7 has published the largest series of outpatient 
thyroidectomies, with over 1000 procedures in their cohort. Postoperative hematoma 
requiring re-operation was present in only one patient undergoing hemithyroidectomy. 
Table 3. baseline characteristics day care cohort
Daycare setting Clinical setting P
N 18 25
Age in years (median + range) 50 (14,86) 61 (16,37) 0,036
Female sex (percentage ) 14 (78%) 21 (84%) 0,303
ASA score ASA 1 – 6 (33%)
ASA 2 – 10 (56%)
ASA 3 – 2 (11%)
ASA 1 – 10 (40%)
ASA 2 – 13 (52%)
ASA 3 – 2 (18%)
0,440
Indication for surgery Mechanical complaints – 16 (89%)
Suspected malignancy – 2 (11%)
Other reasons - 0
Mechanical complaints - 14 (56%)
Suspected malignancy – 8 (32%)
Other reasons – 3 (12%)
0,029
Type of operation LHT – 7 (38%)
RHT – 11 (61%)
LHT – 10 (40)
RHT – 15 (60%)
0,471
Total complication 1 (5,6%) 2 (8,0%) 0,378
Transient hoarseness or vocal 
changes
1 (5,6%) 2 (8,0%)
Rebleed 0 (0,0%) 0 (0,0%)
Wound infection 0 (0,0%) 0 (0,0%)
Meet daycare criteria n.a. 13 (52%)
Values displayed as N + percentage unless stated otherwise
LHT = left hemithyroidectomy
RHT = right hemithyroidectomy
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31 patients met the international guidelines for daycare thyroid surgery, however only 
18 were treated in daycare surgery. In 6 patients our own logistics failed, so this is a 
major item to improve with this new strategy. Furthermore, it is important to interview 
patients to determine factors for which they chose to stay overnight, after which preop-
erative information can be adapted to address this factors. 
Patients expressed their satisfaction when contacted by telephone on the next day, 
however no objective measurement of patient satisfaction was performed. Measure-
ment and documentation of patient satisfaction is important to improve patient selec-
tion and improve pre-operative information.
Despite the logistical hurdles and the low number of patients in this study, we advocate 
the introduction of daycare thyroid surgery in the Netherlands. 
However, although complications rates are supposedly very low, it is important to stay 
vigilant and carefully select patients suitable for day care surgery adhering to interna-
tional guidelines.
ConCluSIon 
Hemithyroidectomy performed in day care is feasible and safe with low complication 
rates provided that adequate patient selection is performed. 
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abSTraCT
background
Physical and mental complaints are common in patients with primary hyperparathy-
roidism (PHPT) and negatively impact quality of life. Subjective symptoms in current 
guidelines are not considered an indication for surgery. The aim of this study was to 
assess the effect of parathyroidectomy on quality of life (QoL) in patients with PHPT. 
methods
This multicentre case-control study investigated preoperative and postoperative QoL 
scores in patients operated for PHPT, measured with the SF-36 questionnaire. Results 
were compared with patients undergoing an hemithyroidectomy, the control group. 
results
Fifty-two patients and 49 controls were included. PHPT patients had significantly lower 
QoL scores preoperatively and improved significantly after successful surgical treat-
ment. Postoperatively, no differences were observed between the two groups. 
Conclusion
QoL was significantly lower in patients with untreated PHPT. Surgical treatment was 
associated with a significant increase in QOL. Decreased QoL should also be considered 
as an indicator for surgical treatment in patients with PHPT. 
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InTroDuCTIon
Primary hyperparathyroidism (PHPT) is caused by overproduction of parathyroid 
hormone (PTH) leading to hypercalcaemia. In 85-95%1 of the cases PHPT is caused by 
a single parathyroid adenoma. Serum calcium levels are increased through enhanced 
bone resorption, increased intestinal calcium absorption and decreased urinary excre-
tion2. Classical symptoms are often referred to as “bones, stones, abdominal moans 
and psychic groans”. Osteopenia/osteoporosis, nephrolithiasis, constipation, anorexia, 
nausea and fatigue are among the most common symptoms. However, mental symp-
toms can also be present, including disorientation, confusion, mood swings, inability to 
concentrate and memory problems.
Surgical removal of hyper functioning gland(s) is the only curative option for patients 
with PHPT. Current indications for treatment are documented in a consensus statement 
of the National Institutes of Health (2009) and include different parameters e.g. osteopo-
rosis, serum calcium levels, high calcium excretion in urine and kidney stones3. Impaired 
mental functioning is not considered to be an indication for surgery in these treatment 
guidelines. 
Several recent nonrandomized, longitudinal studies have focussed on the effect of treat-
ment of PHPT on QoL. These studies suggested that hyperparathyroidism is associated 
with impaired QoL, which is indeed restored after surgery, both short-4 and long term5-8 
after the parathyroidectomy. One small study did not show a positive effect of surgery 
on quality of life, however an unvalidated measure of QoL was used9. Two randomized 
trials10,11 comparing surgery with observation in PHPT patients showed improved quality 
of life scores after surgery. The workshop on the Management of “Asymptomatic Primary 
Hyperparathyroidism” in 2009 also addressed neurocognitive domains in patients with 
PHPT. It identified a number of categories for further investigation, i.e. prospective 
cohort studies with emphasis on neurocognitive functioning and impact of parathy-
roidectomy on quality of life3. 
The aforementioned studies10-13 compared patients who were surgically treated for PHPT 
with patients who were only observed. Although these studies are important indicators 
of the presumed beneficial effects of parathyroidectomy on QoL in PHPT patients, a 
control group that is subject to a neck operation is mandatory. We therefore included a 
control group undergoing an almost similar surgical procedure to minimize the possible 
placebo effect induced by surgery. Euthyroid patients scheduled for diagnostic hemithy-
roidectomy were included as control group. The aim of this study was to investigate 
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whether surgery for primary hyperparathyroidism improves QoL as measured by means 
of the SF-3614 and a symptom questionnaire.
meThoDS
This is a prospective multicentre case-controlled trial. Cases were defined as patients 
with biochemically proven primary hyperparathyroidism scheduled for surgery, ac-
cording to the criteria of the 2002 NIH meeting15. Patients underwent either a targeted 
approach by means of one small incision (including unilateral explorations) or a conven-
tional four gland exploration on both sides. Controls were euthyroid patients scheduled 
for open hemithyroidectomy because of benign disease. Exclusion criteria were: pre- or 
postoperative diagnosis of malignant disease, secondary or tertiary hyperparathyroid-
ism, primary hyperparathyroidism in multiple endocrine neoplasia (MEN-syndrome) pa-
tients, hyper- or hypothyroidism, lithium therapy, inability to give informed consent and 
age < 18 years. Patients were recruited from April 2007 until December 2010. All patients 
were followed for one year. Patients were recruited from two academic hospitals and 
two peripheral hospitals. However, the majority was recruited from one academic center 
and one peripheral center. Logistical difficulties led to early cessation of inclusions in 
the second academic hospital. The second peripheral hospital joined the study later and 
included 7 consecutive patients after which the study was completed. Figure 1 outlines 
the study flow chart. The Medical Ethical committee approved this study protocol.
General data such as gender, age, blood values, preoperative diagnosis, postoperative 
pathology results and follow-up laboratory results were obtained from medical records. 
Quality of Life was measured using the validated SF-36 questionnaire16. The Short-Form 
36 (SF-36) questionnaire is a validated instrument for the measurement of QoL. It mea-
sures both physical and mental functioning16, and it’s widespread use renders it useful 
to compare different studies. 5-7,10,11,17-22 It is composed of 36 questions and standard-
ized response choices, organized in eight dimensions of health related quality of life. It 
generates scores for physical functioning, bodily pain, role limitations due to physical 
problems (role physical), general health, vitality, social functioning, role limitations due 
to emotional problems (role emotional) and mental health. From these scales, 2 sum-
mary measures can be obtained, physical health and mental health. 
In addition patients were asked about physical complaints possibly related to primary 
hyperparathyroidism (table 2). We designed a custom-made “symptom questionnaire” 
including 17 symptoms related to primary hyperparathyroidism. These are all symptoms 
that are associated with primary hyperparathyroidism. Patients could indicate if they did 
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not experience that symptom (1), experienced this sometimes (2) or experienced this 
often (3). This is not summarized in a separate score. All questionnaires were completed 
pre-operatively and 3 and 12 months post-operatively. 
Statistical analysis was performed using IBM SPSS statistics 21 software. The SF-36 data 
was normalized for the Dutch population. With this transformation, the Dutch popula-
tion has a mean of 50 and a standard deviation of 10, and higher scores represent more 
favourable quality of life. The Mann-Whitney U test was used for analysing differences 
between the two groups. A general linear model was used in order to compare means 
of the SF36 (sub)scores, adjusted for age. The Wilcoxon signed ranks test was used for 
the differences between time points. The symptom questionnaire was analysed using 
respectively the chi-squared and McNemar test for the group and time point differences. 
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Assessed for eligibility PHPT    
(n= 128) 
AC 1 = 4 
AC 2 = 80 
PH 1 = 44 
PH 2 = 0 
Excluded  (n= 240 )
♦Not meeting inclusion criteria (n = 160) 
 AC2 = 84. PH1 = 76 . 
♦Declined to participate (n = 1) 
 AC2 = 0. PH1 = 1. 
♦Eligible but not approached (n = 79) 
 AC2 = 13. PH1 = 66.  
Total inclusion (n = 52) 
AC 1 = 4 
AC 2 = 29 
PH 1 = 19 
PH 2 = 0
Total inclusion (n = 49) 
AC 1 = 2 
AC 2 = 9 
PH 1 = 31 
PH 2 = 7
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Excluded  (n=76 )
♦Not meeting inclusion criteria (n=41) 
 AC2 = 33. PH1 = 8. 
♦Declined to participate (n=2) 
 AC2 = 0. PH1 = 2. 
♦Eligible but not approached (n=33) 
 AC2 = 18. PH1 = 15.  
Assessed for eligibility Thyroid
(n= 289) 
AC 1 = 2 
AC 2 = 106 
PH 1 = 174 
PH 2 = 7 
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figure 1. Flow diagram
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reSulTS
We included 101 patients according to the inclusion and exclusion criteria, fifty two 
cases (“PHPT”) and 49 controls (“thyroid”) (figure 1). PHPT patients were significantly 
older, with a mean difference of 6 years (58 vs 52, p=0.026). Gender distribution was 
equal between both groups. 
The response rates for the SF-36 questionnaire were 96.2% and 88.5% at 3 and 12 month 
assessments respectively for the PHPT group. The thyroid group had response rates 
89.8% and 89.8% at 3 and 12 months respectively. The rates for the symptom question-
naire were 88,5% and 82,7% for the PHPT group, and 87.7% and 87.5% for the thyroid 
group at 3 and 12 months respectively.
Overall complication rate was low. In the PHPT group one patient had persisting disease 
and 4 patients experienced transient vocal change. In the thyroid group one patient 
had a haemorrhage requiring reoperation, and one patient had a transient neurological 
event. 
All PHPT patients had elevated preoperative serum calcium levels (2.75 (2.68-2.87) 
mmol/L), which normalized after surgery (Table 1). Control thyroid patients underwent 
surgery for benign disease, either goitre or nodular disease. All patients had normal 
levels of serum thyroid stimulating hormone, free thyroxin and calcium.
Quality of life was measured with the SF-36 questionnaire. Preoperatively, PHPT patients 
had significantly lower results in the role physical and general health domain(Table 3). 
The median physical component score was significantly lower preoperatively in the 
PHPT group compared to the thyroid group (42.24 vs. 46.65, p < 0.05). Three and twelve 
months after surgery these differences had disappeared (Table 3). Significant improve-
ments on all domains were observed in the pHPT group within three months after 
surgery (Table 4a). Thereafter quality of life remained unchanged. For thyroid patients, 
almost no changes in quality of life occur after the surgical procedure. Only the mental 
health domain improved significantly within the first three months postoperatively 
(Table 4b).
Prior to surgery the PHPT group revealed significantly more complaints about dyspepsia, 
polydipsia and polyuria in the symptom questionnaire compared to the thyroid group 
(Table 2). Three months after surgery these differences disappeared, however PHPT 
patients complained significantly more often about nycturia. One year after surgery no 
significant differences in complaints between the groups were present. 
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Focussing on the within-group changes of the PHPT group the symptom questionnaire 
shows that three and twelve months after surgery patients in the PHPT group had 
significantly fewer complaints of fatigue, muscle aches and nycturia (figure 2). At three 
months there were fewer complaints about dyspepsia, polyuria and nausea, however 
this difference does not last at 12 months. 
In total, 87% of PHPT patients underwent a targeted surgical procedure (35% minimally 
invasive parathyroidectomy (MIP), 52% unilateral exploration). Bilateral four gland ex-
ploration was performed in 11% of the cases and a hemithyroidectomy in 2%. Both the 
median domain scores and the median physical component, mental component and 
overall SF-36 score did not differ between the 2 groups (MIP vs other procedures). 
Table 1. baseline characteristics
PHPT Thyroid P value °
Patients 52 49
age (years) 58 (50-68) 52 (43-63) 0.03*
male frequency (percent) 17 (32%) 13 (27%) NS†
marital status (percentage married) 32 (61.5%) 30 (61.2%) NS†
education level1 (percentage lower education) 19 (36.5%) 18 (36.7%) NS†
Pre-operative
Calcium (mmol/l) 2.75 (2.68-2.87) 2.38 (2.36-2.43) 0.00*
Phosphate (mmol/l) 0.87 (0.70-0.97) -
PTh (pmol/l) 13.90 (8.6-27.1) -
albumin (g/l) 44.50 (40.25-47.75) -
3 months postoperative
Calcium (mmol/l) 2.36 (2.30-2.48) 2.35 (2.31-2.43) NS
Phosphate (mmol/l) 0.96 (0.89-1.07) -
PTh (pmol/l) 7.80 (4.14-11.1) -
albumin (g/l) 44.00 (40.00-46.00) -
12 months postoperative
Calcium (mmol/l) 2.38 (2.29-2.47) 2.31 (2.22-2.39) NS
Phosphate (mmol/l) 0.97 (0.86-1.09) -
PTh (pmol/l) 7.10 (4.30-9.40) -
albumin (g/l) 43.00 (40.00-45.75) -
PHPT, primary hyperparathyroidism; PTH, parathyroid hormone. 
Values displayed as median (p25-p75), unless stated otherwise. 
°The Mann-Whitney U test † Chi-squared test 
* p < 0.05
NS: not significant
Reference values: Calcium: 2.20-2.65 mmol/L, Phosphate: 0.8-1.4 mmol/L, PTH: 1.4-7.3 pmol/L, Albumin: 
35-50 g/L.
1Basic education: primary school or basis levels of high school
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Table 2. Symptom Questionnaire, PHPT compared with controls preoperatively and 3 and 12 months post-
operatively.
Category^
Pre-operative 3 months postoperative 12 months postoperative
PHPT Thyroid p† PHPT Thyroid p† PHPT Thyroid p†
fatigue 1 8 (15,4) 13 (26.5)
NS
17 (37.0) 12 (27.9)
NS
21 (50.0) 12 (27.9)
NS2 15 (28.8) 15 (30.6) 23 (50.0) 17 (39.5) 15 (35.7) 17 (39.5)
3 29 (55.8) 21 (42.9) 6 (13.0) 14 (32.6) 6 (14.3) 14 (32.6)
muscle ache 1 20 (38.5) 24 (49.0)
NS
27 (57.4) 22 (51.2)
NS
23 (52.3) 20 (46.5)
NS2 20 (38.5) 19 (38.8) 16 (34.0) 12 (27.9) 16 (36.4) 14 (32.6)
3 12 (23.1) 6 (12.2) 4 (8.5) 9 (20.9) 5 (11.4) 9 (20.9)
back pain 1 26 (50.0) 22 (44.9)
NS
26 (53.1) 24 (55.8)
NS
26 (60.5) 24 (55.8)
NS2 17 (32.7) 13 (26.5) 16 (32.7) 10 (23.3) 12 (27.9) 8 (18.6)
3 9 (17.3) 14 (28.6) 7 (14.3) 9 (20.9) 5 (11.6) 11 (25.6)
Weakness 1 23 (45.1) 23 (46.9)
NS
26 (56.5) 22 (51.2)
NS
25 (61.0) 23 (53.5)
NS2 19 (37.3) 18 (36.7) 17 (37.0) 15 (34.9) 14 (34.1) 15 (34.9)
3 9 (17.6) 8 (16.3) 3 (6.5) 6 (14.0) 2 (4.9) 5 (11.6)
Dyspepsia 1 32 (61.5) 41 (83.7)
0.04*
41 (83.7) 34 (81.0)
NS
29 (65.9) 32 (74.4)
NS2 15 (28.8) 7 (14.3) 7 (14.3) 6 (14.3) 14 (31.8) 7 (16.3)
3 5 (9.6) 1 (2.0) 1 (2.0) 2 (4.8) 1 (2.3) 4 (9.3)
Polydipsia 1 26 (51.0) 36 (75.0)
0.05*
33 (68.8) 34 (79.1)
NS
29 (65.9) 35 (81.4)
NS2 18 (35.3) 9 (18.8) 12 (25.0) 5 (11.6) 12 (27.3) 6 (14.0)
3 7 (13.7) 3 (6.3) 3 (6.3) 4 (9.3) 3 (6.8) 2 (4.7)
Constipation 1 32 (65.3) 36 (75.0)
NS
41 (85.4) 29 (72.5)
NS
34 (79.1) 30 (69.8)
NS2 10 (20.4) 8 (16.7) 5 (10.4) 7 (17.5) 8 (18.6) 9 (20.9)
3 7 (14.3) 4 (8.3) 2 (4.2) 4 (10) 1 (2.3) 4 (9.3)
Polyuria 1 23 (45.1) 36 (73.5)
0.01*
33 (67.3) 34 (79.1)
NS
30 (68.2) 33 (76.7)
NS2 20 (39.2) 7 (14.3) 12 (24.5) 5 (11.6) 12 (27.3) 7 (16.3)
3 8 (15.7) 6 (12.2) 4 (8.2) 4 (9.3) 2 (4.5) 3 (7.0)
nycturia 1 23 (44.2) 32 (65.3)
NS
31 (63.3) 35 (81.4)
0.02*
29 (65.9) 28 (65.1) 
NS2 23 (44.2) 12 (24.5) 15 (30.6) 3 (7.0) 14 (31.8) 12 (27.9)
3 6 (11.5) 5 (10.2) 3 (6.1) 5 (11.6) 1 (2.3) 3 (7.0)
anorexia 1 40 (76.9) 35 (71.4)
NS
46 (93.9) 35 (81.4)
NS
41 (93.2) 35 (81.4)
NS2 10 (19.2) 14 (28.6) 2 (4.1) 7 (16.3) 2 (4.6) 7 (16.3)
3 2 (3.8) 0 (0.0) 1 (2.0) 1 (2.3) 1 (2.3) 1 (2.3)
Itch 1 42 (80.8) 39 (79.6)
NS
39 (81.3) 33 (76.7)
NS
33 (76.7) 31 (72.1)
NS2 7 (13.5) 7 (14.3) 7 (14.6) 7 (16.3) 8 (18.6) 9 (20.9)
3 3 (5.8) 3 (6.1) 2 (4.2) 3 (7.0) 2 (4.7) 3 (7.0)
nausea 1 37 (71.2) 40 (81.6)
NS
41 (83.7) 33 (76.7)
NS
38 (86.4) 36 (83.7)
NS2 10 (19.2) 7 (14.3) 7 (14.3) 7 (16.3) 6 (13.6) 6 (14.0)
3 5 (9.6) 2 (4.1) 1 (2.0) 3 (7.0) 0 (0.0) 1 (2.3)
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Table 2. Symptom Questionnaire, PHPT compared with controls preoperatively and 3 and 12 months post-
operatively. (continued)
Category^
Pre-operative 3 months postoperative 12 months postoperative
PHPT Thyroid p† PHPT Thyroid p† PHPT Thyroid p†
Depression 1 26 (51.0) 30 (61.3)
NS
34 (69.4) 26 (60.5)
NS
24 (55.8) 27 (62.8)
NS2 19 (37.3) 14 (28.6) 12 (24.5) 11 (25.6) 15 (34.9) 13 (30.2)
3 6 (11.8) 5 (10.2) 3 (6.1) 6 (14.0) 4 (9.3) 3 (7.0)
amnesia 1 23 (44.2) 28 (57.1)
NS
28 (58.3) 25 (58.1)
NS
27 (61.4) 26 (61.9)
NS2 21 (40.4) 16 (32.7) 16 (33.3) 16 (37.2) 13 (29.5) 12 (28.6)
3 8 (15.4) 5 (10.2) 4 (8.3) 2 (4.7) 4 (9.1( 4 (9.5)
Weight loss 1 38 (73.1) 42 (87.5)
NS
43 (87.8) 38 (88.4)
NS
37 (84.1) 39 (90.7)
NS2 11 (21.2) 5 (10.4) 4 (8.2) 4 (9.3) 6 (13.6) 4 (9.3)
3 3 (5.8) 1 (2.1) 2 (4.1) 1 (2.3) 1 (2.3) 0 (0.0)
bruises 1 44 (86.3) 43 (87.8)
NS
43 (87.8) 39 (90.7)
NS
38 (90.5) 37 (86.0)
NS2 6 (11.8) 4 (8.2) 4 (8.2) 3 (7.0) 4 (9.5) 4 (9.3)
3 1 (2.0) 2 (4.1) 2 (4.1) 1 (2.3) 0 (0.0) 2 (4.7)
hematuria 1 47 (92.2) 48 (98.0)
NS
47 (97.9) 42 (97.7)
NS
42 (97.7) 43 (100.0)
NS2 4 (7.8) 1 (2.0) 1 (2.1) 1 (2.3) 1 (2.3) 0 (0.0)
3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PHPT, primary hyperparathyroidism; † chi-squared test;* p < 0.05
^ 1= no complaints, 2= sometimes, 3= often Data presented as frequency (percentage)
Table 3. Mean SF-36 outcomes, comparing PHPT and Thyroid patients, both before and after surgery and 
adjusted for age
Pre-operative 3 months 12 months
PHPT Thyroid p† PHPT Thyroid p† PHPT Thyroid p†
Pf 43.12 (1.54) 46.05 (1.58) 0.19 46.71 (1.45) 48.24 (1.56) 0.48 46.92 (1.63) 46.69 (1.67) 0.92
rP 38.93 (1.80) 44.26 (1.85) 0.04* 45.80 (1.83) 45.14 (1.93) 0.81 46.24 (1.83) 45.67 (1.87) 0.83
bP 46.28 (1.61) 49.12 (1.66) 0.23 48.54 (1.64) 48.98 (1.75) 0.86 48.83 (1.79) 47.33 (1.83) 0.56
Gh 41.86 (1.37) 46.51 (1.42) 0.02* 44.61 (1.53) 46.83 (1.61) 0.32 45.77 (1.74) 46.39 (1.82) 0.81
VIT 45.38 (1.60) 48.13 (1.63) 0.24 50.46 (1.53) 48.93 (1.63) 0.50 50.27 (1.63) 49.28 (1.65) 0.68
Sf 42.79 (1.58) 45.74 (1.62) 0.20 47.09 (1.61) 46.24 (1.71) 0.72 47.47 (1.57) 47.23 (1.63) 0.92
re 44.05 (1.80) 46.39 (1.88) 0.38 48.93 (1.60) 47.73 (1.70) 0.61 47.57 (1.68) 48.70 (1.70) 0.64
mh 46.51 (1.64) 46.03 (1.68) 0.84 49.97 (1.61) 49.00 (1.72) 0.68 49.10 (1.71) 49.86 (1.73) 0.76
PSC 42.24 (1.56) 46.65 (1.59) 0.05* 45.58 (1.46) 47.47 (1.56) 0.39 46.23 (1.72) 45.75 (1.74) 0.85
mCS 47.31 (1.50) 47.21 (1.53) 0.96 51.34 (1.43) 49.39 (1.53) 0.36 50.59 (1.34) 50.09 (1.36) 0.80
Data are presented as marginal mean (SD). 
PHPT = Primary Hyperparathyroidism
PF = Physical functioning; RP = Role-Physical; BP = Bodily Pain; GH = General Health; VT = Vitality; SF = Social 
Functioning; RE = Role-Emotional; MH = Mental Health; PCS = Physical Component Score; MCS = Mental 
Component Score
† F-test for comparing marginal means using a General linear model
* p < 0.05
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Table 4a. Median SF-36 outcomes in PHPT patients preoperatively, 3 months and 12 months postopera-
tively
Pre-operative 3 months 12 months p† 0-3 p† 0-12 p† 3-12
Pf 45.84 (34.92 - 51.85) 49.80 (41.47 - 54.58) 49.12 (41.47-56.76) 0.001* 0.01* 0.893
rP 33.37 (25.97 -55.56) 55.56 (33.37-55.56) 48.17 (33.37-55.56) 0.000* 0.002* 0.967
bP 44.27 (35.57-60.40) 49.38 (40.03-60.40) 49.37 (39.61-60.40) 0.02* 0.02* 0.707
Gh 39.98 (35.27-49.89) 44.94 (34.77-52.37) 44.94 (35.02-54.85) 0.04* 0.04* 0.245
VT 44.71 (39.91 - 54.29) 51.89 (42.31-59.08) 51.89 (41.11-56.68) 0.001* 0.000* 0.650
Sf 40.57 (34.99 - 51.74) 51.74 (40.57-57.33) 51.74 (40.57-57.33) 0.01* 0.01* 0.772
re 45.57 (30.44 - 55.66) 55.66 (45.57-55.66) 55.66 (35.48-55.66) 0.01* 0.08 0.383
mh 50.64 (37.32 -55.09) 52.87 (41.76-59.53) 50.64 (41.76-57.31) 0.01* 0.03* 0.553
PCS 42.29 (33.91 - 50.91) 47.20 (38.21-53.51) 45.31 (38.96-55.74) 0.01* 0.002* 0.476
mCS 49.15 (38.35 - 55.33) 54.59 (44.04-58.40) 52.22 (41.30-57.68) 0.002* 0.01* 0.064
Data are presented as median (p25-75). 
PHPT = Primary Hyperparathyroidism
PF = Physical functioning; RP = Role-Physical; BP = Bodily Pain; GH = General Health; VT = Vitality; SF = Social 
Functioning; RE = Role-Emotional; MH = Mental Health; PCS = Physical Component Score; MCS = Mental 
Component Score
* p < 0.05
† Wilcoxon Signed ranks test 
SF-36 scores on the different time points were compared. Pre-operative vs. 3 months, pre-operative vs. 12 
months and 3 months vs. 12 months.
Table 4b. Median SF-36 outcomes in thyroid patients preoperatively, 3 months and 12 months postop-
eratively
Pre-operative 3 months 12 months p† 0-3 p† 0-12 p† 3-12
Pf 50.21 (37.10 - 56.76) 51.03 (47.75 - 56.76) 52.39 (41.47-56.76) 0.09 0.16 0.262
rP 48.17 (25.97-55.56) 55.56 (25.97-55.56) 55.56 (33.37-55.56) 0.78 0.58 0.703
bP 53.61 (35.57-60.40) 51.91 (41.09-60.40) 49.37 (35.36-60.40) 0.82 0.19 0.056
Gh 47.41 (39.98-52.37) 47.42 (39.98-54.23) 47.42 (41.59-55.47) 0.52 0.97 0.400
VT 51.89 (37.51-55.49) 49.50 (42.31-54.29) 51.89 (39.91-59.08) 0.33 0.64 0.578
Sf 46.16 (37.78 - 57.33) 51.74 (34.99-57.33) 51.74 (40.57-57.33) 0.42 0.72 0.864
re 55.66 (35.48 - 55.66) 55.66 (35.48-55.66) 55.66 (45.57-55.66) 0.32 0.34 0.904
mh 48.42 (35.10 - 55.09) 52.87 (39.54-57.31) 50.64 (39.54-59.53) 0.002* 0.03* 0.756
PCS 50.62 (39.54 - 55.10) 49.31 (41.78-55.83) 49.45 (34.72-56.39) 0.63 0.62 0.334
mCS 49.51 (37.24 - 56.28) 53.33 (41.95-60.48) 53.65 (40.72-57.16) 0.05* 0.06 0.883
Data are presented as median (p25-75). 
PF = Physical functioning; RP = Role-Physical; BP = Bodily Pain; GH = General Health; VT = Vitality; SF = Social 
Functioning; RE = Role-Emotional; MH = Mental Health; PCS = Physical Component Score; MCS = Mental 
Component Score
* p < 0.05
† Wilcoxon signed ranks test 
SF-36 scores on the different time points were compared. Pre-operative vs. 3 months, pre-operative vs. 12 
months and 3 months vs. 12 months.
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DISCuSSIon
This study investigated quality of life in patients undergoing parathyroidectomy for 
primary hyperparathyroidism compared to patients undergoing thyroid surgery. These 
results demonstrated a low preoperative QoL compared to the control group and a 
significant increase in QoL after parathyroidectomy to comparable levels as the control 
patients. 
PHPT patients complained significantly more often about nycturia 3 months after sur-
gery. This is probably a coincidental finding, as no medical explanation exists.
Four studies included PHPT patients and a control group consisting of patients with 
thyroid disease. First, in the study of Eigelberger et al.23 202 cases and 63 controls were 
included. They found that patients in both parathyroid groups (those who met or did 
not meet the NIH criteria for parathyroidectomy) benefited from successful parathyroid-
ectomy. Unfortunately, no quality of life analysis was performed. 
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figure 2. Changes in reported symptoms regarding PHPT. The first bar per symptom represents the preop-
erative score, the second the three month score and the third the one year score.
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Recently Weber et al.22 described a large multicentre case-control study with 194 PHPT 
patients and 186 controls. Quality of life was evaluated using the SF-36 questionnaire and 
reported as physical and mental component scores. The authors reported significantly 
lower pre-operative SF-36 scores, on both components, in PHPT patients compared to 
the thyroid controls, in line with the results of the present study. In addition, they de-
scribed a similar increase in quality of life after parathyroidectomy, which seemed to be 
sustained over a period of one year. However, 57% of the control patients underwent a 
total thyroidectomy leading to life-long thyroid hormone supplementation and a risk for 
alterations in neuropsychological symptoms. This is not addressed in the study results. 
Kahal et al.24 described a smaller series of 24 PHPT patients and 23 controls undergoing 
diagnostic hemithyroidectomy for benign thyroid nodules. They used the Hospital Anxi-
ety and Depression scale (HAD) and the Mood Rating Scale (MRS)measuring symptoms 
pre-operatively and 3 months after surgery. They reported that parathyroidectomy was 
associated with improved symptoms, as measured by the HAD and the MRS. Follow-up 
in this study was only three months and therefore no conclusions on long-term effect 
could be drawn. Furthermore, all patients were subjected to a four gland exploration, 
which could be associated with less improvement in quality of life19. Nowadays, the 
targeted approach by means of small incisions is used more frequently. In our study only 
11% of the cases were operated by means of a bilateral neck exploration. Although this 
group is too small for further subgroup analysis, we assume that the influence on the 
overall results is limited. However, the impact of type of surgery remains an interesting 
point for future studies.
In addition, Roman et al.4 described a series of 27 PHPT patients and 28 controls. They 
used the Beck Depression Inventory and Spielberger State-Trait Anxiety Inventory as-
sessing depression and anxiety, and the Rey Auditory Verbal Learning Test and Groton 
Maze Learning Test evaluating cognitive function. They found that PHPT was associated 
with higher depression scores and greater problems in spatial learning, relative to the 
control group, and that these outcomes improved after parathyroidectomy. No data 
regarding QoL were reported.
This study provides additional information regarding the effect of parathyroidectomy 
on quality of life in PHPT patients. We were able to achieve high response rates (almost 
90%) during follow-up of one year after surgery. Furthermore we included only euthy-
roid patients undergoing hemithyroidectomy for benign disorders as controls. 
There are some limitations that need to be mentioned as well. The median age of the 
cases was higher than the median age of the controls. We have adjusted the analysis for 
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this difference. Marital status and educational level was comparable between the two 
groups. Information about other possible covariates is not available. 
Our study is a non-randomized study. We used a non-validated symptom questionnaire 
to assess the complaints related to hyperparathyroid disease. A validated thyroid-
specific questionnaire is not available. The SF-36 gives us information about QoL, but 
does not give us information on cognitive functioning or other sequelae. In addition, we 
acknowledge the fact that no correction for multiple comparisons was made, increasing 
the risk for type 1 errors. Due to our difficulties with the accrual of patients, we missed a 
large group of potential subjects, with a risk of selection bias. We evaluated the baseline 
characteristics of the missed subjects and compared them with the included group. 
They were comparable by means of age and gender. Furthermore it would have been 
interesting to address other factors such as long term risk of fractures, nephrolithiasis 
and recurrence. Our study size was too small to analyse these outcomes and larger trials 
are needed to assess these long term effects of parathyroidectomy in pHPT patients.
ConCluSIon
This study evaluates quality of life in patients with primary hyperparathyroidism using 
the SF-36 questionnaire before and after surgery. Regarding role physical domain, 
general health domain and the physical component score, quality of life in patients 
with PHPT was significantly lower preoperatively compared with patients undergoing 
thyroid surgery. After surgery for PHPT, quality of life increased on all domains, and was 
comparable to that of control patients. Our findings suggest that patients with PHPT, if 
fit for surgery, might benefit from surgical treatment and might be considered candidate 
for surgical treatment, even if they do not meet the current NIH criteria. Quality of life 
should be considered in adjunct to the NIH criteria.
acknowledgements
The authors would like to thank the WAC committee of the RdGG hospital Delft for their 
financial support.
56 Chapter 4
referenCeS
 1. Ruda JM HC, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyper-
parathyroidism from 1995 to 2003. Otolaryngology - Head and Neck Surgery 2005;132:359-72.
 2. EM B. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and 
other ions as extracellular (first) messengers. Physiological reviews 1991;71:371-411.
 3. Bilezikian JP KA, Potts JT. Guidelines for the Management of Asymptomatic Primary Hyper-
parathyroidism: Summary Statement from the Third International Workshop. Journal of Clinical 
Endocrinology and Metabolism 2009;94:335-9.
 4. Roman SA SJ, Mayes L, Desmond E et al. Parathyroidectomy improves neurocognitive deficits in 
patients with primary hyperparathyroidism. Surgery 2005;138:1121-9.
 5. Sheldon DG LF, Neil NJ, Ryan JA jr. Surgical treatment of hyperparathyroidism improves health-
related quality of life. Archives of Surgery 2002;137:1022-6.
 6. Gopinath P SG, Mihai R. Persistent symptomatic improvement in the majority of patients un-
dergoing parathyroidectomy for primary hyperparathyroidism. Langenbecks Archives of Surgery 
2010;395:941-6.
 7. Adler JT SR, Schaefer S, Chen H. Surgery improves quality of life in patients with “mild” hyperpara-
thyroidism. The American Journal of Surgery 2009;197:284-90.
 8. Venkat R KG, Tufano RP, Schneider EB, Dackiw APB, Zeiger MA. Long-term outcome in patients 
with primary hyperparathyroidism who underwent minimally invasive parathyroidectomy. World 
Journal of Surgery 2012;36:56-60.
 9. Tsukahara K SI, Fujimoto Y, Kawabata K. Surgery did not improve the subjective neuropsycho-
logical symptoms of patients with incidentally detected mild primary hyperparathyroidism. 
European Archives of Otorhinolaryngology 2008;265:565-9.
 10. Ambrogini E CF, Cianferotti L, Vignali E et al. Surgery of surveillance for mild asymptomatic primary 
hyperparathyroidism: a prospective, randomized clinical trial. Journal of Clinical Endocrinology 
and Metabolism 2007;92:3114-21.
 11. Talpos GB BH, Kleerekoper M, Phillips ER et al. Randomized trial of parathyroidectomy in mild 
asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health 
survey. Surgery 2000;128:1013-21.
 12. Bollerslev J JS, Mollerup CL, Nordenstrom J et al. Medical observation, compared with parathy-
roidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trail. 
Journal of Clinical Endocrinology and Metabolism 2007;92:1687-92.
 13. Sudhaker Rao D PE, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus 
no surgery in patients with mild asymptomatic primary hyperparathyroidism. Journal of Clinical 
Endocrinology and Metabolism 2004;89:5415-22.
 14. Brazier JE HR, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 
Health Survey Questionnaire: New outcome measure for primary care. British Medical Journal 
1992;305:160-4.
 15. Bilezikian JP PJ, Fuleihan GEH, Kleerekoper M et al. Summary statement from a workshop on as-
ymptomatic primary hyperparathyroidism: A perspective for the 21st century. Journal of Clinical 
Endocrinology and Metabolism 2002;87:5353-61.
 16. Aaronson NK MM, Cohen PD, Essink-Bot ML et al. Translation, validation, and norming of the 
Dutch language version of the SF-36 Health Survey in community and chronic disease popula-
tions. Journal of Clinical Epidemiology 1998;51:1055-68.
QoL after PTx in primary HPT 57
4
 17. Caillard C SF, Mathonnet M, Gibelin H et al. Prospective evaluation of quality of life (SF-36v2) and 
nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). 
Surgery 2007;141:153-9.
 18. Cheng SP LJ, Liu TP, Yang TL, Chen HH, Wu CJ, Liu CL. Parathyroidectomy improves symptomatol-
ogy and quality of life in patients with secondary hyperparathyroidism. Surgery 2014;155:320-8.
 19. Adler JT SR, Chen H. The influence of surgical approach of quality of life after parathyroid surgery. 
Annals of Surgical Oncology 2008;15:1559-65.
 20. Tang T DS, Robinson B, Delbridge L. Does the surgical approach affect quality of life outcomes? 
- A comparison of minimally invasive parathyroidectomy with open parathyroidectomy. Interna-
tional Journal of Surgery 2007;5:17-22.
 21. Egan KR AJ, Olson JE, Chen H. Parathyroidectomy for primary hyperparathyroidism in octogenar-
ians nonagenarians: A risk-benefit analysis. Journal of Surgical Research 2007;140:194-8.
 22. Weber T EJ, Messelhauser U, Schiffmann L et al. Parathyroidectomy, elevated depression scores, 
and suicidal ideation in patients with primary hyperparathyroidism. JAMA Surgery 2013;148:109-
15.
 23. Eigelberger MS CW, Ituarte PHG, Streja L, Duh QY, Clark OH. The NIH criteria for parathyroidec-
tomy in asymptomatic primary hyperparathyroidism: are they too limited? Annals of Surgery 
2004;239:528-35.
 24. Kahal H AM, Rigby AS, Sathyapalan T, England RJA, Atkin SL. The effect of parathyroidectomy 
on neuropsychological symptoms and biochemical parameters in patients with asymptomatic 
primary hyperparathyroidism. Clinical Endocrinology 2012;76:196-200.

Chapter 5 Effect of Parathyroidectomy 
and Cinacalcet on Quality 
of Life in Patients with End-
Stage Renal Disease Related 
Hyperparathyroidism: a Systematic 
Review
Willemijn Y. van der Plas, Roderick R. Dulfer, Anton F. Engelsman, 
Liffert Vogt, Martin H. de Borst, Tessa M. van Ginhoven, Schelto 
Kruijff, on behalf of the Dutch Hyperparathryoid Study Group 
(DHSG)
Nephrology, Dialysis and Transplantation. 2017 Apr 10. 
[Epub ahead of print]
60 Chapter 5
abSTraCT 
background
Patients with end-stage renal disease (ESRD) have a decreased quality of life (QoL), 
which is in part attributable to ESRD-related hyperparathyroidism (HPT). Both cinacalcet 
and parathyroidectomy (PTx) are treatments for advanced HPT, but their effects on QoL 
are unclear. We performed a systematic review to evaluate the impact of cinacalcet and 
PTx on QoL. 
methods
A systematic literature search was performed using PubMed and Embase databases to 
identify relevant articles. The search was based on the following keywords: “parathyroid-
ectomy” or “cinacalcet”, “secondary hyperparathyroidism” or “renal hyperparathyroidism” 
combined with “quality of life” or SF-36” or “symptomatology”. Only studies reporting on 
QoL at baseline and during follow-up were included. QoL scores were extracted from 
the selected manuscripts and weighted means were calculated. Due to lack of available 
data on QoL improvement in patients using cinacalcet, a meta-analysis could not be 
performed. 
results
Eight articles reached our inclusion criteria. Five articles reported on the effect of PTx on 
QoL. All PTx studies were observational and non-controlled. The physical component 
scores (PCS) of SF-36 increased significantly with a weighted mean of 35.5% (p<0.05). 
Mental component scores (MCS) increased with 13.7% (p<0.05). Parathyroidectomy 
Assessment of Symptoms (PAS) scores improved from 561 preoperatively to 302 postop-
eratively (-259 points; -46.2%). Visual Analogue Scale (VAS) scores reduced significantly 
for skin itching (46.6%), joint pain (30.4%) and muscle weakness (28.7%) (p<0.05). Three 
studies on the effect of cinacalcet on QoL were included, including one RCT. None of 
these studies showed significant improvement of PCS and MCS scores. 
Conclusions
PTx improves QoL in patients treated for ESRD-related HPT, whereas cinacalcet did not. 
The difference of impact between PTx and cinacalcet on QoL has not been compared 
directly. 
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InTroDuCTIon
Deregulated mineral metabolism is a hallmark of end-stage renal disease (ESRD).(1) 
Specifically, hyperparathyroidism (HPT) with hyperplastic or hypertrophic parathyroid 
glands occurs commonly in patients with ESRD (30-50%).(2, 3) Eventually HPT con-
tributes to progressively disturbed calcium-phosphate homeostasis and eventually to 
autonomous PTH overproduction and hypercalcaemia remaining irrespective of renal 
function: tertiary HPT. Clinical HPT-related manifestations vary from somatic symptoms 
such as fatigue and abdominal pain, to psychological symptoms such as forgetfulness, 
mood swings and concentration difficulties.(4) Furthermore, HPT has been associated 
with versatile detrimental effects on health status, especially with respect to bone disor-
ders, cardiovascular disease, increased risk of mortality and even reduced quality of life 
(QoL).(5-8) QoL of ESRD patients is often already decreased both due the symptoms of 
ESRD itself and the burden of dialysis treatment.(9) 
In the management of HPT, different treatment modalities are available. According 
to the Kidney Disease Improving Global Outcome (KDIGO) guidelines patients with 
ESRD related HPT should initially receive medical therapy, with vitamin D analogs and 
phosphate binders. Upon failure of initial therapy, prescription of the calcimimetic agent 
cinacalcet is recommended.(10) Cinacalcet increases the sensitivity of the calcium-sens-
ing receptor (CaSR) located within the parathyroid glands, aiming to reduce excretion 
of PTH and balance calcium-phosphate homeostasis.(11) KDIGO guidelines recommend 
parathyroidectomy (PTx) only in patients with severe HPT (>800 pg/mL) who are refrac-
tory to medical therapy. Since its introduction in 2004, cinacalcet has gained a dominant 
role in the treatment algorithm of ESRD related HPT and PTx is less often performed.(12) 
However, emerging data suggest that the reticent position of surgery in the treatment 
algorithm of HPT might be questionable. In a previous study, we showed that PTx is 
a very safe and effective treatment.(13) Furthermore, Narayan and co-authors showed 
that PTx is more cost-effective than cinacalcet after 7.25 months of treatment.(14) Since 
no randomized controlled trial (RCT) comparing PTx with cinacalcet has been performed 
so far, the optimal treatment of ESRD related HPT remains unclear. 
In order to provide a patient-tailored approach to HPT it is of paramount importance 
to also assess the effect of these interventions QoL, in line with the increasing interest 
in patient reported outcome measures (PROMs).(15) It is known that PTx improves QoL 
in patients with primary HPT, however whether there is an additional positive effect of 
PTx or cinacalcet in patients with concurrent ESRD remains uncertain.(16) Therefore, 
we performed a systematic review of studies measuring QoL in patients with HPT who 
received cinacalcet or underwent (sub)total PTx. 
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meThoDS
Search strategy
To identify relevant articles a systematic literature search was conducted using PubMed 
and EMBASE. The following search terms were used to identify articles on the effect of PTx 
on QoL: parathyroidectomy, secondary hyperparathyroidism, tertiary hyperparathyroidism, 
quality of life, SF-36, symptomatology. Next, we used the following search terms to iden-
tify articles describing the effect of cinacalcet on QoL: secondary hyperparathyroidism, 
tertiary hyperparathyroidism, cinacalcet hydrochloride, quality of life, SF-36, symptomatol-
ogy. Additionally, we searched for abstracts and unpublished studies on the websites of 
the FDA, EMA, ASN and EDTA. The search protocol has not been published or submitted 
to an ethical committee.
article selection and data extraction
Only original research papers written in English and published between 1980 and 
2015 were included for further analysis. These abstracts were screened by two inde-
pendent reviewers (RD, WYvdP) and all articles complying with the following criteria 
were selected: (1) studies assessing QoL using any kind of health questionnaire. Both 
general and disease-specific questionnaires were included. (2) QoL was assessed both 
at baseline and during follow-up after PTx or initiation of cinacalcet in HPT patients. 
In case of disagreement a third reviewer was consulted (TMvG or SK). After this selec-
tion process all full text articles were studied and cross reference check was performed. 
Our online search yielded 277 articles, to which two articles were additionally found 
by cross-referencing. Eventually, five publications on PTx met the inclusion criteria and 
were included in this review. Three relevant manuscripts on the effect of cinacalcet on 
QoL were selected (Figure 1). Corresponding authors were asked to provide additional 
data if the articles did not contain the required information. Secondary endpoints of 
our analyses were biochemical measurements including parathyroid hormone (PTH), 
calcium and phosphate levels before and after intervention. No additional studies or 
abstracts where found on the websites of the FDA, EMA, ASN or EDTA. 
Quality assessment
All eligible articles were independently scored regarding their quality by three reviewers 
blinded to each other’s results (WYvdP, RD and SK). In case of disagreement the article 
was discussed and a definitive score was calculated based on consensus. Case series were 
assessed by means of the 18-criteria checklist by the Delphi panel.(17) This validated 
checklist includes the quality of the study objective, population, intervention and co-
intervention, outcome measures, and statistical analysis. A maximum of 18 points could 
be awarded. A score of 14-18 points was considered high-quality, a score of 9-13 fair 
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quality. For case-control and cohort studies, the Newcastle-Ottawa scale was appraised.
(18) The scale consists of three domains addressing the aspects of methodology includ-
ing selection, comparability and outcome (cohort studies) or exposure (case-control 
studies) for which stars could be allotted. A total of 9 stars could be awarded. A score 
of 7-9 was considered high quality, 4-6 was considered fair quality. Articles reporting a 
randomized controlled trial (RCT) were assessed using the CONSORT 2010 statement.
(19) Also, the risk of publication bias will be assessed using a funnel plot.
Quality of life and symptoms measurement tools 
The Medical Outcomes Study Short-Form Health Survey® (SF-36®) is a commonly applied 
questionnaire of 36 simple questions on eight health domains. Each dimension can be 
transformed into a 0-100 scale, where a higher score represents better self-perceived 
well-being and QoL. These eight domains can be distinguished into two summery 
scores: the physical component summary score (PCS) and the mental component sum-
mary score (MCS). For both the PCS as the MCS a score of 50 represents the mean of the 
United States population with a standard deviation (SD) of 10. In hemodialysis patients, 
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figure 1. Flowchart of study selection
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reported mean PCS ranges from 31.6-49.8 and MCS varies from 46.0-50.2.(20-22) A 
change in PCS or MCS scores of minimally 2 points is thought to be clinically meaningful.
(23)
The European Quality of Life 5 Dimensions (EQ-5D) assessment is another classification 
instrument. It encompasses 5 domains: mobility, self-care, usual activities, pain or dis-
comfort, and anxiety or depression each with three response levels.(24)
Pasieka et al. developed a disease-specific outcome tool for hyperparathyroidism. The 
Parathyroidectomy Assessment of Symptoms (PAS) is a questionnaire which contains 
all HPT-related symptoms initially designed for primary HPT.(4) This 13-item question-
naire has been validated for secondary and tertiary HPT and is correlated to the SF-36 
questionnaire.(25) The visual analogue scale (VAS) ranging from 1-100 was used to 
assess the degree of severity per symptom. The 13 included symptoms are bone pain, 
fatigue, mood swings, feeling “blue” or depressed, abdominal pain, feeling weak, feeling 
irritable, joint pain, forgetfulness, difficulty getting out of a chair or car, headaches, itchy 
skin, and being thirsty. Subsequently, a maximum PAS score of 1,300 can be reached.
Statistics
Mean QoL scores were extracted from the selected manuscripts. Weighted means were 
calculated as follows: (amount of patients * the mean score difference) / total amount 
of patients. 
reSulTS
Description and quality of the included studies 
A description of the included studies is shown in Table 1. Of the five included studies on 
PTx, four articles provided SF-36 scores, three of which reported the summary scores. 
Two papers also assessed quality of life by means of the PAS score and one article used 
a general VAS system. There were no multicenter studies and follow-up ranged from 
3-12 months. All studies stated a complete objective and/or hypothesis and outcome 
measures were clearly described in all studies. In 80% of the studies patients had been 
recruited consecutively. All studies reported length of follow-up, but only one of the 
five studies mentioned the number of participants lost to follow-up. All authors drew 
conclusions fully supported by their results. We considered 3 articles to be of high qual-
ity and 2 of fair quality. 
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Three studies reporting the effect of cinacalcet on QoL were included. One was based 
on the EVOLVE trial, a multicenter RCT comparing cinacalcet with placebo.(26) All manu-
scripts stated clear hypotheses and endpoints were fully described.
The risk of publication bias could not be tested since <10 studies were included in this 
analysis. 
effect of parathyroidectomy on quality of life
All studies reported significant improvement in QoL after PTx (Table 2). These positive 
effects were reported both after short-term (3 months) and longer-term follow-up (12 
months). The weighted mean physical component scores were 33.2 preoperatively and 
increased significantly to 45.3 postoperatively (weighted mean increase of 35.5%). The 
mental component scores increased from 44.6 preoperatively to 50.9 postoperatively 
(+13.7%). PAS scores improved from 561.5 preoperatively to 302.3 postoperatively (-259 
points, -46.2%). Yang et al. reported VAS scores on three domains: skin itching, joint pain 
and muscle weakness. Pain scores of these items reduced significantly by 46.6%, 30.4% 
and 28.7%, respectively.
In the study by Yang et al, the MCS slightly decreased 1 month postoperatively compared 
with the preoperative situation. 
effect of cinacalcet on quality of life
Filipozzi et al. (N=124) reported absolute values. At baseline, PCS and MCS scores were 
38.6 ± 5.3 and 45.5 ± 7.4 respectively. At the end of follow-up, PCS score was 38.7 ± 5.3 
and MCS score 44.6 ± 7.7. No p-value was provided. Briggs et al. (N=1780) reported QoL 
data expressed as EQ-5D scores. The estimated treatment effect of cinacalcet at the end 
of follow-up did not reach statistical significance compared to placebo. Chertow and 
co-authors analyzed 567 patients who participated in an open-label clinical trial that 
showed that cinacalcet had a significant positive effect on 4 of 14 related symptoms at 
the end of study (dry skin, ache in bones, joint pain, and trouble with memory). However, 
no significant changes were seen in PCS and MCS scores both at the end of the efficacy 
assessment (16-22 weeks) and at end of follow-up (12 months). 
DISCuSSIon
This is the first systematic review to examine the impact of PTx and cinacalcet for the 
treatment of HPT on QoL. Eight peer-reviewed studies published between 2000-2015 
were analyzed. Patients with secondary and tertiary hyperparathyroidism who under-
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went PTx experienced a significant improvement of QoL. Cinacalcet on the other hand, 
did not convincingly have a positive effect on QoL. 
HPT develops in 30-50% of all patients with ESRD.(2) It is well recognized that ESRD 
and accompanying complications are associated with polypharmacy, a decreased life 
expectancy, and a reduced QoL.(27) Strikingly, only few studies assessed the effect of 
PTx and cinacalcet on QoL as an endpoint in the fragile ESRD population. In this review 
we summarized available data related to the impact of PTx and cinacalcet on QoL in 
ESRD patients with HPT. Our data suggest that PTx might improve QoL in these patients, 
whereas cinacalcet does not seem to influence QoL.
The improvement of QoL after PTx is probably caused by the resection of almost all 
parathyroid tissue, resulting in a strong correction of PTH overproduction. Due to the 
extremely short half-life of PTH (<2 min.) serum PTH drops immediately, leading to low 
serum PTH levels.(28) In line, HPT related symptoms as described by Pasieka et al., such 
as bone pain, fatigue and depression diminish almost directly after PTx. It should be 
noted that none of the included articles on the effect of PTx were sham-controlled. It 
is likely that bias introduced by the lack of sham-controlled surgery plays a substantial 
role in the improvement patients experienced after PTx. Thus, although the individual 
studies in our meta-analysis were considered to be of reasonable to good quality, the 
level of evidence to support the effect of PTx on QoL remains low. On the other hand, 
patients require less medications after surgery, which also benefits QoL. 
Several studies have investigated the influence of cinacalcet on QoL of the ESRD patient 
population.(29-32) These studies showed less promising results when compared to the 
QoL improvement after PTx. Our findings are in line with data by Cunningham et al, 
who undertook a compared analysis of four unpublished RCTs that QoL in patients with 
HPT treated with either cinacalcet (N=665) or placebo (N=471). The main outcome was 
that only two (bodily pain and general health) of the eight domains of SF-36 improved 
significantly in the cinacalcet group compared to the control group with a difference 
of less than two points, while only a difference of 3 to 5 points is considered clinically 
meaningful.(23, 29) The fact that cinacalcet does not seem effective in improving QoL 
may at least partly be explained by the occurrence of side effects such as nausea, vomit-
ing, and diarrhea that may counteract potential QoL improvements due to PTH lower-
ing.(26) We found no study comparing the effects on QoL of cinacalcet with PTx directly.
The strength of this systematic review is our methodological approach. After establishing 
a well-designed reproducible search string in collaboration with an experienced medi-
cal librarian, the selection and analysis were conducted by three individual reviewers. 
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Afterwards, selected manuscripts were assessed on their quality using validated quality 
assessment tools also independently by three authors. This assessment indicates that 
all studies were of enough quality to address our question. Limitations of this review 
are inherent to the study population. QoL is influenced by many factors and it remains 
difficult to assess the true benefit of surgery alone in the absence of sham-controls. In 
addition, data is limited and unfortunately, no meta-analysis was possible. Due to lack 
of data, we could not test the risk for publication bias. However, we do acknowledge the 
potential risk for publication bias, which should be taken into account when interpreting 
the results. Lastly, a search protocol has not been published or presented to an ethical 
committee.
Since the availability of calcimimetics, in daily practice PTx is now only indicated in 
patients with uncontrollable HPT.(10) Meanwhile, in the last decade the quality of 
parathyroid surgery has improved with the use of less invasive operations, heat sealing 
devices and improved imaging for preoperative localization.(33, 34) Notwithstanding, 
PTx remains a surgical procedure executed in a fragile population with cause-specific 
morbidity, including hypocalcaemia, emergency admissions (myocardial dysrhythmias, 
cerebrovascular events) as described in a large nationwide US study.(35) These data 
might explain the hesitance of nephrologists to refer their patients for surgery and their 
increased motivation for treatment with cinacalcet.(36) The intravenous calcimimetic 
etelcalcetide was recently approved by the European Medicines Agency and will be-
come available on the European market in 2017, which may provide a further impulse 
for upfront medical management of HPT.(37) On the other hand, we demonstrated that 
PTx is a safe procedure with low complication rates when performed in a tertiary referral 
center. Postoperative complications, including surgical site problems (3.5%), temporary 
recurrent laryngeal nerve damage (1.8%) and intensive care admissions (0.8%) were 
rare. Postoperative hypocalcaemia was seen 39.8% of the patients.(13) This difference 
might indicate the necessity of referring these fragile patients to high-volume centers. 
Despite data indicating that surgical intervention is highly effective, has a positive ef-
fect on QoL, and is safe when performed in an experienced center, pharmacological 
treatment has so far remained the first-line treatment for advanced HPT.(13, 14, 38) In 
order to ultimately compare the short-term and long-term effects of cinacalcet and PTx 
on QoL in HPT patients both short-term as well as long-term, a randomized controlled 
trial (RCT) soon will be conducted (EudraCT no. 2016-002174-12). Along with results of 
comparing biochemical effects and cost-effectiveness, recommendations for renewed 
guidelines should be established.
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Conclusions
Parathyroidectomy improves quality of life in patients treated for ESRD-related HPT, 
whereas cinacalcet did not. In order to provide a patient tailored-approach for the treat-
ment of HPT biochemical, clinical and quality of life changes must be taken into account.
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Introduction
A significant portion of patients with chronic kidney disease and secondary hyperpara-
thyroidism (HPT) remain hyperparathyroid after kidney transplantation, a state known 
as tertiary hyperparathyroidism (HPT). Without treatment, tertiariy HPT can lead to 
diminished kidney allograft and patient survival. Parathyroidectomy was commonly 
performed to treat tertiary HPT until the introduction of the calcimimetic drug, cinacal-
cet. It is not known whether surgery or medical treatment is superior for tertiary HPT. 
methods
A systematic review was performed and medical literature databases were searched 
for studies on the treatment of tertiary HPT that were published after the approval of 
cinacalcet. 
results
A total of 1669 articles were identified, of which 47 were included in the review. Fol-
lowing subtotal and total parathyroidectomy, initial cure rates were 98.7% and 100% 
respectively, but in 7.6% and 4% of patients tertiary HPT recurred. After treatment with 
cinacalcet, 80.8% of the patients achieved normocalcaemia. Owing to side effects, 6.4% 
of patients discontinued cinacalcet treatment. The literature regarding graft function 
and survival is limited; however, renal graft survival after surgical treatment seems 
comparable to therapy with cinacalcet. 
Conclusion
Side-effects and complications of both treatment modalities were mild and occurred 
in a minority of patients. Surgical treatment for tertiary HPT has higher cure rates than 
medical therapy. 
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InTroDuCTIon
Hyperparathyroidism (HPT) is a disease caused by excessive secretion of parathyroid 
hormone (PTH) due to either parathyroid hyperplasia or adenomas. In primary hyper-
parathyroidism (HPT), an enlargement of one or more of the parathyroid glands causes 
overproduction of PTH, resulting in hypercalcaemia, which can cause a variety of clinical 
symptoms. Surgery is currently the treatment of choice for patients fulfilling the criteria 
as defined by the guidelines of the fourth international workshop on asymptomatic 
primary HPT1. A targeted surgical approach, with a mini-incision, is considered the stan-
dard treatment2-4. 
In secondary HPT, hypocalcaemia and phosphate retention stimulate the parathyroid 
glands, and this results in parathyroid hyperplasia and increased PTH concentrations. 
Secondary HPT is one of the first metabolic complications of chronic kidney disease (CKD) 
and has been associated with untoward effects such as renal bone disease, increased 
cardiovascular morbidity and death from (cardio)vascular calcifications5,6. Successful 
kidney transplantation can reverse secondary HPT7. The greatest decline in serum PTH 
concentrations is observed during the first 3 months after kidney transplantation, with 
a more gradual decline during the rest of the first post-transplant year8,9. Unfortunately, 
one year after an otherwise successful transplant, 17-50% of transplanted patients still 
have HPT, which is unlikely to improve spontaneously8,10. This condition is referred to as 
tertiary or post-transplant HPT7,11. Treatment of tertiary HPT is important as raised serum 
calcium concentrations and hypercalciuria increase the risk of renal allograft dysfunc-
tion12 and graft loss13. In addition, tertiary HPT is a major risk factor for bone fractures 
during the first 5 years after transplantation14. 
Historically, secondary and tertiary HPT were treated surgically. However, since 2004 
medical treatment with the calcimimetic agent cinacalcet (Mimpara®, Amgen, Thou-
sand Oaks, CA, USA) has gained popularity15. Cinacalcet increases the sensitivity of the 
calcium-sensing receptor of the parathyroid gland, thereby suppressing the production 
of PTH16. Cinacalcet was approved for the treatment of secondary HPT by the US Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2004. 
However, it has not been approved to treat tertiary HPT. Nonetheless, off-label use of 
cinacalcet for tertiary HPT has increased, and in small non-randomized studies with 
short follow-up the drug appears to be safe, with gastrointestinal intolerance being the 
most common side effect17. At present, there is only limited literature to guide clinicians 
when faced with making treatment decisions regarding tertiary HPT. Therefore, the aim 
of this systematic review was to compare the outcomes of surgical and medical treat-
ment of tertiary HPT.
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meThoDS
Search strategy
A systematic search for articles on the treatment of tertiary HPT was conducted. The 
definition of tertiary HPT varies in international literature, and includes serum PTH 
levels more than twice the upper limit of normal” and persistent hypercalcaemia with 
increased PTH concentration after successful kidney transplantation14,18. In the present 
study, all definitions used were included. 
The aim was to compare the outcomes of surgical and medical treatment of tertiary HPT. 
Primary endpoints were cure rate (defined as normalization of hypercalcemia), recurrent 
tertiary HPT (definition of recurrence dependent on the definition of tertiary HPT used), 
and the complications and sid- effects of each treatment modality. Second, the impact 
of surgical and medical therapy on renal allograft function and survival was assessed. 
Publications were selected using MEDLINE, Embase, Web-of-science, the Cochrane Li-
brary, Pubmed Publisher and Google Scholar. Articles had to be original full-text articles 
written in English, published after 2004 (when cinacalcet received FDA/EMA regulatory 
approval) and describing an adult human population. To ascertain that no surgical trials 
were missed, the search strategy was extended to include articles published before 2004. 
No additional studies comparing surgical treatments for tertiary HPT were identified.
Articles describing treatment of tertiary HPT, both surgical and medical, were included, 
as well as articles describing renal function after initiation of these therapies. The fol-
lowing search terms were used: Hyperparathyroidism, Parathyroid hormone, Kidney/
renal transplantation, Calcimimetic/Cinacalcet/Mimpara, Parathyroidectomy/Endocrine 
surgery.
Two authors were involved in selecting articles. Any disagreement was discussed until 
consensus was reached.
Methodological quality of included case-control and cohort studies was assessed by 
means of the Newcastle-Ottawa scale (NOS)19. A score of 7-9 was considered high qual-
ity, and 4-6 as fair quality. An 18-criteria checklist developed by Moga and colleagues20 
served to assess the quality of included case series. Here, a maximum of 18 points could 
be rewarded to each study. A score of 14-18 was considered high quality, and a score of 
9-13 as fair quality. RCTs were assessed by means of the 25-item checklist of the Consort 
Statement21. 
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Statistical analysis
No meta-analysis could be performed owing to the lack of sufficient RCTs. When similar 
studies reported individual data regarding similar endpoints, data were pooled and 
percentages for the outcome of interest were calculated. Descriptive statistics reported 
in the tables consists of absolute numbers of patients and follow-up. No other statistical 
analysis was applied.
reSulTS
The primary search identified 2963 records, with 16 records identified through reference 
search. After exclusion of duplicates, publication dates and case reports, reviews, letters 
to the editor and conference abstracts, all titles and abstracts were screened. Eventually 
232 full-text articles were assessed for eligibility. Following exclusions at this stage, a 
total of 47 articles were finally included in the review (Fig. 1). 
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figure 1. Flow diagram of articles included in the systematic review
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Surgical management of tertiary hyperparathyroidism
Fourteen studies described the outcome of parathyroidectomy for tertiary HPT. These 
included one RCT22, three prospective cohort studies23-25, nine retrospective cohort 
studies26-34 and one case series35 (Table 1). Of the 13 observational studies, seven were 
considered of high quality and six fair quality. Group sizes differed between 15 and 136 
patients, and follow-up ranged from a minimum of 9 months to as long as 116 months 
after transplantation. Data regarding persistent or recurrent tertiary HPT after parathy-
roidectomy was available for 240 patients25-28,30. Seventy-one (29.6%) of these patients 
had undergone a total parathyroidectomy either with (28 patients) or without (43) 
autotransplantation. No patient had persistent disease, although three (4%) developed 
recurrent disease after a mean follow-up of 31-79 months. These three patients all had 
a total parathyroidectomy without autotransplantation. A subtotal parathyroidectomy 
was performed in 158 of the 240 patients (65.8%) of whom two (1.3%) had persisting 
tertiary HPT and 12 (7.6%) were found to have recurrent disease after a mean follow-up 
of 41-79 months. The remaining 11 patients (4.6%) had undergone a limited parathy-
roidectomy, of whom ten (91%) had persistent or recurrent disease (not specified). A 
surgical procedure was defined as limited parathyroidectomy when fewer than four 
glands were identified or when only one or two glands were removed deliberately. 
Persisting disease was defined as persistent hypercalcaemia in two studies28,30, with no 
definition in the other studies. Recurrent disease was defined as recurrent hypercalcae-
mia 6 months after surgery in two studies28,30, with no definition in the other studies. 
There were two patients (0.7% of 274) who developed chronic hypocalcaemia. Transient 
hypocalcaemia24,28,30-32,34 was observed in 15% to 23% of the patients. One study24, how-
ever, reported a rate of 67% (8 of 12 patients) after total parathyroidectomy.
Complications after surgery, besides hypocalcaemia or persistent disease28,30,32,33, were 
rare. Vocal cord paralysis, probably due to damage of the recurrent nerve, was seen 
in six of 280 patients (2.1%). Other rare complications were pneumonia (3 of280) and 
postoperative hematoma (2 of 280). No studies directly compared the different surgi-
cal strategies (subtotal parathyroidectomy, total parathyroidectomy with or without 
autotransplantation). 
medical management of tertiary hyperparathyroidism with cinacalcet
The experience with cinacalcet after kidney transplantation was reported in 24 articles: 
two RCT’s22,36 and 22 smaller observational studies 37-58 (Table 2). Of the 22 observational 
studies, nine were considered of high quality, and 13 were considered fair quality. The 
indication to prescribe cinacalcet was hypercalcaemic tertiary HPT in 22 studies, nor-
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mocalcaemic tertiary HPT in one study and both hypercalcaemic and normocalcaemic 
tertiary HPT in one study. A total of 713 patients were treated during a wide range of 
periods (from 2 weeks up to 53 months) after renal transplantation. All studies showed a 
decline in mean serum calcium and PTH concentrations. Eleven studies, including 297 pa-
tients, describe the outcome “achieving normocalcaemia”. Of these patients, 240 (80.8%) 
achieved normocalcaemia, with individual studies reporting rates ranging from 28% (10 
of 36) to 100%22,36,38,42,45,48,50,51,54,55,57. Overall, of 578 patients treated with cinacalcet, 37 
(6.4%) discontinued treatment due to persisting hypercalcaemia or side effects such as 
hypocalcaemia, gastrointestinal complaints, or paraesthesia. Dose of cinacalcet ranged 
between 30 mg and 180 mg daily. No subgroups according to dosage were described. 
Table 2. Summary of included studies reporting of treatment of tHPT with Cinacalcet
Study, year Study design Study
patients (N)
FU
(months)
Normocal-
caemia
Discontinued
treatment
Study
quality
Kruse38 2005 Case serie 14 3 12/14 1/14 15/18^
Serra42 2005 Case serie 11 2.5 11/11 1/11 14/18^
apostolou37 2006 Case serie 7 3-18 N/A 0/7 13/18^
leca39 2006 Cohort, retrospective 10 12 N/A 0/10 6/9~
Srinivas57 2006 Case serie 11 3-18 8/11 2/11 13/18^
Szwarc46 2006 Case serie 9 6 N/A 3/9 13/18^
bergua47 2007 Case serie 13 6 N/A N/A 12/18^
el-amm43 2007 Case serie 18 6 N/A 1/18 14/18^
bergua56 2008 Case serie 9 12 N/A 1/9 15/18^
Serra44 2008 Case serie 10 0.5 N/A N/A 12/18^
Carrasco40 2009 Case serie 14 6 N/A 2/14 13/18^
Gomez margues45 2009 Cohort, retrospective 48 12 13/15 4/48 7/9~
lopez48 2009 Case serie 29 3-29 27/29 1/29 14/18^
Toro Prieto49 2009 Case serie 27 6 N/A N/A 14/18^
borchhardt55 2010 Case serie 10 18-34 10/10 N/A 13/18^
borstnar41 2010 Case serie 11 12 N/A 1/11 12/18^
Copley50 2010 Case serie 41 3-6 10/36 N/A 12/18^
Schwarz54 2011 Case serie 58 12 53/58 4/58 15/18^
Courbebaisse52 2012 Cohort, retrospective 34 12 N/A N/A 9/9~
Paschoalin58 2012 Case serie 23 53 N/A 0/23 12/18^
Paschoalin51 2012 Case serie 41 31 41/41 0/41 11/18^
evenepoel, 201436 RCT 57 12 45/57 5/57 19/25†
Torregrosa53 2014 Cohort, retrospective 193 22 N/A 10/193 6/9~
Cruzado22, 2015 RCT 15 12 10/15 1/15 20/25†
~ NOS quality assessment
^ Moga quality Assessment
† Consort checklist
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effect of surgery for tertiary hyperparathyroidism on renal graft function 
Twelve studies9,18,26,29,59-66 described the effect of parathyroidectomy for tertiary HPT on 
renal function after kidney transplantation (Table 3). Eleven of the 12 articles were con-
sidered of high quality, one article66 was considered fair quality. In these studies, group 
sizes varied between 18 and 90 patients. Follow-up ranged from 6 to 62 months, with one 
exception64 describing 10 year follow-up. One study reported stable renal function after 
parathyroidectomy; in five studies a transient decline in renal function was observed: 
and in six studies a permanent decline in renal function was reported. Interpretation of 
these studies is hampered by the lack of control groups. The two retrospective studies 
that compared patients undergoing parathyroidectomy with a matched cohort showed 
either a permanent decline at 6 months follow up62 or a transient decline in renal func-
tion with 24 months follow-up60. 
Two studies18,64 addressed the effect of parathyroidectomy on graft survival. Although a 
permanent decline in renal function was observed in many patients having parathyroid-
ectomy, this did not reduce graft survival when compared to that following parathyroid-
ectomy in patients with no decline in renal function, with a follow-up of 3 and 10 years 
respectively18,64. Furthermore 3- and 10-year graft survival rates were similar to those in 
patients undergoing renal transplantation without parathyroidectomy. 
effect of cinacalcet for tertiary hyperparathyroidism on renal graft function 
Five articles40,52-54,65 described the effect of cinacalcet on graft function after renal trans-
plantation. Three of these were considered of high quality, two of fair quality. Three small 
studies40,52,65 with a total of 61 patients, described stable graft function during treatment. 
This was confirmed by a large observational study of Torregrosa and co-workers53 who 
found stable graft functions during treatment with cinacalcet in a group of 193 patients 
with tertiary HPT. 
In contrast, Schwarz et al54 described a cohort of 58 patients and observed a significant 
decline in estimated glomerular filtration rate of 9% during treatment with cinacalcet. 
These studies did not report data on the effect of cinacalcet on graft survival or overall 
survival. No studies are available that directly compared medical therapy with surgical 
therapy.
DISCuSSIon
From this systematic review of studies reporting surgical and medical therapy with cina-
calcet for tertiary HPT it can be concluded that surgical treatment has higher cure rates 
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with low complication rates. The only RCT22 comparing surgical therapy with medical 
therapy with cinacalcet included 2 cohorts of 15 patients, with the primary endpoint be-
ing normocalcaemia at 12 months. After parathyroidectomy 100% of patients achieved 
normocalcaemia, compared with 10 of the 15 patients (67%) treated with cinacalcet. 
This is the only RCT to date, and therefore it was not possible to perform a meta-analysis. 
Unfortunately, trials focussing on major clinical endpoints are lacking, and in the avail-
able literature regarding this topic there is no uniform definition regarding tertiary HPT. 
With regard to surgical treatment, three procedures are commonly performed: total 
parathyroidectomy with or without autotransplantation, subtotal parathyroidectomy 
and limited parathyroidectomy. An international survey among 86 endocrine surgeons67 
reports that 85 (99%) performed a (sub)-total parathyroidectomy with or without auto-
transplantation for secondary or tertiary HPT. A limited approach, when only enlarged 
parathyroid glands are removed, was rarely used. Although there are no studies directly 
comparing these procedures, persisting and recurrent disease rates shown in the pres-
ent review indicate that limited parathyroidectomy should be avoided: 4, 8.9 and 91% 
for total, subtotal and limited resection respectively.
Renal function after parathyroidectomy for tertiary HPT seems to decline transiently or 
permanently. In cohorts of patients undergoing renal transplant, overall allograft func-
tion will decline eventually. Whether this decline in function is due to the parathyroidec-
tomy or to chronic rejection can be determined only from studies with a control group. 
At present, no such studies are available. The studies in the present review show that 
there is no effect of parathyroidectomy on overall graft survival18,64. Surgical complica-
tions are rare, and parathyroidectomy appears to be a safe and feasible treatment option 
Table 4. Summary of included studies reporting on renal graft function after treatment with Cinacalcet
Study, year Study design FU
(months)
Study
patients (n)
Effect of Cinacalcet on renal 
function
Study
Quality
Carrasco40, 2009 Case serie 6 14 Stable creatinine levels 13/18^
Schwarz54, 2011 Case serie 12 58 Rise in serum creatinine levels 
of 13 µmol/L
15/18^
Courbebaisse52, 2012 Cohort, 
retrospective
12 34 Stable creatinine levels 9/9~v
yang65, 2012 Cohort, 
retrospective
12 13 Creatinine level increase by 
0,056 mg/dl (mean) in 1 year
8/9~
Torregrosa53, 2014 Cohort, 
retrospective
22 193 Stable creatinine levels 6/9~
~ NOS quality assessment
^ Moga quality Assessment
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for tertiary HPT. Unfortunately, the literature regarding this topic is sparce, consisting 
mostly of case series or cohort studies.
Medical treatment of tertiary HPT with cinacalcet significantly decreases serum calcium 
concentrations, but only 80.8% of the patients achieved normocalcaemia and 6.4% 
discontinued treatment due to side-effects such as gastro-intestinal intolerance. Renal 
graft function is stable during treatment with cinacalcet or may decline minimally. A 
meta-analysis of observational studies by Henschkowski and colleagues68 reported an 
increase in serum creatinine levels of 5 µmol/l after three months of treatment with 
cinacalcet: no long-term data are available from this study. Again the literature consisted 
mostly of observational studies, with only nine of 22 studies being considered of high 
quality.
The present endpoints did not focus on cardiovascular morbidity or mortality, although 
this is an important complication for all patients undergoing dialysis or renal transplan-
tation. Included studies did not report data regarding the effect of parathyroidectomy or 
cinacalcet on cardiovascular complication rates in patients with tertiary HPT. However, 
there is some evidence from patients with secondary HPT. In this group, parathyroidec-
tomy leads to a decreased risk of major cardiovascular events and death in comparison 
with conservative treatment69,70. Furthermore, in 2012 the results of the EVOLVE trial71, 
which randomised patients with secondary HPT to best medical treatment or best medi-
cal treatment with cinacalcet, were published. The addition of cinacalcet did not reduce 
the risk of death or major cardiovascular events. In addition, a meta-analysis of RCTs72 
reported that the use of cinacalcet in patients undergoing dialysis did not improve over-
all survival. Cardiovascular morbidity and mortality in patients with tertiary HPT should 
be a focus of future trials.
Another important complication for patients with tertiary HPT patients is bone disease. 
The rate of osteoporosis is high patients with a renal transplant73-79, and tertiary HPT 
is associated with an increased risk of osteoporosis73, and is a major risk factor for 
fractures14. Small trials41,49,80-83 have suggested that parathyroidectomy increases bone 
mineral density, in contrast to cinacalcet. The development of osteoporosis should also 
be a focus of future trials.
Finally, cost-effectiveness remains an important consideration in the choice of treat-
ment. Uncontrolled HPT increases the economic burden of patients with secondary HPT 
undergoing dialysis owing to higher medication and hospitalization costs84. Compared 
with cinacalcet treatment, parathyroidectomy is more cost-effective in these patients85, 
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mainly due to the significant additional cost and chronic use of cinacalcet. Currently, 
there are no data regarding cost-effectiveness in treatments for tertiary HPT.
Although high quality evidence is lacking, this systematic review shows that surgical 
treatment for HPT appears to be more effective than medical treatment. Furthermore, 
complication rates after surgery are low and graft survival is comparable to that obtained 
with cinacalcet. Higher-quality data on important clinical end-points such as cardio-
vascular morbidity and renal bone disease are lacking. Future research should include 
randomized trials focussing on clinical end-points such as quality of life, cardiovascular 
morbidity and renal bone disease so that the optimal treatment for an individual patient 
can be chosen.
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abSTraCT
Introduction
Persistent hyperparathyroidism(HPT) after kidney transplantation, also known as ter-
tiary HPT, occurs in 17-50% of patients. Treatment of tertiary HPT is mandatory since 
persistent elevated PTH levels after kidney transplantation increase the risk of renal 
allograft dysfunction as well as osteoporosis. The introduction of cinacalcet in 2004 of-
fered a medical treatment alternative to parathyroidectomy(PTx). However, the optimal 
management of tertiary HPT remains unclear. In this study we compared the outcomes 
of PTx and cinacalcet for tertiary HPT.
methods
A retrospective analysis was performed of patients that received a kidney transplant in 
one of 2 academic centers in the Netherlands. Patients undergoing a PTx within 3 years 
of transplantation and patients requiring cinacalcet 1 year after transplantation were 
included. Primary outcomes were serum calcium and PTH concentration one year after 
kidney transplantation and after PTx.
results
Our study cohort consisted of 30 patients undergoing PTx and 64 still treated with cina-
calcet after kidney transplantation. Patients in the cinacalcet group had PTH concen-
trations above the upper limit of normal (median 22.0 pg/ml) 1 year after KT, whereas 
serum calcium concentrations normalized (median 2.40 mmol/L). After PTx, both serum 
calcium (median 2.34 mmol/L) and PTH concentrations (median 3.7 pg/ml) returned to 
within the normal range. 
Conclusion
In patients with tertiary HPT, cinacalcet normalizes serum calcium, but does not lead to 
a normalization of serum PTH concentrations. In contrast, PTx leads to a normalization 
of both serum calcium and PTH concentrations. These findings suggest that PTx is the 
treatment of choice for tertiary HPT.
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InTroDuCTIon
Hyperparathyroidism (HPT) is a state of overproduction of parathyroid hormone (PTH) 
due to over activity of one or more of the parathyroid glands1. Secondary hyperpara-
thyroidism (sHPT) frequently complicates chronic kidney disease (CKD). CKD causes 
phosphate retention, hypovitaminosis D [1,25-(OH)2-D] and hypocalcaemia, leading to 
stimulation of the parathyroid glands and increased PTH production. Secondary HPT 
occurs in 25-30% of patients with end-stage renal disease (ESRD) and is associated 
with severe bone mineral disease2. Importantly sHPT is also associated with increased 
cardiovascular morbidity2 and mortality3,4. The first line of treatment of sHPT used to 
consist of calcium and vitamin D supplementation followed by either medical therapy 
using calcimimetics5 or surgical treatment by parathyroidectomy (PTx)6. For dialysis 
patients requiring PTH-lowering therapy the current recommendation is to treat with 
calcimimetics, calcitriol or vitamin D analogs, or a combination of these therapies7. 
Secondary HPT can be corrected by a successful kidney transplantation (KT)8. Neverthe-
less, 17-50% of patients who receive a kidney transplant remain hyperparathyroid one 
year after transplantation9-11. This is referred to as tertiary or post-renal transplantation 
HPT (tHPT), which is a state of excessive and autonomous production and excretion of 
PTH8,12. In general, the PTH concentration rapidly declines within the first three months 
after KT and then continues to decline more gradually over the course of the next nine 
months. One year after transplantation, PTH concentrations are unlikely to decline 
further9-11.
As tHPT increases the risk of renal allograft dysfunction and renal allograft loss13,14, 
osteoporosis15 and bone fractures16, adequate management is essential. Introduced in 
2004, the calcimimetic drug cinacalcet (Mimpara®, Amgen Inc. Thousand Oaks, CA, USA) 
is frequently used for the treatment of ESRD related HPT17,18. Cinacalcet suppresses the 
production of PTH by increasing the sensitivity of the calcium-sensing receptor of the 
parathyroid gland to calcium19. The United States Food and Drug Administration and the 
European Medicines Agency have approved cinacalcet for the treatment of secondary 
but not tertiary HPT. This is despite a number of small non-randomized studies demon-
strating the safety of cinacalcet in tHPT, with gastrointestinal intolerance being the most 
common side effect20.
Before the introduction of cinacalcet, the only treatment option for patients with tertiary 
HPT was (PTx)21. This surgical procedure involves either subtotal parathyroidectomy or 
total parathyroidectomy (with or without auto-transplantation), both which are effec-
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tive and safe procedures22,23. In secondary HPT, PTx was even associated with a lower risk 
of major cardiovascular events after surgery24. 
The effect of cinacalcet on cardiovascular morbidity and mortality has recently been 
studied in the EVOLVE trial25. This study in dialysis patients demonstrated that treatment 
with cinacalcet does not reduce the risk of major cardiovascular events or death. In an 
additional meta-analysis of randomized controlled trials cinacalcet did not improve 
overall survival in dialysis patients26. Consequently, the Australian Government stopped 
the reimbursement of cinacalcet27.
The only randomized controlled trial comparing the effects of PTx and cinacalcet in the 
treatment of tertiary HPT included 30 patients concluded that 66% of patients treated 
with cinacalcet achieved normocalcaemia compared to 100% after PTx28. As this is 
the only trial, albeit with a small sample size, comparing these treatment modalities, 
additional studies with larger cohorts are warranted. Therefore, today the optimal 
management of tHPT remains unclear. In this study the outcomes of treatment with 
PTx or cinacalcet for tertiary HPT were compared in a larger cohort of patients from two 
academic centers. 
meThoDS
Study population
All patients who underwent a first KT at one of the 2 participating university medical 
centers between 1994 and 2015 and had a history of PTx or calcimimetic use, both be-
fore or after KT, were included in a large cohort and their demographic and clinical data 
were stored in a central database. This study was approved by the institutional review 
boards of all participating centers
Inclusion criteria for this study were tertiary HPT, age ≥ 18 years at time of KT and the 
availability of calcium and serum PTH concentrations after KT. Tertiary HPT was defined 
as the need for PTx after KT or the (continued) need of cinacalcet treatment at month 12 
after kidney transplantation. Patients with previous parathyroid surgery were excluded. 
From this database 2 groups were identified. Group 1 (cinacalcet group) consisted of 
patients who received treatment with cinacalcet at 12 months after their 1st KT without 
a history of PTx. Group 2 (PTx group) consisted of patients who underwent a PTx within 
three years of their 1st KT. Outcomes of the PTx group in the first year after KT are pre-
sented for patients who had not undergone PTx at the set time points. 
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Primary outcomes were serum calcium and PTH concentration one year after KT and one 
year after PTx. Secondary outcomes were the use of co-medication (calcium supplemen-
tation, vitamin D supplementation, cinacalcet) after KT and PTx, as well as complications 
after KT and PTx.
Data collection
Electronic patient files were reviewed for patient data. Baseline characteristics were 
gender, age, primary kidney disease, type and duration of dialysis, medication use and 
relevant co-morbidity (e.g. diabetes mellitus and cardiovascular disease). 
KT data included donor type and age, ischemia times, complications graded by the Cla-
vien-Dindo scale29, delayed graft function (defined as the need for dialysis in first week 
after KT), primary non-function, biochemical parameters until 5 years after KT (calcium, 
phosphate, albumin, creatinine, alkaline phosphatase and PTH) and medication use 
after KT (calcium or vitamin D supplementation, phosphate binders and calcimimetics). 
Data on the use of diuretics were not systematically collected.
PTx data included type of the surgical procedure (total or subtotal), complication rate, 
imaging before PTx, laboratory data before PTx until 5 years after PTx (calcium, phos-
phate, albumin, creatinine, alkaline phosphatase and PTH) and medication use after PTx 
(calcium or vitamin D supplementation, phosphate binders and calcimimetics). 
Serum calcium concentrations were adjusted for albumin according to the following 
formula: adjusted total calcium (mmol/L) = measured calcium (mmol/l) + (0.025 * (40 
– [albumin (g/L)])). The reference value for calcium was 2.20 – 2.60 mmol/L. Reference 
value for PTH was 1.4 – 7.3 pmol/L. PTH values were measured with the Vitros ECi as-
say (Ortho diagnostics) and with the Roche Cobas assay (Roche). Reference values 
for creatinine were 65 – 115 umol/L for male patients and 55 – 90 umol/L for female 
patients. Persistent postoperative hypocalcemia was defined as the need for calcium 
supplementation 6 months after PTx. 
Statistical analysis
Distribution was assessed using the Shapiro-Wilk normality test. Continuous variables 
are presented as median with interquartile range, and categorical variables were 
described as count (n) and percentage (%). Differences between the two groups were 
analyzed using the Mann-Whitney U test for continuous variables and the Pearson Chi-
square or Fisher’s exact test for nominal variables. The Wilcoxon signed ranks test was 
used to compare the differences between time points. Statistical analysis was performed 
using IBM SPSS Statistics 21 software (IBM Corp., Chicago, IL, USA). 
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reSulTS
Study Population
A total of 277 patients were included in our database. A total of 94 patients were included 
in this study based on the before mentioned in and exclusion criteria. Thirty patients 
were included in the PTx group whereas 64 patients were included in the cinacalcet 
group. A flowchart of patient selection is listed in figure 1.
baseline characteristics
Patient characteristics at the time of KT are listed in Table 1. Median age of all patients 
at time of KT was 56.0 years (45.8 – 62.0). The median age of PTx patients at time of 
transplantation was lower (52.5 years (35.8 – 57.3)) compared with patients using calci-
mimetics (59.0 years (50.0 – 64.0)). The median duration of dialysis before KT was 42.5 
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figure 1. Flowchart of patient selection
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months (21.0 – 63.0), 43.6% of patients were female and 25.5% of patients had a history 
of diabetes mellitus. At the time of KT, 81.3% of patients received phosphate binders, 
66.0% received vitamin D supplements, 23.3% received calcium supplementation and 
45.7% received calcimimetics. Of all KT, 55.3% was performed with a deceased donor 
kidney. Delayed graft function occurred in 27.7% of patients.
Table 1. Baseline characteristics
Characteristic Cinacalcet group PTx group p-Value
No. of patients 64 30
Age at start dialysis (years) 53.5 (45.3 – 61.8) 49.5 (32.8 – 55.8) 0.034
Sex (female) 27 (42.2) 14 (46.7) NS
Charlson score 3 (2-5) 3 (2-4) NS
Dialysis type NS
- No dialysis 12 (18.8) 2 (6.7)
- Peritoneal dialysis 19 (29.7) 11 (36.7)
- Hemodialysis shunt 29 (45.3) 15 (50.0)
- Hemodialysis line 4 (6.3) 2 (6.7)
Duration of dialysis (months) 42.5 (21.3 – 67.5) 42.5 (18-54.8) NS
History of diabetes 15 (23.4) 9 (30.0) NS
Use of medication before KT
- Vitamin D 47 (74.6) 15 (53.6) NS
- Phosphate binders 52 (82.5) 22 (78.6) NS
- Calcium suppletion 12 (19) 9 (32.1) NS
- Cinacalcet 38 (60.3) 5 (17.2) <0.001
Transplant characteristics
Age at transplantation (years) 59.0 (50.0 – 64.0) 52.5 (35.8 – 57.3) 0.034
Donor type NS
- DCD 17 (26.6) 8 (26.7)
- DBD 18 (28.1) 9 (30.0)
- LR 13 (20.3) 6 (20.0)
- LUR 16 (25.0) 7 (23.3)
Complications NS
- Grade 2 16 (25.0) 9 (30.0)
- Grade 3 6 (9.4) 6 (20)
Delayed graft function 19 (29.7) 7 (23.3) NS
Primary non function 0 (0) 2 (6.7) NS
Cold-ischemia time (hours) 15 (12 – 19.8) 21 (16 – 24) 0.023
Warm-ischemia time (minutes) 23.5 (18 – 32) 29 (22 – 35) 0.048
Data are expressed as median (interquartile range) or n (%)
PTx: Parathyroidectomy 
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outcomes after kidney transplantation
Pre- and post-operative laboratory values before and after KT are listed in table 2. Se-
rum calcium concentrations were higher in the PTx group preoperatively (2.51 vs 2.42 
mmol/L). There was a significant increase in serum calcium concentrations at 3 months 
after transplantation in both groups (cinacalcet group: p = 0.002; PTx group: p = 0.001) 
but this did not persist after 6 months in the cinacalcet group (p = 0.148). PTx patients 
not yet operated in the first post-transplant year remained hypercalcemic during the 
first post-transplant year. Calcium concentrations in the PTx group were higher at all 
time points, with a median calcium of 2.76 one year after transplantation ( p < 0.001).
Table 2. KT outcomes
Group 1 (cinacalcet) Group 2 (PTx) p-value number at risk PTx
N 64 30
Corrected calcium, mmol/L
- Pre-transplantation 2.42 (2.23 – 2.54) 2.51 (2.33 – 2.69) 0.030 30
- 3 months 2.50 (2.36 – 2.63) 2.84 (2.64 – 2.90) <0.001 30
- 6 months 2.44 (2.34 – 2.59) 2.79 (2.65 – 2.85) <0.001 25
- 1 year 2.40 (2.23 – 2.49) 2.76 (2.56 – 2.90) <0.001 18
PTH, pmol/L
- Pre-transplantation 54.4 (29.7 – 91.0) 90.0 (61.4 – 156.4) 0.013 30
- 3 months 22.7 (14.0 – 32.7) 34.3 (25.3 – 80.3) 0.007 30
- 6 months 18.2 (14.0 – 27.9) 26.3 (16.3 – 55.1) 0.056 25
- 1 year 22.0 (13.7 – 33.1) 29.8 (15.3 – 57.1) NS 18
Creatinine, µmmol/L
- 3 months 119 (103 – 163) 126 (112 – 179) NS 30
- 6 months 125 (100 – 164) 118 (100 – 142) NS 25
- 1 year 122 (101 – 161) 127 (102 – 173) NS 18
Use of Vitamin D
- Pre-transplantation 47 (74.6) 15 (53.6) NS 30
- 3 months 15 (26.8) 3 (10.3) NS 30
- 6 months 9 (15.8) 2 (8.3) NS 25
- 1 year 9 (14.1) 2 (11.1) NS 18
Use of Cinacalcet
- Pre-transplantation 38 (60.3) 5 (17.2) <0.001 30
- 3 months 38 (67.9) 2 (6.9) <0.001 30
- 6 months 50 (87.7) 3 (12.5) <0.001 25
- 1 year 64 (100) 3 (17.6) <0.001 18
Data are expressed as median (interquartile range) or n (%)
PTx: Parathyroidectomy 
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Median PTH concentrations were significantly higher in the PTx group before KT (90.0 
vs 54.4 pmol/L, p = 0.013) and 3 months after transplantation (34.3 vs 22.7 pmol/L, p 
= 0.007). Both groups showed a decline in serum PTH concentrations after kidney 
transplantation. In the PTx group this was statistically significant at 6 months after trans-
plantation (p = 0.012), but this was not observed at 1 year post transplantation. In the 
cinacalcet group here was a statistically significant decline of PTH concentrations after 
KT at all time points (p = < 0.001 at all time points). In the PTx group 10.3% of patients 
used cinacalcet 1 year after transplantation. In total, 34.5% of patients in the PTx group 
used vitamin D analogs 1 year after transplantation, whereas 14.1% of patients in the 
cinacalcet group used vitamin D analogs. 
Parathyroidectomy
Characteristics of the patients who underwent PTx are listed in table 3. Median age at 
time of PTx was 54.5 years, 66.7% of patients were classified as ASA III. Twelve patients 
(40%) underwent a PTx in the first year and 18 underwent (60%) PTx in the second or 
third year after KT. Subtotal parathyroidectomy was performed in 83.3% of patients. 
Re-exploration due to persistent tHPT was performed in 3 (10%) patients. Two patients 
required a second operation within the first postoperative month and one 10 months 
after initial surgery due to persistent HPT. There were no recurrent laryngeal nerve inju-
ries, no postoperative cardiovascular events and there was no postoperative mortality. 
Postoperative hypocalcemia was apparent in 40% of patients. 
Laboratory values before and after PTx are listed in table 4. Serum calcium concentra-
tions declined significantly after PTx, no patients were hypercalcaemic one year after 
PTx. PTH concentrations declined significantly after PTx and were in the reference range. 
Vitamin D analogs were used in 42.9% of patients 1 year after PTx. One patient used 
cinacalcet (3.6%) after PTx. A total of 40% of patients used calcium supplementation at 
6 months after surgery.
DISCuSSIon
This study describes a cohort of patients treated for tHPT, either by PTx or cinacalcet. 
After PTx patients were normocalcaemic and PTH concentrations normalized. Treatment 
with cinacalcet resulted in normocalcaemia but not in normalization of PTH concentra-
tions. After kidney transplantation the PTH concentrations declined in both groups, but 
were higher in the group of patients that would still undergo PTx. Median PTH concen-
trations in both groups remained above the upper limit of normal (7.3 pmol/L) up to 12 
months after transplantation. In the cinacalcet group the serum calcium concentrations 
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remained normal, whereas patients who would undergo PTx became hypercalcemic. 
After parathyroidectomy both serum calcium concentrations and PTH concentrations 
were in the normal range. 
These findings raise questions about the efficacy of off-label use of cinacalcet in the treat-
ment of tertiary hyperparathyroidism. Adequate control of PTH in the post-transplant 
period is paramount given the increased risk of allograft dysfunction, allograft loss13,14, 
all-cause mortality30, fractures and osteoporosis15,16. These reservations concerning the 
treatment of tHPT with cinacalcet are also supported by a study of Cruzado and col-
leagues28. 
Patients with ESRD are fragile as shown from high ASA-scores, and it is therefore under-
standable that there is some reluctance to refer patients for surgical treatment31. Still, in 
Table 3. PTx characteristics
Characteristic PTx group
Age at parathyroidectomy (years) 54.5 (36.8 – 59.3)
ASA classification
- II 10 (33.3)
- III 20 (66.7)
Pre-operative imaging
- No imaging 18 (62.1)
- Ultrasound 4 (13.8)
- MIBI-scan 3 (10.3)
- Ultrasound and MIBI-scan 4 (13.8)
Type of PTx
- Total parathyroidectomy 3 (10.0)
- Subtotal parathyroidectomy 25 (83.3)
- Other 2 (6.7)
Complications
- Postoperative hypocalcaemia 12 (40)
- Recurrent laryngeal nerve damage 0 (0)
- Surgical site infection 1 (3.3)
- Pneumonia 1 (3.3)
- ICU admission 1 (3.3)
- Mortality 0 (0)
- Re-exploration 3 (10)
Weight of parathyroid glands (grams) 1.9 (1.2 – 3.0)
Data are expressed as median (interquartile range) or n (%)
PTx: Parathyroidectomy 
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this study surgical complications after PTx were rare. Cardiovascular events and recurrent 
laryngeal nerve injuries did not occur and only one patient developed pneumonia. This 
is comparable with the results of another large Dutch study31. The rate of postoperative 
hypocalcaemia in this study was 40% at six months. This was higher than expected in 
view of results from older studies32,33. However, patients in our PTx group were mainly 
hypercalcemic patients, who more frequently have hungry bone syndrome and require 
longer calcium supplementation. Overall, PTx is a safe procedure, even in this fragile 
population22,31,33,34. 
In our study, both total and subtotal parathyroidectomies were performed, which are 
both safe and effective procedures23. A randomized controlled trial comparing these 
Table 4. PTx Outcomes
PTx group p-Value^
Corrected calcium, mmol-L
- Pre-operative 2.76 (2.62 – 3.04)
- 3 months 2.30 (2.23 – 2.43) <0.001
- 6 months 2.31 (2.16 – 2.37) <0.001
- 1 year 2.34 (2.14 – 2.41) <0.001
PTH, pmol/L
- Pre-operative 35.5 (20.3 – 62.8)
- 3 months 9.0 (4.7 – 20.8) 0.001
- 6 months 9.5 (3.3 – 22.6) 0.009
- 1 year 3.7 (1.2 – 9.3) 0.012
Creatinine, µmmol/L
- Pre-operative 122 (104 – 173) NS
- 3 months 141 (107 – 177) 0.015
- 6 months 147 (121 – 214) NS
- 1 year 140 (107 – 214) NS
Use of Vitamin D
- 3 months 14 (50.0)
- 6 months 15 (53.6)
- 1 year 12 (42.9)
Use of Cinacalcet
- 3 months 1 (3.6)
- 6 months 1 (3.6)
- 1 year 1 (3.6)
Data are expressed as median (interquartile range) or n (%)
^ p-value: compared with pre-operative measurements
PTx: Parathyroidectomy 
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procedures in sHPT found similar results for both techniques with a slightly higher rate 
of recurrence after subtotal parathyroidectomy32. Such a study has not been performed 
for tHPT35. However, favorable results have been reported concerning subtotal parathy-
roidectomy for tHPT, albeit not in an RCT22,28. Considering that the underlying metabolic 
disorders responsible for the occurrence of HPT have been corrected after successful 
transplantation, we prefer subtotal parathyroidectomy. This procedure is associated 
with a lower risk of postoperative hypocalcemia and persistent hypoparathyroidism 
whilst recurrences are unlikely due to the metabolic changes. 
This study was not designed to evaluate cost-effectiveness and therefore we cannot re-
port on this. To date, no studies evaluating cost-effectiveness in tertiary HPT have been 
published. However, for sHPT is was demonstrated that uncontrolled HPT increases 
the economic burden due to higher medication and hospitalization costs36, and PTx 
is more cost-effective than treatment with cinacalcet after 15 months of treatment37. 
Considering the increasing survival of kidney transplant patients, one could assume PTx 
to be even more cost-effective in patients with tHPT, especially when considering that in 
dialysis patients the cinacalcet costs for one QALY exceed $ 100,00038. 
Some limitations of this study should to be addressed. First, the retrospective design 
makes this study susceptible to bias as demonstrated by the difference at baseline be-
tween our groups. There is no clear guideline on indications for PTx, so indications may 
differ between participating centers. The PTx group was younger and had higher PTH 
levels at baseline. But though the baseline PTH levels were higher in the PTx group, the 
effect was more profound than compared with the cinacalcet group. 
Second, in the Netherlands KT patients are followed in the transplant center in the first 
year after transplantation. If uneventful, follow-up will then be performed at the refer-
ring hospital, with only annual follow-up at the transplant center. Thus some outcome 
data after the first post-transplant year was incomplete. Only the short-term outcomes 
of the first post-transplant year have therefore been reported. 
Third, outcomes in this study are primarily of biochemical nature. Comparison of clinical 
outcome parameters (e.g. cardiovascular disease or bone mineral density values and 
fracture risks) was not possible due to lack of BMD measurements and lack of follow-up 
at our centers. 
A minority of patients in our cohort received vitamin D supplementation, recommended 
in the KDIGO guideline CKD-MBD as a first line treatment for HPT since 20036. However, 
our cohort encompasses over 20 years of treatment, including the years up to 2003. 
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This is not applicable for the group of patients treated with cinacalcet, as cinacalcet was 
registered after the first KDIGO guideline. This under treatment with vitamin D might 
have resulted in overtreatment with cinacalcet in the cinacalcet group. 
Lastly, in the present study side effects of cinacalcet were not reported. These outcomes 
are often not reported in patient charts, although reporting has been reliable in the 
EVOLVE trial. In this RCT 46% of the subjects reported side-effects and 18.1% of patients 
discontinued the treatment25. In other studies with cinacalcet, the rate of side effects 
was unfortunately not reported39,40. 
In conclusion, treatment with cinacalcet in patients with tHPT normalized serum cal-
cium concentrations , but did not lead to normalization of PTH concentration. After 
parathyroidectomy both calcium and PTH normalized in the PTx group. Due to the 
heterogeneity of the two study groups and the retrospective design of this study, defini-
tive recommendations for daily practice cannot be made. Given the effects of high PTH 
concentrations on renal allograft survival we favour PTx in all patients with tHPT. Future 
prospective randomized studies with long term follow-up are needed to define the role 
of surgery in patients with tHPT considering clinical outcomes and economic benefits.
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abSTraCT
Introduction
Surgical treatment of both benign and malignant thyroid diseases often necessitates 
total thyroidectomy. This procedure is considered safe, but has some specific postopera-
tive complications such as hypoparathyroidism. This recovers in 90-95% of the patients, 
but the remaining patients require lifelong calcium supplementation. It is not yet 
possible to predict in which patient hypoparathyroidism will recover. Identification of 
high risk patients for persistent hypoparathyroidism can tailor treatment of individual 
patients. In this study we explore whether PTH levels measured within 24 hours after 
surgery are able to identify patients with a high risk for persistent hypoparathyroidism 
1 year after thyroidectomy.
methods
This is a prospective multicentre study, where patients undergoing total or completion 
thyroidectomy are included. PTH levels are measured on the day of surgery and on the 
first postoperative day. Patients with unmeasurable PTH levels postoperatively (PTH-
UM) were compared to those with measurable PTH levels (PTH-M). 
results
A total of 110 patients are included of which PTH levels on the first postoperative day 
were available in 100 patients. Group PTH-UM consisted of 16 patients, group PTH-M 
of 84. Persistent hypoparathyroidism occurred in 60% and 10.4% of patients in group 
PTH-UM and PTH-M, respectively. This is a statistically significant difference. Patients 
with persistent hypoparathyroidism more frequently underwent a cervical lymph node 
dissection and had a longer hospital stay. A PTH level under the limit of detection on the 
first postoperative day is an risk factor for persistent hypoparathyroidism, with an odds 
ratio of 13,8.
Conclusion
A postoperative PTH level under the limit of detection on the first day after total or 
completion thyroidectomy is a predictive factor for persistent hypoparathyroidism.
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InTroDuCTIon
Surgical treatment of both benign and malignant thyroid diseases often necessitates 
total thyroidectomy. This procedure is considered safe, but has some specific postopera-
tive complications such as hypoparathyroidism. In this situation, parathyroid glands are 
unable to maintain calcium homeostasis due to no or insufficient parathyroid hormone 
secretion. This can be due to surgery related factors such as inadvertent devascularisa-
tion, bruising or accidental removal of one or more parathyroid glands. Clinical signs 
of hypocalcaemia are perioral numbness, paraesthesia and muscle cramps. Severe 
hypocalcaemia can cause seizures, spasms and cardiac arrhythmias. Patients are there-
fore routinely monitored for clinical signs and symptoms of hypocalcaemia and serum 
calcium levels are measured at set times. Postoperative hypocalcaemia is treated with 
oral or intravenous calcium supplementation, and in some cases additional vitamin D 
supplementation1. In most cases parathyroid function will recover within weeks and 
calcium levels will normalize2,3.However, up to 5 - 10% of the patients develop persistent 
hypoparathyroidism (defined as persistent need for calcium supplementation 1 year 
after surgery) and require lifelong calcium supplementation4,5. This number may even 
be higher, when considering the survey performed by the Thyroid Cancer Alliance6. The 
rate of persistent hypoparathyroidism in this survey was 13,8%. The risk for persistent 
hypoparathyroidism may be higher than generally published.
Persistent hypoparathyroidism impairs quality of life7 of an otherwise relatively healthy 
population and poses a burden of disease8. Therefore, early identification of high risk 
patients allows clinicians not only to inform patients, but also schedule personalised 
postoperative outpatient follow-up visits. Patient with low risk for persistent hypo-
parathyroidism can be offered less visits and blood withdrawals and early reduction of 
calcium supplementation, being favourable from both patient and costs-effectiveness 
perspective. Current predictive factors for (persistent) hypoparathyroidism include 
perioperative calcium and parathyroid hormone (PTH) levels as well as surgical fac-
tors9,10. Serum PTH concentration obtained 4-24 hours postoperatively is currently the 
best parameter to predict direct postoperative hypocalcaemia11-15. However, evidence to 
predict persistent hypoparathyroidism is scarce. Nowadays, to our knowledge, the only 
known determinant for persistent hypoparathyroidism is an undetectable PTH level one 
month after surgery3. It is the ambition of this study to assess whether postoperative 
PTH levels obtained within 24 hours after surgery are able to predict the risk for persis-
tent hypoparathyroidism. In this prospective multi-centre study we explored whether 
PTH levels measured within 24 hours after surgery are able to identify patients with a 
high risk for persistent hypoparathyroidism 1 year after thyroidectomy. 
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meThoDS
This prospective study includes patients of 18 years and older undergoing a total 
thyroidectomy or a completion thyroidectomy. Patients are recruited at one university 
medical centre (Erasmus MC, Rotterdam) and one peripheral hospital (Reinier de Graaf 
Gasthuis, Delft). Recruitment took place from March 2014 until March 2016. Approval is 
obtained from the local Medical Ethical committee. 
Exclusion criteria are: unable or unwilling to provide informed consent and pre-operative 
disorders in calcium homeostasis. Patients undergoing concurrent cervical lymph node 
dissection during thyroidectomy are not excluded. General data such as gender, age, 
preoperative diagnosis and baseline blood values are obtained at the outpatient clinic. 
Following surgery patient’s blood is sampled around 18:00 PM on day of surgery and 
around 08:00 AM on the first postoperative day. Values assessed are: calcium, albumin, 
phosphate and PTH levels. Primary outcome measurement for the analysis is the PTH 
level the morning after surgery. This enables relatively easy implementation in daily 
practice and is shown to accurately predict direct postoperative hypocalcaemia2,16. Stan-
dard study follow-up including laboratory screening is performed at two weeks and one 
year postoperatively. Other outpatient visits are scheduled according to the discretion 
of the treating medical specialist. 
Serum calcium levels are adjusted for albumin levels according to the formula: adjusted 
total calcium (mmol/L) = measured calcium (mmol/L) + (0.025 * 40 – [albumin (g/L)])). 
The reference interval for calcium is 2.20 – 2.65 mmol/L. The reference interval for PTH is 
1.4 – 7.3 pmol/L. Hypocalcaemia is treated according to the local calcium supplementa-
tion protocol with calcium carbonate and alfacalcidol. A corrected calcium level lower 
than 2.20 mmol/L warrants calcium supplementation and a persistent hypocalcemia 
after two days warrants supplementation with active vitamin D.
To assess which change in PTH levels is clinically relevant we used the continuously up-
dated data for clinically important quantities by Ricos et al17. The index of individuality 
for PTH (ratio of the intra- and inter- individual biological variation coefficients) is 0.4 
and therefore the reference interval is not well suited to interpret clinical changes in 
PTH levels. The reference change value for PTH (an objective tool for assessment of the 
significance of differences in serial results from an individual based on intra-individual 
biological and methodological variation coefficient), one-sided with 95% probability 
and statistical power > 0.9 is 100%. Therefore, all patients in this study with a serial PTH 
level change of ≥100% (PTH below the limit of detection) are named group “PTH-UM”, 
the others group “PTH-M”. In other words, only undetectable PTH levels may be con-
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sidered to represent true changes of PTH levels and not represent biological variations 
within the individual. 
Primary outcome of the study is the difference in proportion of patients with persistent 
hypoparathyroidism when comparing the group with unmeasurable PTH levels postop-
eratively (group “PTH-UM”) versus measurable PTH levels (group “PTH-M”). Secondary 
outcomes are direct postoperative PTH kinetics, calcium and vitamin D supplementa-
tion percentages and risk factors for persistent hypoparathyroidism. 
Statistical analysis
Sample size was estimated a priori using G*Power software (University of Kiel, Germany, 
Version 3.1), using an alpha of 0.05 and a power of 0.96. At least 12 patients with per-
sistent hypoparathyroidism (“the cases”) are required. Assuming a case percentage rate 
of around 10% in our study population and approximately 70 eligible patients per year, 
we set the first accrual period on 2 years. Inclusion would continue during the year of 
follow-up of this cohort. If the “12 case scenario” is not met, patients included in this ex-
tra year will be included in the study and follow-up in continued another year. If the “12 
case scenario” is met, these patients are not included in the study. Data were assessed for 
near-Gaussian distribution using the Shapiro-Wilk test and for equal distributions using 
the Kolmogorov-Smirnov test. Descriptives were used to express continuous variables 
as mean ± SD or median with interquartile range, categorical variables were described 
as counts (n) and percentages (%). Differences between groups were analysed using the 
independent samples Welch’s t-test or the Wilcoxon-Mann-Whitney test for continuous 
variables and the Pearson Chi-squared rest or Fisher’s exact test for categorical variables. 
Two-tailed p-values < 0.05 were considered statistically significant. Univariate and multi-
variate logistic regression analyses were performed. Statistical analyses were performed 
using SPSS (IBM, version 21) software.
reSulTS
Study population and baseline characteristics
A total of 110 patients were included in this study between April 2014 and April 2016 
out of 172 patients assessed for eligibility (Figure 1). An additional 36 patients were 
included after this period, but where excluded from this study after meeting the primary 
number of cases required in the power analysis. The primary outcome parameter (PTH 
value obtained around 08:00 AM the day after surgery) was available for 100 patients. 
This cohort is used for the analysis of the primary outcome. All other analyses are per-
formed with the complete cohort of 110 patients, unless otherwise specified. Baseline 
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characteristics of the total study cohort are listed in Table 1. A total of 72% of patients is 
female, 24% of all patients underwent a completion thyroidectomy, 33% underwent a 
concomitant cervical lymph node dissection. Of this cohort, 41% was treated for benign 
thyroid disease, Graves disease in 13.6% of patients, 20.0% for multinodular goiter, and 
7.3% for other indications. 
unmeasurable PTh levels and risk of persistent hypoparathyroidism (n=100)
Sixteen patients have PTH levels under the limit of detection on the first postoperative 
day (group PTH-UM) The other 84 patients have PTH levels above the limit of detec-
tion (group PTH-M). Baseline characteristics are summarized in Table 2. There were no 
statistical significant differences at baseline between groups PTH-UM and PTH-M. 
Patients in group PTH-UM had significantly lower postoperative corrected serum calcium 
levels when compared to PTH-M patients (2.06 vs 2.14 mmol/L, p = 0.033). By definition, 
PTH levels in the PTH-UM group where not detectable, whereas median postoperative 
day 1 PTH levels in group PTH-M are 2.05 pmol/L (range: 0.4 – 5.1 pmol/L, reference in-
terval 1.4 – 7.3 pmol/L). The percentage of patients with persistent hypoparathyroidism 
was 60% in group PTH-UM versus 10.4% in group PTH-M (Figure 2). This is a statistically 
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figure 1. Flowchart of patient selection
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significant difference (p-value < 0.001). In the multivariate analysis, a PTH level under 
the limit of detection on the first postoperative day is an independent risk factor for 
persistent hypoparathyroidism, with an odds ratio of 13,8 (95% confidence interval 3.4 
– 55.4). A postoperative PTH level under the limit of detection at the day of surgery was 
also an independent risk factor for persistent hypoparathyroidism, with an odds ratio of 
10.8(95% confidence interval 2.4 – 49.8).
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figure 2. Calcium supplementation after thyroidectomy
Table 1. Baseline characteristics
Characteristic Total cohort n = 110
Age (median 25/75) 53.5 (39.8-66.0)
Female (n + %) 79 (71.8%)
ASA-classification 1 –27 (24.5%)
2 – 74 (67.3%) 
3 – 9 (8.2%) 
Calcium preoperative (mean +/ SD) 2.26 (± 0.08)
PTH preoperative (median 25/75) 4.6 (3.5-5.5)
Vit D preoperative (median 25/75) 49 (32-68)
Surgical procedure
Total thyroidectomy 86 (78.2%)
Completion thyroidectomy 24 (21.8%)
CLND 36 (32.7%)
CCLND 35 (32.7%)
LLCLND 13 (11.8%)
RLCLND 18 (16.4%)
Benign disease 45 (40.9%)
Cervical lymph node dissection = CLND
CCLND = central CLND (level VI)
LLCLND = Left lateral CLND (level II-IV)
RLCLND = Right lateral CLND (level II-IV)
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unmeasurable PTh levels and follow-up data regarding PTh kinetics and 
treatment for hypocalcaemia (n=100)
There were six patients in group PTH-UM (38%) that had measurable PTH levels the 
day of surgery and unmeasurable levels on the first postoperative day. In contrast, four 
patients had unmeasurable PTH levels the day of surgery, and measurable levels the day 
after surgery. In other words, 29% of the patients with undetectable PTH levels on the 
day of surgery, had detectable PTH levels within 24 hours after surgery. Of these patients 
7 (50%) developed persistent hypoparathyroidism. Figure 3a shows PTH kinetics during 
follow-up of PTH-UM vs PTH-M groups. Both short term (2 weeks) and long term (1 year) 
PTH levels are significantly lower in the PTH-UM group vs the PTH-M group. Two weeks 
after surgery 66.7% of the PTH-UM group had measurable PTH levels, indicative of (par-
tial) restoration of parathyroid function. Of these patients 70% were in need of calcium 
supplementation after 1 year. After 1 year, only 1 patient of the PTH-UM group had 
unmeasurable PTH levels, and was supplemented with calcium. The other 14 patients 
of the PTH-UM group had measurable PTH levels after 1 year, of these 8 patients (57.1%) 
was supplemented with calcium. Only 1 patient in the PTH-M group, had unmeasur-
able PTH levels 2 weeks after surgery and developed persistent hypoparathyroidism. 
Table 2. Baseline characteristics 
Characteristic PTh-um n=16 PTh-m n=84 p
Age (median 25/75) 56.5 (45.8-65.0) 53.0 (35.8-65.8) NS
Female (n + %) 9 (56%) 63 (75%) NS
ASA-classification 1 – 3 (18.8%) 1 – 23 (27.4%) NS
2 – 12 (75.0%) 2 – 55 (65.6%) 
3 – 1 (6.3%) 3 – 6 (7.1%) 
Calcium preoperative (mean +/ SD) 2.28 (± 0.09) 2.25 (± 0.08) NS
PTH preoperative (median 25/75) 5.1 (3.4-6.0) 4.6 (3.5-5.6) NS
Vit D preoperative (median 25/75) 56 (43-73) 48 (30-67) NS
Surgical procedure
Total thyroidectomy 13 (81.3%) 65 (77.4%) NS
Completion thyroidectomy 3 (18.8%) 19(22.6%) NS
CLND 8 (50.0%) 25 (29.8%) NS
CCLND 8 (50.0%) 24 (28.6%) NS
LLCLND 2 (12.5%) 9 (10.7%) NS
RLCLND 5 (31.3%) 12 (14.3%) NS
Benign disease 7 (43.8%) 32 (38.1%) NS
Cervical lymph node dissection = CLND
CCLND = central CLND (level VI)
LLCLND = Left lateral CLND (level II-IV)
RLCLND = Right lateral CLND (level II-IV)
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Figure 3a. Postoperative PTH levels after thyroidectomy
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Figures 3b and 3c show PTH kinetics stratified for PTH-UM, PTH-M and need for calcium 
supplementation after one year. Calcium and vitamin D supplementation is summarised 
in Table 3. Three patients (18%) of group PTH-UM were discharged on day 2 or 3 after 
surgery without the need for calcium and/or vitamin D supplementation. Only 1 of them 
had a measurable PTH level after 2 weeks. 
Tabel 3. 
Day of surgery
Characteristic PTh-um n=16 PTh-m n=84 p
- Serum calcium 2.17 (±0.13) 2.18 (± 0.10) NS
- Serum PTH 0.00 (0.00 – 0.40) 2.10 (1.10 – 3.45) p < 0.001
- Oral calcium supplementation 5 (31.3%) 15 (17.9%) NS
- IV calcium supplementation 4 (25.0%) 13 (15.5%) NS
first postoperative day
Characteristic PTh-um n=16 PTh-m n=84 p
- Serum calcium 2.06 (± 0.17) 2.14 (± 0.14) p = 0.033
- Serum PTH 0.00 (0.00 – 0.00) 2.05 (1.00 – 3.18) p < 0.001
- Oral calcium supplementation 14 (87.5%) 54 (64.3%) NS
- IV calcium supplementation 5 (31.3%) 13 (15.5%) NS
- Vitamin D supplementation 7 (43.8%) 26 (31.0%) NS
Discharge
Characteristic PTh-um n=16 PTh-m n=84 p
- Calcium supplementation 13 (81.3%) 58 (69.0%) NS
- Vitamin D supplementation 7 (43.8%) 26 (31%) NS
2 after weeks surgery
Characteristic PTh-um n=16 PTh-m n=84 p
Serum calcium (mean) 2.21 (.21) 2.28 (±0.11) NS
Serum PTH (median) 0.60 (0.00 – 0.80) 2.05 (1.40 – 4.28) p < 0.001
Calcium supplementation 14 (87.5%) 47 (56.0%) p = 0.024
Vitamin D supplementation 9 (56.3%) 20 (23.8%) p = 0.015
6 months after surgery
Characteristic PTh-um n=15 PTh-m n=77 p
Serum calcium (mean) 2.11 (±0.15) 2.19 (±0.11) p = 0.04
Calcium supplementation 9 (60.0%) 13 (16.7%) p < 0.001
Vitamin D supplementation 8 (53.3%) 7 (9.0%) p < 0.001
1 year after surgery
Characteristic PTh-um n=15 PTh-m n=77 p
Persistent hypoparathyroidism 9 (60.0%) 8 (10.4%) p < 0.001
Serum calcium (mean) 2.15 (± 0.17) 2.22 (± 0.12) NS
Serum PTH (median) 1.1 (0.85 – 2.45) 2.9 (2.33 – 4.90) p < 0.001
Calcium supplementation 9 (60%) 8 (10.4%) p < 0.001
Vitamin D supplementation 8 (53.3%) 5 (6.5%) p < 0.001
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Total study cohort follow-up (n=102)
As mentioned earlier the total study cohort is comprised of 110 patients of which 
baseline characteristics are mentioned in Table 1. A total of 8 patients were excluded 
during follow-up, 1 patient in the PTH-M group and 7 patients in the PTH-UM group. 
Six patients were excluded due to additional cervical surgical procedures. The other 2 
patients retracted their informed consent, and no additional study follow-up was per-
formed after that moment. 
Four patients underwent a reoperation due to postoperative hematoma (no immedi-
ate surgery due to airway compromise was necessary). Three patients had underwent 
total thyroidectomy, one had underwent total thyroidectomy with cervical lymph node 
dissection. Five patients were treated with oral antibiotics in the outpatient setting for 
possible wound infection, where no re-operations or interventions were needed. 
Of all patients, 68% receives calcium supplementation on the first postoperative day and 
six start calcium supplementation after the first postoperative day. At discharge 71% 
of patients used calcium supplementation and 33% of patients used vitamin D supple-
mentation. 61% received calcium supplementation at 2 weeks after surgery, 23.9% at 
6 months, and 18.5% of patients required supplementation one year after surgery (= 
persistent hypoparathyroidism). The dosage of oral calcium supplementation one year 
after surgery varied from 500 to 4000 mg daily. Of all patients with persistent hypopara-
thyroidism PTH levels were under the lower limit of the reference interval on the first 
postoperative day. Of all patients with a PTH level below the lower limit of the refer-
ence interval on the first postoperative day, 60.5% of patients did not have persistent 
hypoparathyroidism. Patients with persistent hypoparathyroidism had a postoperative 
PTH < 25% of baseline value, in patients without persistent hypoparathyroidism the 
postoperative PTH levels were 0 – 130% of baseline value. 
multivariate analysis regarding risk factors for persistent hypoparathyroidism
Of our cohort of 110 patients follow-up data one year after surgery were available in 
102 patients. A total of 18 patients (17.6%) had persistent hypoparathyroidism one year 
after surgery, 84 had no persistent hypoparathyroidism. Characteristics of these patients 
are listed in Table 4. After univariate analysis the following variables were associated 
with persistent hypoparathyroidism: Undergoing additional lymph node dissection, 
unmeasurable PTH levels on the day of surgery, need for intravenous calcium supple-
mentation, post-operative serum calcium levels and unmeasurable PTH levels on the 
day after surgery. After multivariate analysis only unmeasurable PTH levels on the day 
of surgery and unmeasurable PTH levels on the day after surgery were independent risk 
factors for persistent hypoparathyroidism. Patients with persistent hypoparathyroid-
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Tabel 4. Baseline characteristics
Characteristic Persistent 
hypoparathyroidism
no persistent 
hypoparathyroidism
p
N 18 84
Age (median 25/75) 60 (46.5 – 69.25) 51 (38.25 – 64.75) NS
Female (n + %) 10 (55.6%) 64 (76.2%) NS
ASA-classification 1 – 6 (33.3%) 1 – 19 (22.6%) NS
2 – 11 (61.1%) 2 – 58 (69.0%) 
3 – 1 (5.6%) 3 – 7 (8.3%) 
Calcium preoperative (mean +/ SD) 2.23 (± 0.09) 2.26 (± 0.08) NS
PTH preoperative (median 25/75) 5.15 (3.95 – 6.13) 4.55 (3.35 – 5.30) NS
Vit D preoperative (median 25/75) 40 (22-49) 55 (33-72) p = 0.040
Surgical procedure NS
- Total thyroidectomy 15 (83.3%) 66 (78.6%)
- Totalizing thyroidectomy 3 (16.7%) 18 (21.4%)
CLND 11 (61.1%) 23 (27.4%) p = 0.011
CCLND 11 (61.1%) 22 (26.2%) NS
LLCLND 3 (16.7%) 8 (9.5%) NS
RLCLND 6 (33.3%) 11 (13.1%) NS
Length of stay (median) 6 (4 – 9.25) 3 (3 – 4) p < 0.001
Benign disease 5 (27.8%) 38 (45.2%) NS
No complications 13 (72.2%) 78 (92.9%)
- Rebleeding 1 (5.6%) 3 (3.6%)
- Wound infection 2 (11.1%) 3 (3.6%)
- Other 2 (11.1%) 1 (1.2%)
Day of surgery
Serum calcium 2.13 (± 0.12) 2.18 (± 0.10) p = 0.025
Serum PTH 0.20 (0.00-0.60) 2.05 (1.03 – 3.30) p < 0.001
Oral calcium supplementation 8 (44.4%) 13 (15.5%) p = 0.010
IV calcium supplementation 8 (44.4%) 10 (11.9%) p = 0.003
first postoperative day
Serum Calcium 2.02 (± 0.12) 2.15 (± 0.14) p < 0.001
Serum PTH 0.00 (0.00 – 0.60) 2.00 (1.00 – 3.10) p < 0.001
Oral calcium supplementation 18 (100%) 52 (61.9%) p = 0.001
IV calcium supplementation 5 (27.8%) 12 (14.3%) NS
Vitamin D supplementation 2 (11.1%) 7 (8.3%) NS
Discharge
Calcium supplementation 18 (100%) 56 (66.7%) p =0.003
Vitamin D supplementation 12 (66.7%) 23 (27.4%) p =0.002
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ism had a lower pre-operative vitamin D, with 4 patients having a vitamin D level < 
30 nmol/L (indicative of severe deficiency, reference value > 50 nmol/L). There were no 
other pre-operative differences between the groups. A cervical lymph node dissection 
was performed more frequently in patients with persistent hypoparathyroidism and 
they had a longer hospital stay. 
DISCuSSIon
This study evaluates the value of PTH levels obtained the morning after total or comple-
tion thyroidectomy in predicting the risk for persistent hypoparathyroidism one year 
after surgery. It shows that patients with PTH levels under the limit of detection have a 
60% chance of persistent hypoparathyroidism after thyroidectomy. Unmeasurable PTH 
levels are an independent risk factor for persistent hypoparathyroidism with an odds 
ratio of 13.8. 
This is, to the best of our knowledge, the first study with adequate statistical power to 
evaluate the value of postoperative PTH levels in predicting persistent hypoparathy-
Tabel 4. Baseline characteristics (continued)
Characteristic Persistent 
hypoparathyroidism
no persistent 
hypoparathyroidism
p
2 weeks
Serum calcium 2.19 (± 0.21) 2.29 (± 0.15) p = 0.018
Serum PTH 0.65 (0.43 – 0.88) 2.10 (1.30 – 4.30) p < 0.001
Calcium supplementation 18 (100%) 44 (52.4%) p < 0.001
Vitamin D supplementation 15 (83.3%) 16 (19.0%) p < 0.001
6 months
Serum calcium 2.08 (± 0.11) 2.21 (± 0.10) p < 0.001
Calcium supplementation 17 (94.4%) 6 (7.2%) p < 0.001
Vitamin D supplementation 14 (77.8%) 2 (2.4%) p < 0.001
1 year p < 0.001
Serum calcium 2.09 (± 0.14) 2.25 (± 0.10) p < 0.001
Serum PTH 1.10 (0.88 – 2.48) 3.20 (2.50 – 5.60) p < 0.001
Calcium supplementation 18 (100%) 0 (0%) p < 0.001
Vitamin D supplementation 14 (77.8%) 0 (0%) p < 0.001
CLND = Cervical lymph node dissection
CCLND = central CLND (level VI)
LLCLND = Left lateral CLND (level II-IV)
RLCLND = Right lateral CLND (level II-IV)
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roidism after thyroidectomy, without being biased by intra-individual normal biological 
variations in PTH levels.
Our results are supported by other studies showing that low PTH levels are likely to 
predict persistent hypoparathyroidism, although one must realize that these studies 
are not adequately powered. Hermann et al. evaluated 402 patients undergoing a total 
or completion thyroidectomy18. Six cases (1,5%) had persistent hypoparathyroidism of 
which all had postoperative PTH values lower than 0.63 pmol/L, well under the lower 
limit of normal. In contrast, only 15% of the patients with low PTH levels developed 
persistent hypoparathyroidism. Due to the low number of cases, no formal statistical 
analysis is possible. A second study of 519 patients with 10 patients with persistent hy-
poparathyroidism indicates that patients with a postoperative PTH less than 0.7 pmol/L 
have a 19.1% risk of persistent hypoparathyroidism (calcium supplementation one year 
after surgery)19. In addition, Seo et al. show that postoperative PTH levels less than 0.5 
pmol/L have a sensitivity of 73.9% and a specificity of 68.6% for predicting persistent 
hypoparathyroidism defined as subnormal PTH and need for calcium supplementation 
one year after surgery20. This was studied in 349 patients of which 46 (13.2%) developed 
persistent hypoparathyroidism. Although not adequately powered, the former studies 
indicate that using low but measurable PTH levels as cut-off point is more subject to 
bias and therefore has a lower predictive value for clinical use. The results of Sitges-Serra 
and colleagues support this3. They measured PTH levels in patients with hypocalcae-
mia one months after thyroidectomy. Of those with low PTH levels, 90% recovered to 
normal parathyroid function, compared with 62% of patients with undetectable PTH 
levels. Unfortunately, the study did not measure PTH levels directly after surgery so no 
direct comparison with our results could be made. However, it indicates the difference 
between low and unmeasurable PTH levels. 
93.3% of our patients in the PTH-UM group had measurable PTH levels and restoration of 
parathyroid hormone production after one year, although clinically 60% had persistent 
hypoparathyroidism. This is in contrast to the results of Al-Dhahri et al . They evaluate 
PTH recovery by repeated PTH measured measurements in 53 patients until normaliza-
tion of PTH levels or up to 6 months21. If PTH levels after surgery dropped by more than 
88% compared with baseline measurements, the patient only had a chance of 10% of 
recovery PTH levels within 6 months. However, the use of calcium supplementation is 
not reported in this study, so the clinical implication remains unknown. 
The strengths of our study are the adequately powered design, the reduced bias of bio-
logical variation in intra-individual PTH levels, the low number of lost to follow-up and 
the use of one hypocalcaemia treatment algorithm. Prior to describing the limitations of 
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our study, we would like to provide a framework in which our seemingly above average 
persistent hypoparathyroidism rate should be interpreted. First of all, we used a clinical 
definition of persistent hypoparathyroidism, namely the use of calcium supplementa-
tion one year after surgery. We are currently performing a case-by-case assessment to 
check whether all cases are truly in need of calcium supplementation. Until then, all 
the above described results are based on our current clinical endpoint. Secondly, the 
hypocalcaemia treatment protocol is quite defensive and warrants calcium supplemen-
tation even if calcium levels are just below normal and patients are without complaints. 
We are currently investigating a more liberal protocol based on the study from Cayo 
et al. and Raffaelli et al. who only supplement calcium in case of clinical symptoms22,23. 
This shows the influence of a strict calcium supplementation protocol on the primary 
endpoint. A more liberal protocol would lower the amount of patients with persistent 
hypoparathyroidism. Thirdly, we perceive our patient population as a selected group 
of patients with higher risk for postoperative hypoparathyroidism. Lastly, we question 
ourselves whether we really know the true incidence of persistent hypoparathyroidism. 
Is there a possible publication bias? Most articles report persistent hypoparathyroidism 
rates below 5%. However, in striking contrast, in a survey from the Thyroid Cancer Alli-
ance6, the rate of persistent hypoparathyroidism was reported to be around 14%. This is 
clearly discordant with other studies13,19,24,25. Differences can be explained by publication 
bias, differences in case mix, definitions or data registration of persistent hypoparathy-
roidism. For example, in our study, the definition of persistent hypoparathyroidism is not 
based on biochemical values, but a clinical outcome. Several patients in our cohort have 
a PTH level within the reference interval, but receive calcium supplementation. When 
adjusting our case definition to calcium supplementation one year after surgery and 
PTH levels below the reference value, our rate of persistent hypoparathyroidism would 
be 10.8%. In addition, daily calcium supplementation dosages one year after surgery 
vary from 500 to 4000 mg per patient per day. We could discuss whether 500 mg per day 
supplementation represents real persistent hypoparathyroidism. Current case-by-case 
analysis will provide deeper insights into our cases of hypoparathyroidism. We consider 
our patient selection the first limitation of the study, as extrapolation of the results to 
non-tertiary thyroid surgeries is debatable. Unfortunately, logistics did not allow us 
to fully use the inclusion potential of our participating peripheral hospital, as can be 
seen in Figure 1. Secondly, it would have been interesting to be able to provide details 
about parathyroid glands preserved during surgery or found during pathology. This is 
currently under investigation.
As PTH measurements on day one are able to select patients with a high risk of persistent 
hypoparathyroidism, especially in the setting of tertiary thyroid care, we envision the 
following use in clinical practice. Firstly, patients with measurable PTH levels, without 
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complaints of hypocalcaemia should be thoroughly informed, but not subjected to 
regular vena punctures or outpatient visits to check calcium homeostasis. This would 
presumably improve efficiency in patient care as well as costs effectiveness. In addition, 
patients can be provided with more detailed information regarding their personal risk 
for persistent hypocalcaemia. Furthermore, treatment of persistent hypoparathyroid-
ism is based on supplementation of calcium and vitamin D. The underlying hormonal 
imbalance, a deficit of PTH is not targeted in this schedule. An increasing number of 
studies report on the use of human recombinant PTH (rhPTH) for the treatment of 
hypoparathyroidism. Three RCTs have used intact PTH (rh-PTH(1-84)) as a treatment of 
hypoparathyroidism. A decrease in the dosage of calcium and vitamin D supplemen-
tation was found, although it had no effect on quality of life26-28. In non-randomized 
cohort studies evaluating treatment with rhPTH (1-84) and the N-terminal fragment 
rhPTH (1-34) there was a clear effect on QoL and a reduction in supplemental calcium 
and vitamin D requirements29-33. At this moment, the long-term beneficial effects have 
not been evaluated in RCTs and therefore the European Society of Endocrinology 
discourages routine use of rhPTH34. This view is shared by the participants of the First 
International Conference on the Management on Hypoparathyroidism in 201535. The ap-
proval of the first commercially available rhPTH, Natpara, by the EMA in 2017 has made 
it widely available for further trials. This new treatment option could render it important 
to adequately and early identify patients at risk for persistent hypoparathyroidism, as 
possible interventions might be warranted to improve quality of life. 
In conclusion, we show that a PTH level under the limit of detection on the first postop-
erative day after total or completion thyroidectomy is a predictive factor for persistent 
hypoparathyroidism. These data can be used to improve efficiency of postoperative 
follow-up, provide patients with tailored information regarding the future and aid in 
early identification and selection of patients who might benefit from future PTH replace-
ment therapy.
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Primary hyperparathyroidism
As has been stated in this thesis, the incidence of primary hyperparathyroidism (HPT) 
has been rising and is expected to rise further resulting in more parathyroidectomies be-
ing performed1,2. There has been a large improvement in surgical treatment of primary 
HPT in the last two decades. A major improvement has been the introduction of the 
minimally invasive parathyroidectomy (MIP) in patients with successful identification 
of the parathyroid adenoma. The success rate of the MIP is comparable with the bilat-
eral neck exploration but with lower complication rates, shorter operating times and 
better cosmetic satisfaction3-6. The success of the MIP also lead to the introduction of 
parathyroidectomy in daycare surgery. As described in this thesis, it is safe and feasible 
to perform the MIP in a daycare setting. However, the success of daycare MIP depends 
on two important features. Patients frequently experience symptoms associated with 
hypocalcaemia postoperatively, even if they are normocalcemic at the time of discharge. 
We therefore prescribe all patients prophylactic calcium supplementation after MIP, as 
this has been shown to be successful in a large cohort by Vasher et al7. The other impor-
tant feature of successful daycare surgery is adequate patient selection. In both chapter 
2 and 3 of this thesis there was a strict preoperative patient selection. The criteria used 
(including use of anti-coagulant drugs, comorbidities, ASA classification and disease 
specific criteria) ensured selection of healthy patients with a high propability of success-
ful surgery and a low chance of complications. 
In patients with primary HPT, the introduction of the MIP and daycare surgery has lim-
ited the amount of surgical trauma in patients. Further improvements should therefore 
focus not only on the surgical procedure, but also on other factors such as anaesthesia. 
The MIP has been performed using local anaesthesia in several cohorts but has not been 
implemented in daily practice8-12. This could be a focus of a future study, especially with 
attention postoperative outcomes as nausea and vomiting.
The presentation of patients with primary HPT has changed and the majority of patients 
present without classic symptoms13. The last update of the guidelines on asymptomatic 
primary HPT dates from the Fourth International Workshop in 201314. The recommenda-
tions for future research from both this and the Third International Workshop include 
further studies on neurocognitive function and other non-traditional aspects of primary 
HPT15. In this thesis it has been shown that surgical treatment of primary HPT improves 
Quality of Life (QoL). However, the patients in this study were all patients with indica-
tions for parathyroidectomy (PTx) according the most recent guidelines. Asymptomatic 
patients that do not meet the criteria for treatment were not included. QoL has been 
assessed for this group in 3 randomized controlled trials (RCT)16-18. Only the study of 
Ambrogini et al. showed a clear improvement in QoL in these patients after PTx. This was 
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also the only study where the MIP was performed, whereas the other studies used the 
bilateral neck exploration. Future studies in asymptomatic patients should focus on two 
points. The burden of disease in patients not meeting the criteria should be assessed 
including the effect of annual monitoring of these patients. Second, a cohort of asymp-
tomatic patients should be randomized for monitoring and surgical treatment using all 
improvements in parathyroid surgery, e.g. daycare surgery, the MIP and possibly the MIP 
under local anaesthesia. 
Secondary hyperparathyroidism
Secondary HPT remains an important problem in patients with end-stage renal disease 
(ESRD) and contributes to renal bone disease, cardiovascular disease and a reduced 
QoL19-21. As stated in this thesis, the treatment of secondary HPT has shifted mainly 
from PTx to medical treatment with cinacalcet even though there are no studies directly 
comparing these treatment modalities. In the recent updated guideline it is stated that 
medical treatment is the first line of treatment in dialysis patients with secondary HPT, 
with either vitamin D or calcimimetics, and PTx remains a valid treatment option if medi-
cal PTH lowering options fail22. 
A PTx in a patient with secondary HPT can mean a subtotal parathyroidectomy or a total 
parathyroidectomy with auto-transplantation. These procedures are both effective, 
without significant differences in rates of persisting of recurrent disease23. An advantage 
of PTx is the reduction on the risk of cardiovascular events and mortality24,25. The com-
plication rates of PTx in patients with secondary HPT are very low, despite the fragility 
of dialysis patients26. 
The initial studies on cinacalcet showed very promising results, with clear improvements 
in serum PTH, calcium and phosphate during treatment with cinacalcet27. The EVOLVE 
trial was the first large trial to evaluate the clinical outcomes of cinacalcet, and this study 
did not find a reduction in the risk of death of cardiovascular events28. A meta-analysis of 
RCT’s with cinacalcet confirmed this finding, and cinacalcet appears to reduce only the 
rate of parathyroidectomy without other beneficial effects and consequently causing 
patients to experience hypocalcaemia and nausea29. 
The optimal treatment of secondary HPT remains therefore unclear, and should be a 
major focus in future studies. To date, treatment with cinacalcet has been compared 
in RCT’s with placebo and vitamin D but not with parathyroidectomy. A future study 
should therefore consist of a RCT comparing treatment with cinacalcet and PTx in dialy-
sis patients with secondary HPT. 
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Recently an intravenous calcimimetic has become available (etelcalcetide, Parsabiv). 
Two phase III trials of Block et al. were published comparing etelcalcetide with placebo 
and cinacalcet30,31. It was concluded that etelcalcetide is not inferior to cinacalcet and 
superior to placebo in lowering PTH levels. Adverse effects were comparable in the 
cinacalcet and etelcalcetide group. Studies evaluating clinical outcomes and long term 
effects are not yet available. Before further clinical implementation of etelcalcetide 
these studies should be performed. A comparative study between etelcalcetide and 
parathyroidectomy should be performed only after long-term data of the efficacy and 
safety of etelcalcetide becomes available. 
There are several options for endpoints in such a study. Important aspects of secondary 
HPT remain the risk of cardiovascular disease, as well as the effectiveness of treatment in 
reducing this risk, and renal bone disease. However, as seen in the EVOLVE trial, cardio-
vascular morbidity and mortality as an endpoint require very large group sizes as well as 
long follow-up. Renal bone disease would be very interesting as an endpoint however 
this would require bone biopsies in all patients. The measurement of BMD using a DEXA 
scan in dialysis patients does not predict fracture risk as it does in the general popula-
tion and is therefore not suitable as an endpoint in a trial22. 
In recent years there has been an increasing interest in patient-reported outcome 
measures (PROMs) such as QoL32. In this thesis the effect of both PTx and cinacalcet 
on QoL in patients with secondary HPT was compared, and a clear effect of PTx on QoL 
was found. However the group of patients undergoing PTx had more severe HPT, which 
could increase the beneficial effect on QoL and only one study on PTx included a control 
group. However, QoL should be considered as primary endpoint for future studies. 
Patients on dialysis are fragile with high ASA scores and represent a group of patients 
with complex medical problems and a high morbidity and mortality rate26. Attempting 
trials in this group of patients remains a challenge. This has been seen in the EVOLVE 
trial, one of the largest trials ever undertaken in a dialysis population. The investigators 
encountered many obstacles and challenges before completing this study. Fortunately, 
the EVOLVE investigators published an extensive summary of the valuable lessons 
learned during this study, including lessons on nonadherence, outcome selection and 
the effect of co-interventions33. Before attempting a study on the treatment of secondary 
hyperparathyroidism in dialysis patients, these lessons should be studied extensively as 
this will improve the design of a future study. 
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Tertiary hyperparathyroidism
Successful kidney transplantation corrects the metabolic disturbances responsible for 
the development of secondary HPT. After transplantation the biggest decline in serum 
PTH concentrations occurs in the first three months, with a more gradual decline until 
one year after transplantation34,35. A further decline after this period is unlikely, and 
patients with persistent elevated serum calcium and PTH levels will remain elevated 
without therapy. Important risk factors for the persistence of hyperparathyroidism in-
clude longer duration of dialysis and higher serum PTH, calcium and phosphorus levels 
at the time of transplantation36,37. 
As stated in this thesis, the first line of treatment for tertiary HPT should remain a PTx. 
A PTx, either a subtotal parathyroidectomy or a total parathyroidectomy, has been de-
scribed in many cohort studies. The only RCT including treatment with PTx in patients 
with tertiary HPT showed a clear advantage in treatment with PTx38. A clear lack in this 
study is that it also focussed on biochemical parameters, and clinical outcomes were not 
evaluated. Considering the lesson learned from the Evolve trial, biochemical parameters 
only are insufficient to evaluate treatment success in hyperparathyroidism. 
The use of cinacalcet in tertiary HPT has been described mainly in retrospective studies, 
but also in two RCT’s38,39. The primary endpoints of these studies consisted on the effect 
of cinacalcet on hypercalcemia, compared with either PTx or placebo. Studies focussing 
primarily on the safety of cinacalcet use in transplant patients have not been performed, 
neither on the effect of treatment with cinacalcet on clinical outcomes in transplant 
patients. Considering that hyperparathyroidism in patients after kidney transplantation 
increases the risk of graft loss and all-cause mortality, future studies should include lon-
ger follow-up periods, focus on safety of cinacalcet in transplant patients and in addition 
on clinical endpoints including graft survival40. 
Another important aspect in treatment of tertiary HPT is cost-effectiveness. It is known 
that secondary HPT increases the use costs of medical care41. In these patients the use of 
cinacalcet also adds an additional financial burden, and surgical treatment by means of 
PTx is finally more cost-effective42,43. Given the long overall and graft survival of patients 
with a kidney transplant, it is likely that PTx is even more cost-effectiveness in patients 
with tertiary HPT. In the only study evaluating cost-effectiveness in tertiary HPT it was 
stated that surgical treatment is more cost-effective if treatment duration with cinacalcet 
reached 14 months38. As this is the only study, cost-effectiveness should be an endpoint 
in future studies on the treatment of tertiary HPT. 
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As tertiary HPT occurs in a cohort of patients with persistence of secondary HPT, shifts in 
the treatment of secondary HPT are likely to also influence the development of tertiary 
HPT and characteristics of patients with tertiary HPT. A study comparing PTx and cina-
calcet for the treatment of tertiary HPT and focussing on clinical outcome parameters, 
safety of cinacalcet and cost-effectiveness should therefore be performed after such a 
trial has been performed in patients with secondary hyperparathyroidism. 
hypoparathyroidism
Iatrogenic hypoparathyroidism remains an important complication after thyroid surgery 
and can occur due to accidental removal of the parathyroid glands, bruising of the 
parathyroid glands or devascularisation of the parathyroid glands. The resulting hypo-
calcaemia is frequent directly after total or completion thyroidectomy, in this thesis 71% 
of patients used calcium supplementation at time of discharge. However, the parathy-
roid function is restored in the majority of patients, but a substantial group of patients 
remains dependent on calcium supplementation due to persistent hypoparathyroidism. 
In our cohort, 17.6% of patients were treated for persistent hypoparathyroidism one 
year after surgery. There is a clear discrepancy with other studies reporting rates below 
5%44-48. Possible explanations for this discrepancy can be publication bias, differences 
in case mix and difference in definitions of hypoparathyroidism. However, in a large 
international survey among patients after thyroidectomy for thyroid carcinoma, the 
rate of persistent hypoparathyroidism was 13.8%, in line with a study of Seo. et al49,50. 
Given the rate in this study on patient reported outcomes, we feel there might be a large 
publication bias on persistent hypoparathyroidism. 
As demonstrated in this thesis, it is possible to select patients with a high risk of persis-
tent hypoparathyroidism after total or completion thyroidectomy with the use of direct 
post-operative PTH levels. This finding can be used as a tool for more patient tailored 
calcium supplementation and calcium withdrawal, and should be used as a variable 
in studies on restraining calcium supplementation. This may help to decrease use of 
calcium supplementation, decrease the amount of vena punctures and limit outpatient 
visits to check calcium homeostasis, thereby lowering the burden on patients. The chal-
lenge in implementing such a strategy will be selecting patients that are at either at 
high or low risk of persistent hypoparathyroidism, to ensure that patients with severe 
hypocalcaemia will not be missed or even develop complications due to hypocalcaemia. 
Risk assessment for persistent hypoparathyroidism by means of post-operative PTH 
levels also has another possible application. There are a number of studies reporting 
on the use of human recombinant PTH (rhPTH) in the treatment of hypoparathyroidism, 
including three RCT’s, but in these studies the use of rhPTH only decreases the dosage 
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of vitamin D and calcium supplementation, but does not lead to a cessation of supple-
mentation51-53. Moreover, the use of rhPTH has not yet been evaluated for long -term 
outcomes, and a beneficial effect on QoL has not been found to date. Therefore further 
studies are warranted to assess these outcomes in patients with chronic hypoparathy-
roidism using rhPTH 54. Post-operative PTH levels after surgery could adequately identify 
patients with a high risk of persistent hypoparathyroidism who could benefit most of 
rhPTH
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SamenVaTTInG
Hoofdstuk 1 beschrijft een algemene introductie in de calcium fosfaat as en in de ver-
schillende vormen van bijschildklierziekten. Er zijn drie belangrijke hormonen betrok-
ken in de calcium fosfaat as; parathormoon (PTH), calcitriol en fibroblasth growth factor 
23 (FGF-23). PTH zorgt voor een stijging van het serum calcium en een daling van het 
serum fosfaat. Calcitriol zorgt voor een stijging van zowel het serum calcium als het 
fosfaat en FGF-23 zorgt voor een daling van het fosfaat.
Primaire hyperparathyreoïdie (HPT) word veroorzaakt door een aandoening van de 
bijschildklier, in de meerderheid van patiënten een solitair bijschildklier adenoom. 
Historisch gezien werden patiënten gediagnosticeerd met primaire HPT als gevolg van 
klassieke symptomen. De introductie van routine calcium bepalingen in screenend 
laboratorium onderzoek heeft geleid tot de identificatie van een groep patiënten met 
biochemische ziekte maar geen klinische symptomen. Dit word asymptomatische 
primaire hyperparathyreoïdie genoemd. Hoewel deze patiënten geen klassieke sympto-
men vertonen, kunnen ze ook neuro psychiatrische symptomen ervaren en kan de kwa-
liteit van leven (QoL) verminderd zijn. Deze neuro psychiatrische symptomen zijn geen 
onderdeel van de behandelcriteria van asymptomatische primaire HPT. De behandeling 
van primaire HPT bestaat uit chirurgische excisie van de aangedane bijschildklier(en), 
en heeft een 95% succes percentage. De parathyreoïdectomie (PTx) is een veilige proce-
dure, welke ook uitgevoerd kan worden in dagbehandeling. 
Secundaire HPT ontstaat als reactie op metabole stoornissen, en komt frequent voor 
in patiënten met chronische nierziekten. De eerste stap in de behandeling bestaat uit 
vitamine D suppletie en fosfaat binders. De tweede stap in de behandeling bestond 
historisch gezien uit PTx. In 2004 is het calcimimeticum cinacalcet geïntroduceerd, en 
dit heeft de PTx vervangen als de tweede stap in de behandeling van secundaire HPT. 
De eerste studies met cinacalcet toonden veelbelovende resultaten en het is succesvol 
in het verlagen van de PTH, calcium en fosfaat concentraties. Echter, in de EVOLVE trial 
is aangetoond dat cinacalcet het risico op cardiovasculaire events en overlijden niet ver-
laagd. Derhalve blijft de optimale van secundaire HPT onduidelijk, aangezien cinacalcet 
en PTH niet direct met elkaar zijn vergeleken.
Na niertransplantatie kan HPT blijven bestaan, ondanks een succesvolle transplantatie, 
en dit staat bekend als tertiaire HPT. De behandeling van tertiaire HPT is parathyreoï-
dectomie. Cinacalcet is niet geregistreerd voor gebruik in tertiaire HPT, maar off-label 
gebruik hiervan neemt toe in populariteit. Tot op heden zijn deze behandeling in slechts 
één studie direct vergeleken. 
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Hypoparathyreoïdie is een andere ziekte van de bijschildklier, en dit ontstaat regelmatig 
na schildklier operaties. Passagere hypoparathyreoïdie treed op tot in 60% van de patiën-
ten na een totale of totaliserende thyreoïdectomie, en persisterende hypoparathyreoïdie 
treed op tot in 14% van de patiënten. De behandeling van hypoparathyreoïdie bestaat 
uit suppletie van calcium en actief vitamine D. Het is niet mogelijk om betrouwbaar te 
voorspellen in welke patiënten de functie van de bijschildklier zal herstellen, en welke 
patiënten persisterende hypoparathyreoïdie zullen ontwikkelen. In staat zijn om te voor-
spellen welke patiënten een persisterende hypoparathyreoïdie zullen ontwikkelen kan 
helpen de behandeling per patiënt af te stemmen. Het is onderzocht of postoperatieve 
PTH waarden directe postoperatieve hypocalciëmie kunnen voorspellen, echter het is 
niet onderzocht of postoperatieve PTH waarden kunnen voorspellen welke patiënten 
een persisterende hypoparathyreoïdie zullen ontwikkelen. 
Hoofdstuk 2 presenteert de eerste ervaringen met de parathyreoïdectomie (PTx) in 
dagbehandeling. De resultaten van de eerste 20 patiënten die in dagbehandeling zijn 
behandeld vanwege primaire HPT worden beschreven. In dit cohort waren er geen per-
operatieve complicaties. Er hebben zich 5 patiënten gemeld op de spoedeisende hulp 
met paresthesieën, er was echter maar 1 patiënt met een milde hypocalciëmie. We beve-
len aan de chirurgische behandeling van primaire HPT te verrichten in dagbehandeling, 
echter schrijven we bij ontslag enkele weken profylactisch calcium suppletie voor. 
In hoofstuk 3 beschrijven we de ervaring met het uitvoeren van een hemithyreoïdecto-
mie in dagbehandeling. De veiligheid van de hemithyreoïdectomie was geanalyseerd in 
een retrospectief cohort van 210 patiënten die een hemithyreoïdectomie hebben onder-
gaan. In patiënten die potentieel geschikt waren geweest traden er geen nabloedingen 
op, in patiënten ongeschikt voor dagbehandeling heeft 1 patiënt nog een operatie on-
dergaan vanwege een nabloeding. Er werd geconcludeerd dat de hemithyreoïdectomie 
een veilige procedure is in geselecteerde patiënten, en de dagbehandeling strategie 
werd ingevoerd. We beschrijven de resultaten van de eerste 18 patiënten die een he-
mithyreoïdectomie in dagbehandeling hebben ondergaan. Er was 1 patiënt met een 
passagere stemverandering en geen andere complicaties. Er waren geen heropnames 
of spoedeisende hulp bezoeken. De hemithyreoïdectomie in dagbehandeling is veilig 
en haalbaar mits er adequate patiënt selectie plaatsvind. 
Hoofdstuk 4 presenteert de resultaten van een case-control studie waarin de effecten 
van een PTx vanwege primaire HPT op QoL zijn geëvalueerd. In deze studie hebben 
we 52 patiënten die een PTx hebben ondergaan vergeleken met 49 patiënten die een 
hemithyreoïdectomie vanwege een benigne aandoening hebben ondergaan. De QoL 
was gemeten met de Short-Form 36 (SF-36) vragenlijst en een vragenlijst bestaande 
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uit 17 symptomen die geassocieerd zijn met primaire HPT. Patiënten met primaire HPT 
hadden preoperatief lagere scores op de domeinen rolbeperking (fysiek probleem) en 
algemene gezondheidsbeleving, alsmede als op de fysieke component score. Deze ver-
schillen verdwenen na de operatie. Patiënten met primaire HPT lieten postoperatief een 
significante verbetering op alle domeinen, en dit verschil persisteerde 1 jaar postopera-
tief in 7 domeinen. Patiënten die een hemithyreoïdectomie ondergingen lieten alleen 
een verbetering op het domein mentale gezondheid; de andere domeinen lieten geen 
verschillen zien. Patiënten met primaire HPT hadden meer klachten van dyspepsie, poly-
dipsie en polyurie preoperatief, dit verschil tussen de groepen verdween postoperatief. 
In de primaire HPT groep hadden patiënten 3 maanden na operatie minder last van 
moeheid, spierpijn en nycturie. Deze studie laat zien dat een PTx vanwege primaire HPT 
leid tot een verbetering in de QoL en er moet worden overwogen om dit als aanvulling 
op de huidige criteria voor de behandeling van primaire HPT op te nemen.
Hoofdstuk 5 beschrijft de resultaten van een systematisch review waarin het effect van 
behandeling van secundaire HPT op QoL word beschreven. Er zijn vijf artikelen gevon-
den waarin het effect van PTx op QoL zijn beschreven, en drie artikelen die het effect van 
cinacalcet op QoL beschrijven. De 5 artikelen die het effect van PTx op QoL beschrijven 
bestaan uit vier case series en een case-control studie. In vier studies is een significante 
verbetering van QoL beschreven, gemeten middels de SF-36 vragenlijst. In drie studies 
werd een significante verbetering van symptomen gezien gemeten middels de PAS 
vragenlijst en een studie beschreef een significante verbetering op drie domeinen van 
de VAS schaal (jeuk, gewrichtspijn en spierzwakte). De drie studies die het effect van 
cinacalcet beschrijven bestonden uit twee klinische trials en een cohort studie. Het ge-
bruik van cinacalcet resulteerde niet in een verbetering van de QoL zoals gemeten bij de 
SF-36 vragenlijst of de EQ-5D vragenlijst. Een studie liet zien dat cinacalcet een positief 
effect had op vier HPT gerelateerde symptomen (droge huid, botpijnen, gewrichtspijn 
en geheugen problemen). Dit review laat zien dat PTx een positief heeft op QoL waar 
cinacalcet dit niet heeft. Deze interventies zijn niet direct met elkaar vergeleken en QoL 
zal een eindpunt moeten zijn in toekomstige studies. 
Hoofdstuk 6 presenteert de resultaten van een systematisch review waarin de uit-
komsten van chirurgische en medicamenteuze behandeling van tertiaire HPT worden 
vergeleken. Er zijn 47 artikelen geïncludeerd in deze studie. De uitkomsten na een PTx 
vanwege tertiaire HPT zijn beschreven in 14 studies. Residu ziekte was aanwezig in 0% 
en 1,3% van de patiënten in respectievelijk een totale parathyreoïdectomie en subtotale 
parathyreoïdectomie. Recidief ziekte was aanwezig in 4% en 7,6% van de patiënten. 
Persisterende hypoparathyreoïdie kwam voor in 0,7% van de patiënten, andere compli-
caties waren zeldzaam.
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De uitkomsten van patiënten die zijn behandeld met cinacalcet zijn beschreven in 22 
studies. Normocalciëmie is bereikt in 80.8% van de patiënten. De behandeling is in 6,4% 
van de patiënten gestaakt vanwege bijwerkingen. 
Omdat een PTx een hoger succespercentage heeft dan medicamenteuze behandeling 
adviseren wij chirurgische behandeling van tertiaire HPT.
In hoofdstuk 7 zijn de uitkomsten na behandeling voor tertiaire HPT geëvalueerd in 
twee academische centra. Een retrospectieve evaluatie van 94 patiënten, 30 na PTx en 
64 na behandeling met cinacalcet, is uitgevoerd. Een PTx corrigeerde hypercalciëmie, 
resulteerde in een normalisatie van PTH concentraties en had weinig complicaties. 
Behandeling met cinacalcet resulteerde in normocalciëmie maar PTH waarden bleven 
verhoogd. Gezien de effecten van hoge PTH waarden op de overleving van het nier 
transplantaat, geven wij de voorkeur aan een PTx in alle patiënten met tertiaire HPT. 
In hoofdstuk 8 word de voorspellende waarden van PTH metingen na een thyreoïdec-
tomie voor het ontwikkelen van persisterende hypoparathyreoïdie geëvalueerd. Er zijn 
102 patiënten 1 jaar na totale of totaliserende thyreoïdectomie vervolgd. In dit cohort 
is 71% van de patiënten postoperatief ontslagen met calcium suppletie en ontwikkelde 
17,6% een persisterende hypoparathyreoïdie. Patiënten met een postoperatieve PTH 
waarde onder de detectielimiet hadden een 60% kans op het ontwikkelen van een per-
sisterende hypoparathyreoïdie, terwijl patiënten met een meetbaar PTH een 10,4% kans 
hadden op het ontwikkelen van persisterende hypoparathyreoïdie. Alle patiënten met 
een persisterende hypoparathyreoïdie hadden een PTH lager dan de referentiewaarde 
op de eerste postoperatieve dag. Een PTH waarde onder de detectielimiet op de eerste 
dag na een totale of totaliserende thyreoïdectomie is een voorspellende factor voor het 
ontwikkelen van persisterende hypoparathyreoïdie. 
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enGlISh Summary
Chapter 1 provides a general introduction in the calcium and phosphate homeostasis 
and the different forms of parathyroid disease. There are three important hormones 
involved in the calcium and phosphate homeostasis; parathyroid hormone (PTH), cal-
citriol and fibroblast growth factor 23 (FGF-23). PTH causes a rise in serum calcium and 
a fall of serum phosphate concentrations. Calcitriol causes an increase in serum calcium 
and phosphate concentrations and FGF-23 causes serum phosphate concentrations to 
decrease.
Primary hyperparathyroidism (HPT) is caused due to an ailment of the parathyroid, in 
the majority of patients due to a single parathyroid adenoma. Historically patients were 
diagnosed with primary HPT due to classical symptoms. The introduction of routine 
calcium measurements in biochemical screening has led identification of a group of 
patients with biochemical disease but no clinical symptoms. This is also referred to as as-
ymptomatic primary hyperparathyroidism. Although these patients do not experience 
classical symptoms, they may experience neuropsychiatric symptoms and Quality of Life 
(QoL) can be influenced. These neuropsychiatric symptoms are not part of the criteria 
for treatment of asymptomatic primary HPT. The treatment of primary HPT consists of 
surgical excision of the pathologic parathyroid gland(s), and has a success rate of 95%. 
The parathyroidectomy (PTx) is a safe procedure, which is also performed in a daycare 
setting in some centers.
Secondary HPT occurs as a response to metabolic abnormalities, and is frequent in 
patients with chronic kidney disease. The first line of treatment consists of vitamin D 
supplementation and phosphate binders. Second line of treatment consisted historically 
of PTx. In 2004 the calcimimetic drug cinacalcet was introduced, and this has replaced 
the PTx as second line of treatment for secondary HPT. The first studies on cinacalcet 
showed promising results and it successfully lowers serum PTH, calcium and phosphate 
concentrations. However, in the EVOLVE trial it was shown that cinacalcet does not lower 
the risk of cardiovascular events or death. Therefore the optimal treatment of secondary 
HPT remains unclear, since cinacalcet and PTH have not yet been compared directly. 
After renal transplantation HPT can persist despite a successful transplantation, and this 
is known as tertiary HPT. The treatment for tertiary HPT is parathyroidectomy. Cinacalcet 
is not registered for use in patients with tertiary HPT, but the off-label use is gaining 
popularity. To date the comparison of these two treatment modalities has only been 
performed in one study.
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Hypoparathyroidism is another disease of the parathyroid and frequently after thyroid 
surgery. Transient hypoparathyroidism occurs in up to 60% of patients after total of 
completion thyroidectomy, and persistent hypoparathyroidism occurs in up to 14% of 
patients. The treatment of hypoparathyroidism consists of supplementation of calcium 
and active vitamin D. It’s not possible to reliably predict in which patients parathyroid 
function will recover, and which patients will develop persistent hypoparathyroid-
ism. Being able to predict which patients will develop persistent hypoparathyroidism 
will help tailor treatment of patients. Postoperative PTH measurements have been 
evaluated to predict direct postoperative hypocalcemia, but it has not been evaluated 
if postoperative PTH concentrations can predict which patients will develop persistent 
hypoparathyroidism.
Chapter 2 presents our first experience of a parathyroidectomy performed in a daycare 
setting. The results of the first 20 patients treated for primary HPT in a daycare setting 
are described. In this cohort were no perioperative complications. Five patients reported 
with paresthesia to the emergency department, but only one patient had mild hypocal-
cemia. We recommend parathyroid surgery for primary HPT in a daycare setting, but we 
discharge patients with prophylactic calcium supplementation for a few weeks. 
In Chapter 3 we describe the experience of performing a hemithyroidectomy in a daycare 
setting. The safety of a hemithyroidectomy was analysed in a retrospective cohort of 210 
patients who underwent hemithyroidectomy. In patients who were potentially eligible 
for daycare surgery there were no patients with postoperative bleeding, in patients not 
eligible for daycare surgery there was one patient requiring reoperative surgery due to 
bleeding. It was concluded that a hemithyroidectomy is a safe procedure for selected 
patients, and the daycare strategy was implemented. We describe the results of the 
first 18 patients undergoing a hemithyroidectomy in a daycare setting. There was one 
patient with transient vocal change in this group and no other complications. There 
were no readmissions or emergency department visits. The daycare hemithyroidectomy 
is safe and feasible provided that adequate patient selection is performed. 
Chapter 4 presents the results of a case-control study evaluating the effect of PTx for 
primary HPT on QoL. In this study we 52 compared patients undergoing PTx with 49 
patients undergoing a hemithyroidectomy for benign disease. QoL was measured using 
the Short-Form 36 (SF-36) questionnaire and a questionnaire consisting of 17 symptoms 
associated with primary HPT. Patients with primary HPT had lower preoperative scores 
on the domains role-physical and general health as well as a lower score on the physical 
component score. After surgery these differences had disappeared. The patients with 
primary HPT showed significant improvements on all domains after surgery, and this 
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improvement persisted in 7 domains one year after surgery. Patients who underwent 
hemithyroidectomy had an improvement on the mental health domain; the other do-
mains did not reveal any differences. Patients with primary HPT had more complaints of 
dyspepsia, polydipsia and polyuria before surgery, this difference between the groups 
disappeared after surgery. In the primary HPT group the patients had fewer complaints 
of fatigue, muscle aches and nycturia three months after PTx. This study showed that a 
PTx for primary HPT leads to an improvement on QoL and this should be considered as 
a supplement in the current criteria for treatment of primary HPT.
Chapter 5 describes the results of a systematic review assessing the influence of treat-
ment for secondary HPT on QoL. A total of five articles describing the effect of PTx on QoL 
were found, and three articles describing the effect of cinacalcet on QoL. The five articles 
describing the effect of PTx on QoL consisted of four case series and one case-control 
study. Four studies reported a significant improvement in QoL as measured by the SF-
36 questionnaire. There were three studies that showed a significant improvement in 
symptoms as measured by the PAS questionnaire and one study described a significant 
improvement on three domains of the VAS scale (skin itching, joint pain and muscle 
weakness). The three studies describing the effect of cinacalcet consisted of two clinical 
trials and one cohort study. The use of cinacalcet did not result in an improvement in 
QoL as measured by the SF-36 questionnaire or the EQ-5D questionnaire. In one study it 
was shown that cinacalcet had a positive effect on four HPT related symptoms (dry skin, 
ache in bones, joint pain and trouble with memory). This review showed that PTx has a 
positive effect on QoL whereas cinacalcet did not. These interventions have not been 
compared directly and QoL should be an endpoint in future studies. 
Chapter 6 presents the results of a systematic review comparing the outcomes of surgical 
and medical treatment for tertiary HPT. A total of 47 articles were included in this study. 
The outcomes after PTx for tertiary HPT were described 14 studies. Persistent disease 
was apparent in 0% and 1.3% of patients for respectively total parathyroidectomy and 
subtotal parathyroidectomy. Recurrent disease was apparent in 4% and 7.6% of patients. 
Persistent hypoparathyroidism occurred in 0.7% of patients, other complications were 
rare. 
The outcomes of patients treated with cinacalcet were described in 22 studies. Nor-
mocalcemia was achieved in 80.8% of patients. Treatment was discontinued in 6.4% of 
patients due to side-effects. 
Because PTx has higher cure rates than medical therapy we recommend surgical treat-
ment of tertiary HPT.
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In Chapter 7 the outcomes after treatment for tertiary HPT were evaluated in two 
academic centers. A retrospective evaluation of 94 patients, 30 after PTx and 64 after 
treatment with cinacalcet, was performed. A PTx corrected hypercalcemia, resulted in 
normalization of PTH concentrations and had low complication rates. Treatment with 
cinacalcet resulted in normocalcemia, but PTH values remained elevated. Given the ef-
fects of high PTH concentrations on renal allograft survival, we favour PTx in all patients 
with tertiary HPT. 
In Chapter 8 the predictive value of PTH measurements after thyroidectomy for the de-
velopment of persistent hypoparathyroidism is evaluated. A total of 102 patients were 
followed for one year after total or completion thyroidectomy. In this cohort 71% of 
patients were postoperatively discharged with calcium supplementation and 17.6% of 
patients developed persistent hypoparathyroidism. Patients with a postoperative PTH 
value under the limit of detection had a 60% chance of developing persistent hypo-
parathyroidism, whereas patients with a postoperative PTH within the limit of detection 
had a 10.4% chance of developing persistent hypoparathyroidism. All patients with 
persistent hypoparathyroidism had a PTH under the lower limit of the reference value on 
the first postoperative day. A PTH level under the limit of detection on the day after total 
or completion thyroidectomy is a predictive factor for the development of persistent 
hypoparathyroidism.
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Roderick Dulfer werd geboren op 12 november 1987 te Rotterdam, als oudste van 2 
zoons. Hij groeide op in Mijnsheerenland en later in Goudswaard. Zijn VWO diploma 
werd in 2005 behaald aan de Regionale Scholen Gemeenschap in Oud-Beijerland, in 
datzelfde jaar startte hij met de studie Geneeskunde aan de Erasmus Universiteit Rot-
terdam. Zijn oudste co-schap vond plaats op de afdeling oncologische chirurgie van 
het Erasmus MC – locatie Daniel den Hoed, waarna hij 4 maanden doorbracht op de 
afdeling traumachirurgie van het Groote Schuur Hospital in Kaapstad. In november 2012 
behaalde hij zijn artsexamen waarna hij startte met werken als ANIOS chirurgie in het 
Erasmus MC. In deze periode werd er ook begonnen met promotieonderzoek onder 
begeleiding van prof. dr. C.H.J. van Eijck en dr. T.M. van Ginhoven. Dit onderzoek heeft 
uiteindelijk geleid tot dit proefschrift. Gedurende het onderzoek heeft hij ook gewerkt 
op de afdelingen chirurgie van het Sint Franciscus Gasthuis en het Amphia ziekenhuis. 
Op dit moment werkt hij op de afdeling Heelkunde van het UMCG. 
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Het is eindelijk zover, het proefschrift is af. Dit proefschrift had natuurlijk niet tot stand 
kunnen komen zonder de hulp en ondersteuning van een heel team. Iedereen die op de 
een of andere manier heeft bijgedragen aan dit proefschrift wil ik graag bedanken, maar 
er is een aantal mensen die ik in het bijzonder wil bedanken. 
Allereerst mijn promotor, Prof. Dr. C.H.J. van Eijck. Beste Casper, hartelijk dank voor het 
vertrouwen en de kansen die u mij heeft gegeven. In onze periode samen op 8-Noord 
heb ik veel van u mogen leren en heb ik u leren kennen als een zeer toegewijd chirurg. 
Met weinig woorden heeft u deze jaren precies aangegeven hoe we ons werk konden 
verbeteren. Ik kan altijd rekenen op uw steun.
Tessa, het is gelukt! Jaren terug heb je mij, toen nog als oudste coassistent, onder je 
hoede genomen. We hebben toen al tegen elkaar gezegd, wat zou het leuk zijn als dit 
gaat lukken. En nu ligt dit proefschrift er en sta jij hier als mijn co-promotor. Zonder 
jouw ideeën en supervisie had ik dit nooit voor elkaar gekregen. Dank je wel voor alle 
begeleiding en hulp, en ik hoop dat ik in de toekomst samen met je in de kliniek kan 
werken. 
Graag wil ik de leescommissie, Prof. Dr. W.W. de Herder, Prof. Dr. Y.B. de Rijke en Prof. Dr. 
N.D. Bouvy bedanken voor het beoordelen van dit proefschrift. Wouter en Yolanda, dank 
ook voor de bijdrage aan dit proefschrift. 
Tevens wil ik de overige leden bedanken voor de bereidheid om als opponent deel te 
nemen in de grote commissie. Dr. P.C. Smit, beste Casper, dank voor alle ondersteuning 
met de studies in Delft. Dr. E.J.M. Nieveen van Dijkum, beste Els, tijdens jouw onder-
zoeksdagen in het Erasmus kwamen we elkaar voor het eerst tegen. Dank voor alle hulp 
deze jaren, en gelukkig zullen we de samenwerking de komende jaren voortzetten.
Monica, al die jaren kon ik bij jou terecht voor een werkplek of voor logistieke onder-
steuning. Dank je wel voor het ontvangen van mijn post, voor de hulp in de jacht naar 
handtekeningen en voor alle koffie momenten!
Carola, de steun en toeverlaat van de onderzoeker in de Z-flat. Dank voor alle hulp met 
METc aanvragen, gastvrijheidsovereenkomsten, computerschermen en alle andere on-
dersteuning. Zonder jou zou geen enkele onderzoeker zijn promotie af weten te krijgen.
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Dennis en Ewout, vanaf het eerste moment waren jullie enthousiast over onze samen-
werking. Dank voor jullie frisse en scherpe blik. Zonder jullie medewerking hadden we 
de RHINO pilot nooit op kunnen starten in het Erasmus. Ik hoop dat we dit project in de 
toekomst uit kunnen breiden.
Collega’s van de endocrinologie, Evert en Elske, jullie hebben me ontzettend geholpen 
met de inclusies en het verzamelen van alle formulieren. Robin, zonder jou was de PTH 
studie er nooit gekomen. Dank voor al jullie hulp.
Wanda, spil van de endocrinologie. Ik kon altijd bij je terecht voor hulp. Dank voor het 
begeleiden van de dagbehandeling patiënten, het verzamelen en het bewaren van onze 
vragenlijsten.
Collega’s in de Daniel, Gaston, Pim en Linetta. Dank voor jullie hulp met de uitvoering 
van de PTH studie. Zonder jullie hadden we de studie nooit af kunnen krijgen in deze 
periode.
Mede enthousiastelingen van de DHSG. Ik blijf het uniek vinden dat deze groep bij 
elkaar is gekomen, en dat iedereen er vol voor gaat. Ik ben blij dat we de komende jaren 
door gaan, en dank voor al jullie hulp bij het afronden van dit proefschrift. 
Schelto, dank voor alle hulp, ook buiten alleen het onderzoek. De verhuizing naar Gro-
ningen werd een stuk gemakkelijker dankzij jouw steun, dat zal ik nooit vergeten. 
Willemijn, ondanks dat de RHINO aanvraag niet het beoogde resultaat heeft opgeleverd, 
heb ik ontzettend veel geleerd van onze samenwerking. Ik ben blij dat we dit in Gronin-
gen nu voort kunnen zetten.
Data-verzamelaars van de Elephant-trials, dank voor al jullie input.
Beste co-auteurs, heel veel dank voor al jullie input bij het verbeteren van de manuscrip-
ten. Kim en Viony, dank voor het verzamelen van de gegevens in Delft.
Collega’s in het UMCG. Dank jullie wel voor de fijne ontvangst en alle gezelligheid. 
Collega’s van zowel het SFG en het Amphia. Dank jullie wel voor de gezelligheid, fijne 
samenwerking en alle steun. 
Collega-onderzoekers uit de Z-flat, dank voor alle gezelligheid. Veel succes met het 
afronden van jullie eigen promotie onderzoeken.
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Gideon, sinds we elkaar leerden kennen bij Skadi zijn we al vrienden. Ik ben blij dat we 
samen in Kaapstad hebben gezeten, ik had dit met niemand anders mee willen maken. 
Ik ben blij dat je na mijn bruiloft nu weer aan mijn zijde zal staan. Heel veel geluk samen 
met Sophie, en ik zal zorgen dat er in het Noorden altijd een fles whisky voor je klaar 
staat.
Kimberly, het is nu echt zover. Straks zijn we na al die jaren alle twee gepromoveerd. 
Dank voor alle koffies, biertjes in de Locus en aanhoren van kleine irritaties. Jammer 
genoeg moeten we ons plan om samen de endo-heelkunde poli te draaien nog even 
laten varen, maar wie weet wat de toekomst brengt. Heel veel geluk samen met Michiel, 
en in september gaan we jullie feestje vieren! Ik ben blij dat jij nu aan mijn zijde staat.
Lieve schoonfamilie, dank voor de gezelligheid, gastvrijheid en ondersteuning. Vanaf 
het moment dat ik bij jullie over de vloer kwam hebben jullie me met open armen ont-
vangen.
Lieve Oma, er zijn weinig mensen die zo in het leven staan als u. Met 91 jaar nog steeds 
volledig zelfstandig in het Drentse land. Ik ben blij dat u er op deze dag bij bent, en dat 
u na alle jaren het resultaat van het onderzoek kan zien.
Opa en Oma, het voelde bij jullie altijd als een tweede huis. Niet alleen de weekendjes 
op de boot, maar ook alle middagen in Numansdorp. Ik zal de belangrijkste les qua 
koken ook nooit meer vergeten. Dank voor al jullie steun en gezelligheid. 
Vincent, mijn “kleine” broertje. We verschillen soms als dag en nacht, maar samen blijven 
we een sterk team. Ik ben trots dat je nu doet waar je al die jaren zo hard voor hebt 
gewerkt. 
Pa, Ma, het is echt eindelijk af. Jullie hebben me altijd gesteund en ondersteund bij 
zowel studie, werk, onderzoek als daarbuiten. Bedankt voor al jullie steun, interesse 
en vertrouwen. Dank voor jullie onvoorwaardelijke liefde, ik had het niet zonder jullie 
kunnen doen. 
Lieve Claire. Zonder jou was dit allemaal nooit gelukt. Deze afgelopen jaren heb je me 
altijd gesteund, ook op alle avonden en weekenden dat ik hier aan heb gewerkt. De stap 
naar Groningen had ik nooit gezet zonder jouw steun. Ik kan niet wachten tot wesamen 
in het Noorden zijn. Ik hou van jou en waar we ook terecht komen, we maken er samen 
iets moois van. 
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Supervisor: dr. T.M. van Ginhoven
1. PhD training
year Workload
(hours/eCTS)
General courses 
-  BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 2014 1.5 
-  OpenClinica Training 2016 0.3 
-  Wetenschappelijke Integriteit 2017 0.3 
-  CPO mini-course 2017 0.3 
-  Systematic literature retrieval 2017 1.0 
-  Biomedical English Writing Course 2017 2.0 
Specific courses (e.g. research school, medical Training)
-    
Seminars and workshops
-    
Presentations
-  Operative treatment of primary hyperparathyroidism in daycare surgery, ESSR 2013 1.0 
-  Post-operative PTH measurements after total thyroidectomy; a study design. 
Wetenschapsdag RdGG (poster) 
2015 0.5 
-  Primaire hyperparathyreoïdie heeft een negatieve invloed op de kwaliteit van 
leven hetgeen verbeterd word door chirurgische behandeling, een multicenter 
case-control studie. Chirurgendagen 
2015 1.0 
-  Chirurgische of medicamenteuze behandeling van tertiaire 
hyperparathyreoïdie; een systematic review. Stafdag. 
2017 1.0 
-  Surgical of medical treatment for tertiary hyperparathyroidism; a systematic 
review. ESES (poster) 
2017 0.5 
-  Resultaten van nationale studies betreffende secundaire hyperparathyreoïdie. 
Chirurgendagen.  
2017 1.0 
-  Cinacalcet vs. operatie bij dialysepatiënten. RHINO-studie. The new kids on the 
block meeting. 
2017 1.0 
-  Surgical of medical treatment for tertiary hyperparathyroidism; a systematic 
review. ESOT 
2017 1.0 
168 Appendix
(Inter)national conferences
-  ESSR-congress 2013 2.0 
-  Chirurgendagen 2015 1.0 
-  Chirurgendagen 2016 1.0 
-  ESES meeting 2017 1.5 
-  Chirurgendagen 2017 1.0 
-  The new kids on the block meeting 2017 0.5 
-  ESOT congress 2017 1.5 
-  Thyroid symposium 2017 0.5 
other
-  Scientific committee DHSG 2015-17 3.0 
-  Wetenschapsmiddag RdGG 2013 0.3 
-  Wetenschapsmiddag SFG 2015 0.3 
-  Renal Rounds Westen 2015 0.3 
-  Stafdag Heelkunde 2015-17 1.0 
2. Teaching
year Workload 
(hours/eCTS)
lecturing
-  
Supervising practicals and excursions, Tutoring
-  Examination of Basic Life Support of medical students 2013 1.0 
-  Supervising medical student I. Loncar 2016-17 1.0 
other
-  
